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Patterns of physiological electrical activity in the central nervous system (CNS) cause long-
lasting changes in gene expression that promote neuronal survival.  These changes can be 
mediated by signalling pathways activated by Ca
2+
 influx through synaptic N-methyl D-
Aspartate receptors (NMDARs).  Identification and study of these, and other neuroprotective 
signalling pathways of the CNS, is invaluable; as this may one day lead to therapeutic 
strategies against the deleterious effects of CNS injury or degeneration.  The data presented 
in this thesis focuses on activity-dependent neuroprotection and how it interacts with other 
signalling pathways to protect against apoptotic and oxidative insults. 
 
A previously unobserved role of activity-dependent neuroprotection in mediating the effects 
of the neuropeptide PACAP is demonstrated.  By promoting cAMP/PKA signalling PACAP 
triggers neuronal firing activity, which is essential for the neuroprotective effects mediated 
by PACAP.  This firing activity cooperates with direct signalling by PKA in promoting long-
lasting CREB-mediated gene expression.  The molecular events associated with PACAP 
mediated stimulation of CRE-dependent gene expression are presented.  Investigation of the 
control of neuronal antioxidant defences by neuronal activity, both on its own and in 
cooperation with astrocyte-derived support, was also investigated.  Neuronal activity is 
demonstrated to strongly increase the capacity of the antioxidant glutathione (GSH) system, 
through a program of coordinated transcriptional events.  The utilisation, biosynthesis and 
recycling of GSH is enhanced in neurons, leading to increased resistance against oxidative 
insults.  Since several GSH pathway enzyme genes are regulated by the transcription factor 
Nrf2, the ability of CDDO-F3, a small molecule activator of Nrf2, to mimic the effect of 
firing activity on neuronal GSH levels was examined.  CDDO-F3 sustains neuronal GSH 
levels and confers neuroprotection against oxidative insult.  These actions are dependent on 
the presence of astrocytes; whereas Nrf2 mediated regulation of GSH pathway genes is 
essentially inactive in neurons.  Neuronal activity and activation of the astrocytic Nrf2 
pathway can cooperate, maintaining neuronal GSH levels and protecting neurons against 
strong oxidative insults.  Collectively this work expands our knowledge as to the molecular 
mechanisms of activity-dependent neuroprotection, and how such signals may synergise with 
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PACAP triggers sustained increases in AP firing in cortical neurons 
 Figure 1.1 PACAP enhances AP firing in cortical neurons 
Enhanced AP firing is essential for PACAP induced neuroprotection 
AP firing is required for PACAP induced ERK activation 
Figure 1.2 PACAP promotes resistance to apoptotic stimuli 
which is dependent on AP firing 
Induction of CREB mediated gene expression contributes to PACAP 
mediated neuroprotection 
AP firing underlies PACAP-induced CREB activation 
Figure 1.3 PACAP induces CRE-dependent gene expression, 
which is neuroprotective, and relies on AP firing 
PACAP induced CBP but not CREB phosphorylation, requires AP 
firing 
Figure 1.4 CBP but not CREB phosphorylation requires 


































PACAP-induced AP firing mediates calcineurin-dependent CRTC1 
nuclear import 
Figure 1.5 PACAP induces nuclear translocation of CRTC1, 
necessary for the AP dependent component of CREB 
activation 
Figure 1.6 Schematic illustration of the role of activity-
dependent Ca
2+





Modulation of electrical activity by PACAP and other AC-coupled 
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neuroprotection 
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role of enhanced AP firing 
 
 






Synaptic activity does not increase neuronal GSH levels, but requires 
its synthesis to mediate neuroprotection against oxidative insult 
Figure 2.1 Inhibition of glutathione synthesis blocks synaptic 
activity mediated neuroprotection 
Synaptic activity maintains GSH levels and inhibits its depletion in 
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Synaptic activity increases GSH metabolism 
 Figure 2.3 Synaptic activity increases metabolism of GSH 
GSH depletion block is dependent on NMDAR but not on the 
presence of astrocytes 
Figure 2.4 Block of GSH depletion is NMDAR dependent 
and Astrocyte independent 
Synaptic activity upregulates GSH pathway enzyme activity 
Figure 2.5 Synaptic activity increases GSH pathway enzyme 
activity 
Synaptic activity upregulates GSH pathway enzyme mRNA 
expression 
Figure 2.6 Synaptic activity upregulates GSH pathway 
enzyme mRNA expression 
Figure 2.7 Inhibition of transcription blocks increase in GSH 
pathway enzyme activity 
Upregulation of GR promoter activity by NMDAR signalling 
Figure 2.8 Glutathione Reductase promoter activity is 
increased by synaptic activity 
Blockade of NMDARs decreases GCL activity and expression in 
vivo 
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Chapter 5: Neuroprotection by Nrf2 mediated activation of the 




CDDO-F3 upregulates GSH levels of astrocytes but not neurons in 
an Nrf2 dependent manner 
Figure 3.1 Synthetic triterpenoid CDDO-F3 increases 
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CDDO-F3 and B/4AP treatment protect neurons in an additive 
manner 
Figure 3.9 CDDO-F3 and B/4AP treatment protect neurons in an 
additive manner 
Discussion 
GCL subunit mRNA expression is not regulated by Nrf2 in neurons 
CDDO-F3 is potently neuroprotective 
CDDO-F3 and B/4AP treatment have an additive neuroprotective 
effect 
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Neurons of the central nervous system (CNS) allow their host organism to adapt and 
survive to their environment.  Analogously, neuroprotective pathways exist that 
allow neurons to adapt and survive against the varied intrinsic and extrinsic stressors 
of their environment.  These pathways are vital, in particular within the adult 
mammalian nervous system, where regeneration and de novo generation of neurons 
is severely limited: the majority of these neurons must literally last a lifetime.  
Interest in the neuroprotective pathways of the CNS has piqued due to the rising 
incidence of neurodegenerative diseases: some of which are considered to occur 
through an attenuation of intrinsic neuroprotective pathways (Rosen et al., 1993); 
whilst augmenting the activity of certain pathways has been shown to protect against 
models of neurodegenerative disease (Reglodi et al., 2004; Tamas et al., 2006a; 
Vargas et al., 2008; Stack et al., 2010). 
 
Of particular interest to me are the neuroprotective pathways regulated by 
electrical/synaptic activity, often mediated through signalling by the N-methyl D-
aspartate receptor (NMDAR) (Hardingham and Bading, 2010).  Signalling via the 
NMDAR provides a convergence of pathways that allow neurons to adapt to the 
environment.  Specific patterns of NMDAR stimulation can cause changes of 
synaptic responses, or connectivity (Bliss and Lomo, 1970; Kind and Neumann, 
2001); NMDAR activation may also regulate neuroprotective pathways (Papadia et 
al., 2008; Martel et al., 2009b; Zhang et al., 2009).  Neuronal damage may be caused 
by a variety of stressors, which may be presented in a dynamic fashion throughout 
the lifespan of an organism; thus it is instructive that a receptor intrinsically linked 
with the adaptive responses of neurons may also regulate protective responses. 
 
The data presented in this thesis focuses on activity-dependent neuroprotection and 
how it interacts with other signalling pathways to protect against apoptotic and 
oxidative insults.  This introduction shall attempt to briefly summarise some of the 
current knowledge of the causes of neuronal damage/death and the protective 
pathways that attenuate neuronal damage.  Thus the topics contained in this 
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introduction shall include the NMDAR; neuronal death and anti-apoptotic pathways; 
and oxidative stress and the regulation of antioxidant pathways. 
 
2.1 The NMDA receptor 
 
NMDARs are ionotropic receptors gated by glutamate, the predominant excitatory 
neurotransmitter in the CNS.  NMDARs are present on a number of cell types 
including astrocytes (Krebs et al., 2003), oligodendrocytes (Kolodziejczyk et al., 
2009) and chondrocytes (Ramage et al., 2008).  However NMDARs are 
predominantly expressed in neurons where they mediate glutamatergic 
neurotransmission in the CNS, in concert with α-amino 3-hydroxy 5-methyl 4-
isoxazolepropionic acid receptors (AMPARs) and Kainate receptors.  In contrast to 
other glutamatergic receptors, NMDARs require co-activation with glycine, and are 
blocked at resting membrane potential by Mg
2+
, which is released only after neuronal 
postsynaptic depolarisation; making them both ligand and voltage gated, which 
causes them to act as coincidence detectors of synaptic activity. 
 
Another important aspect of NMDAR function is their permeability to Ca
2+
.  





 influx through NMDARs causes the recruitment of Ca
2+
 
dependent signalling molecules, either directly or through Ca
2+
 binding proteins such 
as calmodulin (Burgoyne, 2007).  Acting as a secondary messenger, Ca
2+
 imparts the 
potential for NMDARs to elicit long lasting changes to the neuron, in both 
excitability and gene expression.  Differences in the consequences of NMDAR 
mediated Ca
2+
 influx are dependent on the intensity of NMDAR stimulation, and 
specifics of the NMDARs activated. 
 
Neuronal NMDARs vary in two important aspects: subunit composition, and cellular 
location.  They are heterotetramers, consisting of two obligatory glycine-binding 
NR1 subunits, and two NR2 subunits which contain the glutamate binding sites.  A 
less common glycine binding NR3 subunit exists, that can replace one or both NR2 
subunits, resulting in a glutamate-insensitive glycine-gated NMDAR (Chatterton et 
 4 
al., 2002).  There are four different NR2 subunits A-D, each differing in their affinity 
to glutamate, and channel properties (Monyer et al., 1992).  The most prevalent in 
the CNS are NR2A and NR2B (with the exception of cerebellum where NR2C is 
predominant), existing either separately or as NR1/NR2A/NR2B heterotetramers 
(Sheng et al., 1994).  Their expression is developmentally regulated; in rodents 
NR2B subunits are highly expressed embryonically, with a subsequent post-natal 
decline, whilst NR2A subunit expression is severely limited in the first week of life, 
with expression increasing into adulthood (Monyer et al., 1994).  With some notable 
presynaptic exceptions (Duguid and Smart, 2004), NMDARs are expressed 
postsynaptically at either synaptic or extra/perisynaptic sites.  Extrasynaptic 
NMDARs are predominantly (but not exclusively) NR2B containing (Tovar and 
Westbrook, 1999), and are activated by glutamate spillover.  Differences in NR2 
subunit expression and location influence the long-term consequences of NMDAR 
activation due to association with different signalling proteins. 
 
Post-synaptic NMDARs are coupled to a large multi-protein signalling complex, 
known as the post-synaptic density (PSD) due to its appearance under electron 
microscopy (Sheng and Hoogenraad, 2007).  The PSD is made up of various 
signalling and scaffolding proteins, held together by protein-protein interactions, the 
most predominant being the PDZ domains (Kim and Sheng, 2004).  Through PDZ 
interactions, the intracellular C-termini of NR2 subunits bind to membrane-
associated guanylate kinases (MAGUKs), which in turn bind to scaffolding proteins 
such as Shank and Homer, and signalling enzymes like neuronal nitric oxide 
synthase (nNOS), protein phosphatase 2b (calcineurin) and calmodulin-dependent 
protein kinase II (CaMKII).  MAGUKs, through PDZ containing protein stargazin, 
mediate synaptic targeting of AMPARs (Chen et al., 2000).  Thus association with 
the PSD facilitates NMDAR activation and signal transduction. 
 
The make up of the PSD varies with NMDA subunit composition and location.  
Dissimilarities between NR2A and NR2B C-termini determine specific signalling 
molecule interactions.  They show greater affinities for different MAGUKs; NR2B 
for SAP102 and NR2A for PSD-95 (Sans et al., 2000); whilst NR2B subunits 
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binding to CamKII is stronger than that of NR2A (Barria and Malinow, 2005).  
Extrasynaptic NR2 subunits associate with MAGUKs and other signalling 
molecules, however they do not form the dense signalling clusters of the PSD, 
appreciable by electron microscopy (Petralia et al., 2010). 
 




 influx allows the adaptation of the neuron, through changes 
in local signalling and gene expression, a process known as synaptic plasticity.  
Specific patterns of NMDAR stimulation may lead to increases (long-term 
potentiation (Bliss and Lomo, 1970)) or decreases (long-term depression (Mulkey 
and Malenka, 1992)) in neuronal excitability, and these are thought to underlie a 
cellular basis of learning and memory (Morris et al., 1986).  Similarly, NMDAR 
mediated changes in local signalling and gene expression can influence the health of 
the neuron, promoting survival or programmed death pathways.  It is beyond the 
scope of thesis to review the processes behind NMDAR dependent synaptic 
plasticity.  However it is instructive that many of the pathways that underlie synaptic 
plasticity also play an important role in the death/survival signalling of the NMDAR.  
Rather than death/survival being the severe conclusion of changes in synaptic 
plasticity; this convergence illustrates the required dynamic nature of neuronal health 
signalling.  Just as neurons will have to modulate their excitability to adapt to an ever 
changing environment, so will the signalling that controls their defences and 
survival.  Thus it is important to note that NMDAR signalling can influence neuronal 
health: its place within a spectrum of physiological states ranging from functional 
and protected to dysfunctional and vulnerable (Bell and Hardingham, 2011b).  
Before discussing these NMDAR regulated pathways in greater detail, the 
mechanisms of cell death shall first be introduced. This is not just to provide context; 
as certain aspects of cell death are under genetic control, and some neuroprotective 





3.1 Neuronal death and survival 
 
Neuronal death can be characterised through differences in their causes, morphology 
and the underlying biochemical processes that control them; however due to 
overlapping phenomenology unequivocal categorisation is fraught with difficulty 
(Kroemer et al., 2009).  The three most distinct categories are autophagy, necrosis 
and apoptosis, the latter two shall be discussed in greater detail in this introduction.  
Autophagy is a catabolic process whereby cellular organelles and cytoplasmic 
material are sequestered in double-membraned vesicles termed autophagosomes, 
wherein they are degraded by lysosomal enzymes generating ATP (Green et al., 
2011).  This process allows cells to generate energy when they lack nutrients, or to 
degrade potentially hazardous internal machinery such as damaged mitochondria 
(mitophagy).  Whilst these processes in general promote cell survival, autophagy 
sufficient to cause the degredation of the entire cell and its death also occurs; recent 
evidence suggests that the activation of survival-promoting and death-promoting 
autophagy are controlled by distinct signalling pathways (McPhee et al., 2010).  Also 
included in this introduction excitotoxicity, an NMDAR dependent cause of cell 
death that may cause both necrosis and apoptosis, shall be described.  Oxidative 
stress, which may act as both a cause and consequence of neuronal death shall be 
described in greater detail in a separate section of this introduction.  The pathways 
through which NMDARs signal to promote or impede cell survival shall be 
discussed.  A final sub-section of this chapter shall discuss the role of neurotrophic 
factors in promoting cell survival; data presented in this thesis describes the role of 
the neurotrophic factor PACAP in promoting synaptic-activity dependent 




Necrosis is characterised morphologically by swelling of the cell and its organelles, 
plasma membrane rupture and degeneration, and release of the cytoplasmic contents 
of the cell (Kerr et al., 1972; Holler et al., 2000; Edinger and Thompson, 2004).  In 
contrast with some other forms of cell death it is not associated with DNA 
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fragmentation, and is independent of caspases - key cysteinyl aspartate proteases that 
are essential for apoptosis.  Necrotic cell death has long been considered to be an 
uncontrolled form of cell death, occurring after severe cell trauma.  Recent evidence 
however suggests that necrosis, similar to other forms of cell death, is controlled by a 
defined signalling pathway regulated by receptor-interacting protein kinases (Holler 
et al., 2000; Oberst et al., 2011; Zhang et al., 2011a), though this programmed 
necrosis, or necroptosis, may be a separate modality of cell death in itself (Kroemer 
et al., 2009).  Since necrosis culminates with the release of cellular contents, it may 
lead to the death of neighbouring cells through release of inflammatory cytokines.  
Whilst this previously was considered evidence of necrosis as accidental and 
uncontrolled form of cell death, this release of pro-inflammatory signalling 
molecules has been shown to play an important role in the defence against viral 
infection (Edinger and Thompson, 2004).  Necrosis occurs during the initial acute 
phase of an ischemic or excitotoxic episode, as occurs during stroke.  Necrosis, as 
opposed to other forms of cell death, occurs during an ischemic episode when Ca
2+
 
entry into the cell through NMDARs is sufficient to cause ionic deregulation of the 
cell, causing Cl
-




Apoptosis is a form of programmed cell death, characterised by cellular and nuclear 
shrinkage (pyknosis), chromatin condensation and DNA fragmentation, with little or 
no morphological changes in cytoplasmic organelles (Kerr et al., 1972; Kroemer et 
al., 2009); in contrast to necrosis these are changes are caused by caspase mediated 
cleavage and are ATP dependent.  Apoptosis of a cell does not allow release of 
cytoplasmic contents and potential damage of neighbouring cells, and has thus long 
been considered a controlled form of cell death (Kerr et al., 1972).  Apoptosis is 
required for correct organogenesis in developing embryos, and is essential 
throughout life to eliminate cells that have suffered DNA damage, to prevent the 
formation of tumours.  Apoptosis plays a key role in the patterning of the CNS, with 
genetic ablation of key apoptotic regulators such as caspases 3 and 9 and Apaf1 
causing ectopic cell masses  in forebrain and increased embryonic lethality (Buss et 
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al., 2006).  Apoptosis may also occur in response to neuronal injury and during 
neurodegeneration, and thus is relevant in both physiology and pathophysiology 
(Thompson, 1995). 
 
Apoptosis may be activated by two pathways, one extrinsic the other intrinsic.  The 
extrinsic pathway is triggered by activation of dedicated transmembrane death 
receptors of the tumour necrosis factor superfamily (Ashkenazi and Dixit, 1998).  
Upon activation these receptors cluster, forming a death-inducing signalling complex 
at their intracellular domain (Riedl and Salvesen, 2007), that recruits apoptosis-
initiator enzymes caspase-8 or 10.  This results in the dimerisation of these caspases,  
which leads to their activation (Boatright et al., 2003).  The intrinsic pathway is 
triggered by the sensing the mitochondrial release of cytochrome-c, an essential 
component of the electron transport chain where it carries one electron between 
complexes III and IV, by the cytosolic protein Apaf-1 (Zou et al., 1997).  Apaf-1 
binds cytochrome-c, and then makes an ATP-dependent conformational change 
allowing it to form a signalling complex termed the apoptosome, which is made up 
of seven Apaf-1 molecules arranged in wheel-like structure (Riedl and Salvesen, 
2007).  This then recruits initiator enzyme caspase-9, which dimerises to its active 
form (Boatright et al., 2003).  The (reversible) activation of initiator caspases of the 
extrinsic and intrinsic apoptotic pathways, causes the cleavage of apoptosis-executor 
enzymes caspase-3 and 7, which in turn causes their irreversible activation (Riedl et 
al., 2001).  The cleavage of the substrates of these enzymes lead to the morphological 
changes associated with apoptosis. 
 
Apoptosis is regulated by the Bcl-2 family of proteins, which can promote or inhibit 
the initiation of apoptosis.  These proteins are characterised by 4 homologous 
domains (BH1-4) that are intrinsic to their activity. Bcl-2 family proteins can be 
grouped into three classes: anti-apoptotic members (e.g.: Bcl-2, Bcl-XL), multi-
domain pro-apoptotic members (e.g.: BAX, BAK) and pro-apoptotic proteins that are 
structurally divergent but with a conserved BH3 domain (BAD, BID, BIM and 
PUMA) (Youle and Strasser, 2008).  Once activated BAX or BAK form oligometric 
structures through BH3 domain binding that permeabilise the outer mitochondrial 
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membrane, allowing release of cytochrome-c (Tait and Green, 2010).  Bcl-2 and Bcl-
XL are localised to the mitochondrial membrane, and inhibit the formation of 
BAX/BAK mediated pores, through binding to BH3 domains.  The BH3 only Bcl-2 
members inhibit this interaction, disinhibiting BAX and BAK, by binding to the anti-
apoptotic Bcl-2 proteins (Youle and Strasser, 2008); and may trigger activation of 
BAX/BAK (Tait and Green, 2010).  Activity of Bcl-2 proteins is regulated by de 
novo gene expression and post-translational signalling cascades.  PUMA mRNA 
expression is upregulated by the tumour suppressor p53 in response to DNA damage 
(Nakano and Vousden, 2001), whilst BIM expression is regulated by the forkhead 
box transcription factor-3A (FOXO3a) in response to neurotrophic factor deprivation 
(Dijkers et al., 2000).  BAD is phosphorylated by Akt kinase (Zha et al., 1996) which 
sequesters it in the cytosol, loss of this signal allows its activation.  BIM provides a 
link between the extrinsic and intrinsic apoptotic pathways, its cleavage by caspase-8 
promotes its mitochondrial translocation to inhibit Bcl-2 (Zha et al., 2000).  Bcl-2 on 
the other hand, is regulated at a transcriptional level by CREB (Wilson et al., 1996) 
and is produced in response to neurotrophic factors (Riccio et al., 1999; Aubert et al., 
2006). 
 
Neuroprotective pathways regulated by synaptic activity are able to inhibit cell death 
by various mechanisms.  We recently observed an NMDAR dependent 
downregulation of PUMA, Apaf1 and caspase-9 mRNA by increased synaptic 
activity, which conferred protection through inhibition of the intrinsic apoptotic 
pathway (Leveille et al., 2010).  Other mechanisms by which synaptic activity may 




It was first reported over 50 years ago that sustained glutamate exposure caused 
neuronal death (Lucas and Newhouse, 1957), in a Ca
2+
 dependent process coined 
excitotoxicity (Olney, 1969; Choi, 1987).  During an ischemic episode, as occurs in 
stroke, a bolus of glutamate is released from dying cells due to reversal of ATP 
driven glutamate transporters (Rossi et al., 2000), causing excessive activation of 
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NMDARs and massive Ca
2+
 influx (Tymianski et al., 1993).  This creates an ionic 
deregulation of the cell, involving Cl- and water entry, causing the cell to burst and 
become necrotic; when cells are exposed to less extreme but still fatal doses of 
glutamate, Ca
2+
 causes mitochondrial depolarisation and cytochrome c release, which 
activates the apoptotic programmed cell death pathway of the cell (Choi, 1994, 
1996).  Excitotoxicity has been shown to mediate neuronal death in traumatic brain 
injury and epilepsy (Meldrum, 1991; Palmer et al., 1993; Biegon et al., 2004); and 
has also been implicated in neurodegenerative disorders such as ALS and 
Huntington’s disease (Roy et al., 1998; Zeron et al., 2002). 
 
Due to the extensive evidence of NMDARs role in excitotoxic injury, antagonist 
based therapies were considered, particularly for treatment of stroke; and showing 
some efficacy in vitro were put into clinical trials (McCulloch, 1992; Lipton and 
Rosenberg, 1994; Muir and Lees, 1995).  Unfortunately, none were successful 
(Birmingham, 2002; Ikonomidou and Turski, 2002).  The failure of these trials could 
be mitigated by some factors, such as an inability to consistently ensure drug 
administration during a defined therapeutic window; or the concentrations used, far 
lower than the equivalent in animal models, due to the psychotomimetic effects of 
NMDAR antagonists (Birmingham, 2002; Muir, 2006).  However this belies the 
adverse effect of NMDAR blockade; some of these drugs actually reduced survival 
rate of patients (Davis et al., 2000; Albers et al., 2001).  Concurrent with this highly 
publicised and expensive failure was the emergence of evidence of the neurotoxic 
effect of NMDAR blockade in animal models (Hwang et al., 1999; Ikonomidou et 
al., 1999; Pohl et al., 1999; Ikonomidou et al., 2000).  This led to the generation of a 
‘bell-shaped curve’ theory of NMDAR mediated toxicity, that both too much and too 
little NMDAR activation caused neuronal death (Lipton and Nakanishi, 1999).  
Advances in research of NMDAR dependent signalling has shown this to be an 
oversimplification; our current understanding of neuroprotective NMDAR signalling 





3.2a Synaptic and Extrasynaptic NMDAR Activity 
 
In the past decades two major additional factors have been determined that influence 
the consequence of NMDAR activation on neuronal health.  A site-specificity of 
NMDAR Ca
2+
 influx has been established, with synaptic NMDAR activation 
promoting neuronal health and survival pathways, whilst extrasynaptic NMDAR 
activation nullify these effects and signal to death-associated pathways (Hardingham 
and Bading, 2010).  A currently contentious issue is a further possible NR2 subunit 
specificity in determining the consequence of NMDAR activation (Kohr, 2006).  
Whilst it is intuitive that different signalling pathways would be preferentially 
associated with the specific C-termini of either NR2, and according examples have 
been observed associating NR2A with survival-associated pathways and NR2B with 
death-associated pathways (Liu et al., 2007; Chen et al., 2008; Tu et al., 2010); this 
subunit specificity has been disputed (von Engelhardt et al., 2007; Martel et al., 
2009a).  The discrepancy is due to the poor specificity of NR2A-specific antagonists, 
an often assumed but incomplete segregation of NR2A subunits to synaptic sites and 
NR2B to extrasynaptic sites (Thomas et al., 2006), and the enigmatic presence of 
NR2A/NR2B tetraheteromers.  A similar controversy surrounds the subunit 
specificity of synaptic plasticity (Massey et al., 2004; Berberich et al., 2005),  
 
The study of synaptic NMDAR signalling has been greatly advanced by work in 
vitro.  In neuronal cultures the GABAA receptor antagonist bicuculline causes a 
network disinhibition by releasing the predominantly excitatory neuronal population 
from tonic inhibition by interneurons (Hardingham et al., 2001b).  This treatment, as 
opposed to bath applied glutamate which would stimulate both synaptic and 
extrasynaptic NMDARs, has allowed delineation of the pathways triggered by 
specific increase of synaptic NMDAR activation.  Extrasynaptic NMDAR activation 
can be exclusively studied using the activity-dependent non-competitive NMDAR 
antagonist MK801, which binds irreversibly to open channel NMDARs (Foster and 
Wong, 1987; Tovar and Westbrook, 2002).  Stimulating with bicuculline and 
MK801, then washing to remove unbound antagonist, renders an extrasynaptic 
specificity to subsequent bath applied NMDA stimulation (Bordji et al., 2010; Dick 
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and Bading, 2010).  Using these methods, both post-translational changes in 
signalling and de novo gene expression have been observed, associated with 
NMDAR dependent signalling to neuronal health. 
 
3.2b The PI3K-Akt kinase signalling cascade 
 
The phosphoinositol-3-kinase (PI3K) and protein kinase B (or Akt kinase) cascade is 
pleiotropic signalling pathway that in neurons is vital in suppressing the expression 
of apoptotic genes.  PI3K activates Akt kinase indirectly, by mediating the synthesis 
of phosphatidylinositol trisphosphate which in turn recruits Akt to the plasma 
membrane; here Akt is activated through phosphorylation by phosphoinositide 
dependent protein kinase 1 (Brazil et al., 2004).  Phosphorylation of targets by 
activated Akt mediates the neuroprotective signalling by this cascade.  Akt activation 
mediates the phosphorylation and subsequent inactivation of glycogen synthase 
kinase-3 (Cross et al., 1995), phosphorylation and nuclear exclusion of pro-apoptotic 
transcription factor FOXO3a (Brunet et al., 1999; Al-Mubarak et al., 2009), and 
blocks the initiation of apoptosis by tumour suppressor p53 (Yamaguchi et al., 2001).  
Akt phosphorylates the BH3-only Bcl2 family member BAD, inhibiting its pro-
apoptotic activity (Zha et al., 1996).  Inhibition of the PI3K/Akt cascade enhances 
unstimulated neuronal death highlighting its basal requirement in suppressing 
apoptosis (Papadia et al., 2005) 
 
Synaptic NMDAR stimulation strongly activates PI3K through Ca
2+
 bound 
calmodulin (Joyal et al., 1997), with a robust anti-apoptotic effect (Papadia et al., 
2005; Soriano et al., 2006; Al-Mubarak et al., 2009).  Bath application of NMDA by 
contrast causes a minimal and transient PI3K/Akt activation, dependent on neuronal 
firing (Soriano et al., 2006; Papadia et al., 2008).  Whilst synaptic NMDAR 
activation causes nuclear exclusion of the pro-apoptotic transcription factor FOXO3a 
through activation of PI3K (Al-Mubarak et al., 2009), specific extrasynaptic 
NMDAR stimulation acts in direct opposition, causing active FOXO3a translocation 





Another key example of the directly opposing effects of synaptic and extasynaptic 
NMDAR activation is the cAMP response element binding protein (CREB).  CREB 
is a transcription factor, regulated by synaptic activity in neurons, where it plays an 
important role in synaptic plasticity and memory (Lonze and Ginty, 2002; Benito and 
Barco, 2010).  It is also vital for survival of central and peripheral neurons (Walton et 
al., 1999; Lonze and Ginty, 2002; Mantamadiotis et al., 2002), where its activation 
contributes to the neuroprotective effects of neurotrophins (Bonni et al., 1999; Riccio 
et al., 1999) and mediates a long-lasting neuroprotection by episodes of synaptic 
activity that lasts after subsequent suppression of NMDAR activation (Papadia et al., 
2005; Zhang et al., 2009).  CREB target genes include negative-regulator of 
apoptosis Bcl2 (Riccio et al., 1999), the neuroprotective peroxisome proliferator-
activated receptor-γ coactivator-1α (PGC-1α) (Soriano et al., 2011) and neurotrophic 
factors BDNF (Shieh et al., 1998; Tao et al., 1998) and PACAP (Fukuchi et al., 
2005; Martel et al., 2009b).  Some of the data presented in this thesis is a result of 
investigation of the neuroprotective properties of PACAP; accordingly neurotrophic 
factors shall be discussed in further detail in this introduction. 
 
CREB activation by synaptic NMDAR stimulation is mediated through the activation 
of Ca
2+
/calmodulin kinases including the Ras-ERK 1/2 pathway and CamKIV 
(Hardingham et al., 2001a; Soriano and Hardingham, 2007).  These mediate its 
phosphorylation at serine-133, allowing its association with CREB binding protein 
(CBP) a transcriptional co-factor that is necessary for transcription from CRE sites 
(Chrivia et al., 1993).  Extrasynaptic NMDAR stimulation however signals to a 
dominant CREB shut-off pathway, that supersedes CREB activation by synaptic 
activity (Hardingham et al., 2002).  This is caused by dephosphorylation of ERK 1/2 
kinases (Ivanov et al., 2006; Leveille et al., 2008) that limit CREB activation.  In 
addition extrasynaptic NMDAR Ca2+ promotes the nuclear localisation of Jacob 
which causes the dephosphorylation of CREB (Dieterich et al., 2008). 
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Another NMDAR/CREB regulated modulator of gene transcription is PGC-1α (St-
Pierre et al., 2006; Soriano et al., 2011).  A key metabolic regulator (Puigserver and 
Spiegelman, 2003), its expression in neurons is strongly protective (St-Pierre et al., 
2006; Volakakis et al., 2010; Soriano et al., 2011).  The loss of PGC-1α activity in 
Huntington’s disease has been demonstrated to be a key aspect of the pathology. 
Mutant-huntingtin protein, the causative agent of the disease which is characterised 
by its cellular aggregation (Wanker, 2000), directly interferes with its CREB 
mediated transcription (Cui et al., 2006) causing neuronal mitochondrial dysfunction.  
This has recently been shown to be exacerbated by extrasynaptic NMDAR activity, 
which is increased in Huntington’s disease models (Milnerwood et al., 2010), as this 
impairs PGC-1α expression through synaptic NMDAR signalling (Okamoto et al., 
2009).  Intriguingly, blockade of extrasynaptic NMDARs by the antagonist 
memantine (which preferentially blocks NMDA at extrasynaptic sites at lower doses) 
protected disease model neurons (Okamoto et al., 2009; Milnerwood et al., 2010); 
thus in this disease, selective blockade of extrasynaptic NMDAR but retention of 
synaptic NMDAR signalling pathways offers a potentially viable therapeutic 
strategy. 
 
3.3 Neurotrophic Factors 
 
Neurotrophic factors are signalling molecules released from cells, which through 
activation of transmembrane receptors promote neuronal survival.  Neurotrophic 
factor signalling plays a vital role in the development and patterning of the CNS; 
however signalling continues in mature neurons, and has been shown to have potent 
neuroprotective properties in adult CNS.  Two neurotrophic factors that have 
received considerable attention are brain derived neurotrophic factor (BDNF), and 




First isolated from pig brain (Barde et al., 1982), BDNF has been the subject of 
considerable study due to its diverse roles in both developing and mature CNS.  It 
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promotes its effect through activation of two receptors; tyrosine kinase receptor B 
(TrkB), and the low affinity neurotrophin receptor p75 (Lewin and Barde, 1996).  
Activation of its receptors by BDNF can activate a variety of internal signal 
transduction cascades, including the PI3K, Ras-ERK 1/2 and phospholipase C 
pathways (Huang and Reichardt, 2001).  BDNF signalling has been shown to 
modulate neuronal plasticity, stimulating hippocampal long-term potentiation (Kang 
and Schuman, 1995; Huang and Reichardt, 2001).  BDNF promotes neuronal 
survival through a number of mechanisms.  Through its activation of the PI3K/Akt 
signalling cascade, it promotes the nuclear exclusion of the pro-apoptotic 
transcription factor FOXO3a (Zheng et al., 2002).  BDNF limits ROS formation 
caused by excitotoxic NMDA administration in vitro by stimulating the activity of 
the GSH antioxidant pathway, increasing both GR and GPX activity (Mattson et al., 
1995).  BDNF stimulates the phosphorylation of the neuroprotective transcription 
factor CREB and subsequent CRE dependent gene transcription by activation of both 
CaMKIV and Ras-ERK 1/2 (Finkbeiner et al., 1997).  Due to its role in CNS 
patterning, BDNF knockout mice display abnormalities in sensory neuron 
development and die within the first few weeks of life (Jones et al., 1994; Conover et 
al., 1995).  Genetic ablation of TrkB causes a more severe phenotype, with knockout 
mice dying shortly after birth (Klein et al., 1993), demonstrating that other 
neurotrophic factors can activate TrkB.  In humans, a polymorphism in the BDNF 
gene that disrupts its secretion is associated with deficits in declarative memory 
(Hariri et al., 2003). 
 
Hippocampal BDNF mRNA expression is increased in response to exercise, 
mediating some of the beneficial effects on the CNS of increased exercise (Cotman 
and Berchtold, 2002).    At a cellular level, BDNF mRNA expression is regulated by 
CREB (Shieh et al., 1998; Tao et al., 1998), accordingly is upregulated by stimuli 
that increase the activity of this transcription factor.  BDNF expression is upregulated 
by synaptic NMDAR activity (Hardingham et al., 2002); this constitutes a key 






Pituitary adenylate cyclase-activating peptide (PACAP) is a neuropeptide first 
isolated from the hypothalamus as an activator of cAMP production in pituitary cells 
(Miyata et al., 1989).  It exists in 27 and 38-amino acid forms and binds to three G-
protein coupled receptors named PAC1, VPAC1 and VPAC2 which are 
predominantly coupled to Gαs that promote cyclic adenosine monophosphate 
(cAMP) production through the activation of adenylate cyclase (AC) (Dickson and 
Finlayson, 2009).  PACAP and its receptors are expressed widely in the CNS, where 
one of their key functions is neuroprotection.  PACAP promotes the protection of 
cerebellar granule neurons against apoptotic and oxidative insults including 
ceramide, ethanol and H2O2 (Vaudry et al., 2009).  PACAP also protects cortical and 
hippocampal neurons against excitotoxic and apoptotic insults (Shioda et al., 1998; 
Vaudry et al., 2009).  In vivo administration of PACAP reduces neuronal loss and 
neurological deficits in models of stroke and traumatic brain injury (Reglodi et al., 
2002; Chen et al., 2006; Tamas et al., 2006b; Vaudry et al., 2009), excitotoxic striatal 
lesions (Tamas et al., 2006a) and Parkinson's disease (Reglodi et al., 2004; Reglodi 
et al., 2006).  Given this, PACAP has received considerable attention as a potential 
therapeutic neuroprotective drug (Somogyvari-Vigh and Reglodi, 2004; Shioda et al., 
2006; Brenneman, 2007; Ohtaki et al., 2008; Vaudry et al., 2009). 
 
PACAP promotes neuroprotection by acting directly on neuronal PACAP receptors 
(Vaudry et al., 2009).  The molecular mechanisms that underlie this neuroprotection 
centre on activation of the cAMP-dependent protein kinase A (PKA), a major 
effector of intracellular cAMP (Botia et al., 2007; Vaudry et al., 2009).  Activation of 
de novo gene expression has been implicated in PACAP-mediated neuroprotection, 
including c-Fos, BDNF, Bcl-2 and PACAP itself (Frechilla et al., 2001; Falluel-
Morel et al., 2004; Fukuchi et al., 2004; Miyashita et al., 2005; Shintani et al., 2005; 
Aubert et al., 2006; Dejda et al., 2008).  Of note, these genes are all regulated by the 
CREB family of transcription factors.  PACAP is known to promote CREB 
activation under conditions where it is neuroprotective (Racz et al., 2006; Falktoft et 
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al., 2009), however a causal link between these two phenomena has yet to be 
determined. 
 
It is generally assumed that PACAP-mediated PKA signalling in neurons triggers 
neuroprotective gene expression and signal pathways by direct modulation of 
upstream effectors of these processes.  However data presented in this thesis 
proposes an alternative explanation: that PACAP-induced PKA signalling exerts at 
least some of its neuroprotective effects indirectly though the enhancement of 
electrical activity.  G-protein coupled receptors that activate cAMP/PKA signals in 
neurons, such as type I mGluRs and D1-type dopamine receptors, can potentiate 
synaptic strength, neuronal excitability and ion channel properties (Nguyen and 
Woo, 2003).  PACAP administration has been recently reported to enhance AMPAR 
currents as well as synaptic NMDAR currents (MacDonald et al., 2007; Costa et al., 
2009) and to suppress the apamin-insensitive slow after-hyperpolarization (IsAHP) 
current (Hu et al., 2010), which can control neuronal excitability.  Data presented in 
this thesis demonstrates an increase in neuronal action potential firing activity, which 
is required for PACAP mediated neuroprotection: thus PACAP could regulate 
neuronal health by influencing neuronal excitability. 
 
4 Oxidative stress and antioxidant defences 
 
The oxidative stress theory of ageing (Harman, 1956) proposes that reactive oxygen 
species (ROS) are the causative agents of the diverse deleterious changes, that over 
time increase the chance of cell dysfunction and death with age.  Whilst this may be 
an oversimplification and has not been unequivocally proved (Shi et al., 2010), the 
damage caused by ROS is a hallmark of many neuronal pathologies (Coyle and 
Puttfarcken, 1993; Dawson and Dawson, 2003; Lin and Beal, 2006; Herring et al., 
2010).  In healthy cells ROS are neutralised by antioxidant pathways; when this 
becomes unbalanced in favour of ROS, oxidative stress occurs.  Oxidative stress is 
associated with a number of neurodegenerative diseases such as ALS (Rosen et al., 
1993), and neuronal injury such as  ischemia (Chan, 2001).  Neurons are particularly 
vulnerable to oxidative stress for several reasons.  They show low expression of 
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antioxidant enzymes, in particular catalase (Mavelli et al., 1982), in comparison to 
other cell types.  Furthermore, certain neuronal signalling pathways are associated 
with the production of ROS (or reactive nitrogen species), either as a by-product or 
as the signalling molecule itself.  We recently observed the upregulation of genes 
that promote antioxidant pathways by synaptic activity (Papadia et al., 2008), 
indicating that the regulation of antioxidants may be a vital protective pathway 
required for neuronal survival.  Data presented in this thesis demonstrates the 
hitherto unobserved upregulation of the antioxidant glutathione pathway by synaptic 
activity.  The neuroprotective potential of this upregulation, in concert with an 
alternative drug treatment previously established to regulate the glutathione pathway 
is also demonstrated.  In this chapter, the sources and formation of ROS, the 
antioxidant pathways that neutralise them, and the transcriptional regulation of 
antioxidants shall be discussed. 
 
4.1 Reactive oxygen and nitrogen species 
 
Free radicals are any atom, ion or molecule that contains unpaired electron orbitals, 
that are capable of independent existence (Halliwell, 1992).  The majority of free 
radicals are highly reactive and thus short lived, a notable exception being molecular 
oxygen O2; which contains two singlet electrons with the same spin number, which 
limits its reactivity.  Due to this parallel spin, oxygen will preferentially react one 
electron at a time.  Oxygen is of course the electron acceptor required for energy 
production through aerobic respiration in the mitochondria of all higher organisms.  
However, whilst oxygen is required for aerobic life, high concentrations of oxygen 
have long been known to be toxic (Gerschman et al., 1954); with enhanced toxicity 
closely correlated to increased metabolism. 
 
Within the electron transport chain of mitochondria, cytochrome-c oxidase (complex 
IV) reduces O2 to H2O through the addition of four electrons; this reduction occurs in 
a step-wise fashion with partially reduced forms of oxygen bound to metal ions in the 
enzyme.  However, premature “leakage” of electrons from complexes I and III react 
with oxygen to form the radical superoxide O2·
- 
(Boveris and Chance, 1973; Turrens, 
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1997; Brookes, 2005).  Put simply, the mitochondrial production of superoxide is 
largely regulated by two factors: the presence of oxygen to act as an electron 
acceptor, and flow of electrons across the electron transport chain (Turrens, 2003).  
Thus increased oxygen concentration will increase superoxide formation, as will 
impediment of electron transfer through the respiratory chain.  Transfer of electrons 
through the electron transport chain is influenced by the mitochondrial membrane 
potential (∆Ψm), as this determines the protonmotive force that drives ATP synthase.  
Elevated aerobic respiration increases ∆Ψm, which can lead to an insufficiency of 
the substrate ADP, causing reduction of the respiratory chain, allowing the 
monovalent reaction of electrons with O2 (Turrens, 2003).  Damage of members of 
the electron transport chain by ROS or reactive nitrogen species also increases O2·
- 
formation (Bolanos et al., 1995; Duchen, 2000).  Reduction of oxygen concentration 
reduces mitochondrial respiration through inactivation of complex I; however 
subsequent reperfusion of oxygen causes O2·
- 
production until this inactivation can 
be reversed (Galkin et al., 2009). 
 
Mitochondria import cytoplasmic Ca
2+
, which increases aerobic respiration and ATP 
synthesis (Jouaville et al., 1999; Duchen, 2000; Duchen et al., 2008).  Mitochondrial 
Ca
2+
 uptake initially reduces ∆Ψm (Garcia et al., 2005), with the increase of 
mitochondrial respiration a compensatory mechanism.  Ca
2+
 entry through NMDARs 
increases mitochondrial respiration, stimulating O2·
- 
formation (Dugan et al., 1995; 
Reynolds and Hastings, 1995; Garcia et al., 2005).  Superoxide is also generated in 
response to extrinsic stimuli such as xenobiotics (Cohen and d'Arcy Doherty, 1987; 
Savolainen et al., 1998) ultra-violet radiation (Devary et al., 1992); and 
enzymatically by a number of enzymes.  One of the most relevant to neurons is 
NADPH oxidase, which has been shown to be the primary source of O2·
- 
formation 
after NMDAR stimulation (Brennan et al., 2009); an observation that is testament to 




is not itself the most reactive of ROS, it is membrane permeable and thus 
able to cause widespread oxidative damage throughout the cell.  O2·
- 
is quickly 
dismutated to H2O2 by superoxide dismutase enzymes (SOD) (Weisiger and 
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Fridovich, 1973).  Mutations in the cytoplasmic Cu/Zn SOD1 gene are associated 
with ALS (Rosen et al., 1993), and mitochondrial Mn SOD2 knockout mice exhibit 
marked mitochondrial damage and neurodegeneration and survive for only three 
weeks (Lebovitz et al., 1996).  H2O2
 
is also produced in neurons by monoamine 
oxidase, as a by-product of the catabolism of dopamine (Halliwell, 1992; Coyle and 
Puttfarcken, 1993).  Recent evidence suggests that H2O2, produced indirectly through 
activation of NADPH oxidase and subsequent O2·
- 
dismutation, may act as a 
secondary messenger in neurons (Avshalumov et al., 2005; Forman et al., 2010; 
MacFarlane et al., 2011).  Whilst it is itself toxic at high concentrations, H2O2 can 
react with Fe
2+
 ions to form the more dangerous hydroxyl radical (·OH) by the 




 + H2O2 → Fe
3+




Hydroxyl radicals are extremely reactive, and quickly react with membrane lipids, 
carbohydrates and DNA.  ·OH is able to abstract a hydrogen atom from the DNA 
deoxyribose phosphate backbone, causing strand cleavage (Hertzberg and Dervan, 
1984).  Abstraction of hydrogen atoms from lipid side chains by ·OH produces a 
carbon-centred lipid radical, which through reaction with oxygen and neighbouring 
lipids sets of a free radical chain reaction, both self propagating and producing more 
lipid hydroperoxides (Halliwell, 1992).  ·OH can also react with neurotransmitter 
dopamine, producing the toxin 6-hydroxydopamine (Slivka and Cohen, 1985).  If 
oxidative damage is sufficient, apoptotic pathways are activated, destroying the cell.  
In contrast with other ROS, ·OH do not have a dedicated enzymatic antioxidant 
pathway that specifically neutralises them, though evidence suggests that they can be 
neutralised by broad-specificity antioxidants such as ascorbate and thioredoxins 
(Cohen, 1994; Das and Das, 2000).  This is perhaps indicative of the transient 
lifespan of ·OH radicals, and their quick reaction with substrates; and accordingly the 
importance of neutralising H2O2 before it can form ·OH radicals. 
 
Reactive nitrogen species may also have a cytotoxic effect.  Nitric oxide (NO), is 
produced by nitric oxide synthase in response to NMDAR activation, and modulates 
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neuronal excitability through nitrosylation of free cysteine residues of ion channel 
and neurotransmitter receptors, and through stimulating production of the secondary 
messenger cGMP by the enzyme guanylate cyclase (Baranano et al., 2001; Ahern et 
al., 2002).  Reaction of NO with O2·
- 
produces the anion peroxynitrite (ONOO
-
), 
which is itself reactive and toxic but may also degrade to ·OH (Halliwell, 1992).  
Both NO and ONOO
-
 can cause inhibition of the mitochondrial electron transport 
chain, that may lead to cell death (Heales et al., 1999); though the toxic effect of NO 
overproduction (but not ONOO
-
) can be largely attenuated by O2·
- 
scavenging by 
superoxide dismutases (Lipton et al., 1993), indicating that ONOO
-
 is the more 
potent toxin. 
 
4.2 Antioxidant Pathways 
 
Oxidative stress occurs when there is an imbalance between the production of ROS 
and the cell’s capacity to deal with them through antioxidant systems.  There are a 
number of heterogeneous antioxidant molecules and associated enzymes within the 
CNS; whilst some share substrate specificity, specific localisation largely limits the 
redundancy between pathways.  Antioxidant molecules/enzymes in the CNS include 





GSH (Hopkins, 1921) is a tripeptide of atypical linkage, consisting of glutamate, 
glycine and cysteine; containing an isopeptide bond between the γ carboxy side chain 
of glutamate and the amine group of cysteine, with a regular peptide link between 
cysteine and glycine.  It is the most abundant thiol containing compound in 
mammalian cells (Meister and Anderson, 1983).  GSH is the electron donor in the 
reduction of peroxides to water catalysed by the enzyme glutathione peroxidase 
(GPX) (Mills, 1957).  GPXs are homotetrameric enzymes, with the exception of 
GPX4 which is a monomeric enzyme that is able to reduce lipid hydroperoxides (Lu 
and Holmgren, 2009).  So far 8 GPXs have been identified through sequence 
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homology (though some do not contain the vital selenocysteine active site and 
consequently do not show GPX activity (Nguyen et al., 2011)).  The five 
selenocysteine containing GPXs are segregated in their localisation at either whole 
body or sub-cellular level: GPX1, the most prevalent, is ubiquitously found in 
cytosol, GPX2 is largely gastrointestinal specific, GPX3 is extracellular and 
concentrated in plasma, GPX6 is mainly localised to the olfactory bulb (Brigelius-
Flohe, 1999; Lu and Holmgren, 2009).  GPX4 is localised to lipid membranes, where 
it maintains membrane integrity; its importance is highlighted by the embryonic 
lethality of GPX4 knockout, in comparison to other GPX knockouts which are viable 
despite a sensitisation to oxidative stress (Brigelius-Flohe, 2006).  Reduction of H2O2 
or lipid hydroperoxides by GPXs can be expressed as the following formula: 
ROOH + 2 GSH → ROH + H2O + GSSG 
 
Reduction of peroxides by GPX is a three step process: the selenocysteine active site 
is oxidised to selenic acid by peroxide, this then reacts with GSH releasing H2O, this 
GSH-GPX intermediate is then reduced by GSH back to the slenoate anion form 
producing glutathione disulfide (GSSG).  This two step process impedes the 
stabilisation of potentially damaging thiyl radicals from GSH, which may occur in 
highly oxidising conditions (Cohen, 1994).  GSSG is then recycled back to GSH by 
glutathione reductase (GR) (Conn and Vennesland, 1951; Mapson and Goddard, 
1951), which transfers an electron from reduced nicotinamide adenine dinucleotide 
phosphate (NADPH). Whilst there is both separation and overlap in the various 
peroxide degrading pathways, the GPX pathway is thought to be the most vital in 















Figure I.1. Catalytic Redox Cycle of GSH.  Selenocysteine in the glutathione 
peroxidase (GPX) active site is oxidised to selenic acid by H2O2 or lipid 
hydroperoxides, then reduced by GSH in a two-step process back to the selenolate
anion form.  GSSG is then reduced to two molecules of GSH by the NADPH 




GSH may also react non-enzymatically with oxidised thiols, forming a disulfide 
bond.  These are reduced by the glutaredoxin (GRX) family of enzymes.  In 
mammalian cells two GRXs have been identified, cytosolic GRX1 and mitochondrial 
GRX2 (Gladyshev et al., 2001).  These enzymes maintain the thiol redox status of 
proteins within the cell.  They contain two cysteines within their active site that act 
as reducing equivalents, forming a disulfide bond.  In a manner similar to GPX, this 
is subsequently reduced in a two step process by GSH, producing GSSG, which is 
subsequently reduced by GR (Holmgren, 1989; Beer et al., 2004).  GRX2 maintains 
the complex I redox status within the electron transport chain, preserving 
mitochondrial function during oxidative stress (Karunakaran et al., 2007). 
 
GSH is also the substrate of glutathione S-transferase (GST) (Booth et al., 1961), 
which forms GSH-conjugates to proteins through Michael-addition, which are then 
excreted from the cell by transmembrane multidrug resistance proteins such as 
MRP1 (Cole and Deeley, 2006).  This pathway is key in defending the cell from 
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xenobiotic compounds (Hayes et al., 2005).  GSH may also act as a cellular reservoir 
for cysteine, which would otherwise auto-oxidise to cystine (Cotgreave and Gerdes, 
1998). 
 
Under normal conditions GSH is found in it reduced form, due to the activity of GR 
(Meister and Anderson, 1983); however after periods of oxidative stress, which 
significantly reduce the GSH:GSSG ratio, then de novo GSH synthesis is required.  
Glutathione synthesis requires the action of two ATP-dependent enzymes γ 
glutamyl-cysteine ligase (GCL) and glutathione synthetase (GSS).  GCL is a 
heterodimer consisting of a catalytic (GCLC) and modulatory (GCLM) subunit.  
GCLC is the larger subunit, containing the active site responsible for the ATP-
dependent bond formation between cysteine and the γ-carboxyl group of glutamate.  
This ligation is the rate-limiting step of GSH synthesis, and levels of GCLC and 
bioavailability of cysteine are considered to be the two key determinant factors 
influencing cellular GSH content (Griffith, 1999); accordingly GCLC knockout in 
mice causes embryonic lethality (Dalton et al., 2000).  GCLM is smaller, and has no 
catalytic properties on its own, but serves to increase activity of GCL by decreasing 
Km for glutamate and ATP (Yang et al., 2007); though GCLC may catalyse γ-
glutamylcysteine (γGC) synthesis in the absence of GCLM.  The activity of GCL 
may also be modulated by post-translational modification; phosphorylation of the 
active site of GCLC by PKA, CAMKII and protein kinase C lead to a decrease in 
GCL activity (Sun et al., 1996); further evidence suggests modulation by 
myristoylation and oxidation (Franklin et al., 2009).  Another important modulation 
of GCL activity is non-allosteric inhibition of the catalytic site by GSH itself 
(Richman and Meister, 1975), thus providing a direct negative feedback of GSH 
synthesis.  GCLM reduces the Ki of GCL by GSH (Huang et al., 1993), thus 
increasing the activity of the enzyme.  GSS binds glycine to the cysteine moiety of 
γGC; this enzyme is not as well studied as GCL, though its deficiency in humans 




Within the CNS, GSH and the enzymes responsible for its synthesis are found in 
greater concentration in astrocytes than neurons (Raps et al., 1989).  Synthesis of 
GSH in astrocytes has been shown to protect neurons from oxidative insult (Dringen 
et al., 1999; Shih et al., 2003), and co-culturing of astrocytes with neurons increases 
neuronal GSH levels (Diaz-Hernandez et al., 2005).  Astrocyte GSH synthesis is 
thought to “feed” neuronal GSH levels, exporting GSH via the transporter MRP1 
(Minich et al., 2006).  Neurons do not express GSH uptake transporters (Vargas and 
Johnson, 2009), thus it is believed that GSH exported from astrocytes is subsequently 
hydrolysed to its precursors in the extracellular space; first to cysteine-glycine by 
γglutamyl-transpeptidase (Dringen et al., 1997a), which is then split by 
aminopeptidase N (Dringen et al., 2001).  Cysteine, which is considered to be the 
limiting substrate in GSH synthesis (Vargas and Johnson, 2009), is imported by 
excitatory amino acid transporters (EAATs); genetic ablation of EAAT3 causes a 
reduction of neuronal GSH levels (Aoyama et al., 2006).  Cysteine is readily 
oxidised to cystine in the extracellular space, and neurons, in contrast to astrocytes, 
do not express the cystine/glutamate exchange transporter XCT (Sato et al., 2002), 
and cannot utilise cystine for GSH synthesis.  Thus extracellular hydrolysis of GSH 













































Figure I.2. GSH Synthesis in Neurons and Astrocytes. γGlutamyl-
cysteine ligase (GCL) catalyses the binding of γ-carboxyl chain of 
glutamate and the N-terminus of cysteine, γglutamylcysteine is bound to 
glycine by GSH synthetase (GSS), forming GSH.  GSH synthesis is 
greater in astrocytes than neurons.  GSH is exported from astrocytes by 
transporter MRP1.  Extracellular GSH is hydrolysed, first by γGlutamyl 
transpeptidase (γGT) to cysteine-glycine, then Aminopeptidase N (Apep-
N), releasing cysteine.  Neurons import cysteine by excitatory amino acid 
transporters (EAAT).  Astrocytes express glutamate/cystine antiporter 
XCT, allowing them to import cystine for utilisation in GSH synthesis.  
Data presented in this thesis suggest that γglutamylcysteine may be taken 
up by neurons; GSH could be hydrolysed by carboxypeptidases (CbxP) to 
produce this dipeptide, however a neuronal γglutamylcysteine transporter 
has not yet been identified (adapted from (Shih et al., 2003)). 
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Pharmacological depletion of GSH by the potent GCL inhibitor buthionine 
sulfoximine (Griffith and Meister, 1979) causes neuronal mitochondrial damage 
(Jain et al., 1991), and a sensitisation to oxidant damage (Mizui et al., 1992; 
Wullner et al., 1996).  Moreover GSH depletion has been implicated in several 
neurodegenerative diseases, such as ALS (Chi et al., 2007; Babu et al., 2008), 
Alzheimer’s disease (Liu et al., 2004) and Parkinson’s disease (Perry et al., 
1982), where its loss from the substantia nigra is pre-symptomatic and one of 
the first biochemical markers of the pathology.  Thus the importance of GSH 
levels in neurons is well documented, and therapeutic strategies have been 
developed that aim to maintain GSH levels in neurons, through supplementation 
with membrane-permeable ethyl-ester forms of GSH or γGluCys (Drake et al., 
2002), or through upregulation of GCL subunit mRNA expression (Vargas et 
al., 2008). 
 
4.2b Ascorbic acid 
 
The human necessity for ascorbate (vitamin C) is commonly associated with its role 
in the stimulation of collagen synthesis, with deficiency of dietary ascorbate causing 
scurvy (Peterkofsky, 1991).  However in the body ascorbate is most concentrated in 
the CNS (Hornig, 1975), where it acts as a neuromodulator, enzyme co-factor and 
antioxidant.  Ascorbate acts as a broad-spectrum free radical scavenger, neutralising 
both ROS and RNS to form its oxidation products semi-dehydroascorbate (ascorbyl 
radical – one electron oxidation) and dehydroascorbate (two electron oxidation) 
(Rice, 2000).  Oxidised ascorbate is either degraded, or reduced (and thus recycled) 
by GSH utilising enzymes GRX and dehydroascorbate reductase (Meister, 1994; 
Fornai et al., 1999).  Intravenous injection of either ascorbate or dehydroascorbate 
produce similar increases in reduced ascorbate levels in the CNS, whilst CNS 
ascorbate levels are maintained during limiting conditions to a greater extent in 
comparison to other organs, suggesting that ascorbate is actively maintained by GSH 
dependent recycling in the CNS (Hornig, 1975; Rice, 2000).  The broad substrate 
specificity of ascorbate means it can neutralise ·OH and ONOO
-
 radicals, which in 
contrast to O2·
- 
or H2O2 are not neutralised by a specific enzymatic antioxidant 
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pathway (Cohen, 1994).  Ascorbate can compensate for loss of GSH in cells, and 
vice versa: administration of membrane permeable GSH ethyl ester prevents the 
onset of scurvy in ascorbate deficient guinea pigs (which unlike rats/mice and similar 
to humans cannot synthesise ascorbate); whilst ascorbate administration prevents 
tissue damage caused by BSO treatment (GCL inhibition) (Meister, 1994).  Within 
cells of the CNS, ascorbate is found in greater concentrations in neurons than 
astrocytes, a reversal of the observed localisation of GSH (Rice, 2000).  The GSH 
dependence of ascorbate recycling further highlights the importance of the GSH 
antioxidant pathway in neutralising ROS in the CNS. 
 
4.2c Thioredoxins and peroxiredoxins 
 
The thioredoxin (Trx) family of enzymes are thiol based reducing enzymes, typified 
by a conserved active site (Cys-Gly-Pro-Cys).  The active site of Trx reduces 
disulfide binds of proteins that occur due to oxidative stress, accepting an electron 
which in turn causes the formation of a disulfide bond between the cysteines of the 
active site (Holmgren, 1989).  This inactivates the enzyme; subsequent reactivation 
occurs through disulfide bond reduction by Trx reductases (TrxR), NADPH utilising 
selenocysteine enzymes that are the only enzymes capable of reducing, and thus 
recycling, the active site of Trx (Lu and Holmgren, 2009).  In the mammalian CNS, 
Trxs and TrxRs are segregated sub-cellularly: Trx1 and TrxR1 are located in the 
cytosol, whilst Trx2 and TrxR2 are located in the mitochondria (Patenaude et al., 
2005).  Trxs have diverse roles in the cell and are vital for cell function; genetic 
ablation of either Trx1 or Trx2 cause embryonic lethality (Matsui et al., 1996; Nonn 
et al., 2003).  Through their reduction of disulfide bonds they can regulate the thiol 
redox status of many target proteins to maintain their function (Arner and Holmgren, 
2000).  Trxs can modulate the activity of transcription factors that regulate the 
viability of the cell: Trx activity causes the activation of transcription factor AP1 
(Hirota et al., 1997), whilst downregulating activity of NFκB (Hirota et al., 1999).  
Trxs also act as electron donating co-factors for ribonucelotide reductase, which is 
required to provide deoxyribonucleotides for DNA synthesis (Holmgren, 1989; 
Arner and Holmgren, 2000).  Whilst GSH and Grx can also reduce disulphide bonds 
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of proteins and thus compensate for some of the reactions mediated by Trxs, the rates 
observed by Trxs are orders of magnitude faster, indicating these two enzymatic 
pathways fulfil distinct roles in the cell (Holmgren, 1989; Arner and Holmgren, 
2000).  In the mitochondria Trx2 interacts with members of the electron transport 
chain, its overexpression increases mitochondrial membrane potential (∆Ψ) 
(Damdimopoulos et al., 2002). 
 
The antioxidant properties of Trxs are important for cell viability, and their 
overexpression decrease ROS in cells, whilst conversely their inhibition increase 
oxidative damage (Yoshida et al., 2005).  Trx overexpressing mice display a 
reduction in oxidative damage following ischemia, and are vital for neuronal 
protection against oxidative stress (Patenaude et al., 2005; Bell and Hardingham, 
2011a).  The antioxidant effects of Trxs, beyond regulation of protein function and 
transcriptional activity, can be mediated by their action as free radical scavengers 
(Das and Das, 2000), and their regulation of the peroxide reducing enzymes 
peroxiredoxins (Prx) (Bell and Hardingham, 2011a).  So far six mammalian Prxs 
have been identified, Prxs1-5 contain a two cysteine catalytic site, whilst Prx6 has 
only a single cysteine (and is not regulated by Trx) (Patenaude et al., 2005; Bell and 
Hardingham, 2011a).  The 2-cysteines of the Prx catalytic site perform specific roles 
in H2O2 reduction: one cysteine performs the peroxidatic reaction with H2O2, 
oxidising the thiolate group to sulfenic acid (-SOH).  The other “resolving” cysteine 
reacts with the sulfenic acid group, forming a disulfide bond and releasing H2O (Bell 
and Hardingham, 2011a).  This disulfide bond is then reduced by Trx, restoring Prx 
activity.  Under oxidising conditions the Prx-SOH can be further oxidised to sulfinic 
(-SO2H) and even sulfonic (-SO3H) acid (Chang et al., 2004); since hyperoxidised 
peroxidatic cysteine is not a substrate for the resovling cysteine of Prx, this 
effectively inactivates the enzyme.  This is thought to occur during normal regulation 
of oxidative stress (rather than solely under extremely oxidising conditions (Lim et 
al., 2008)).  The reactivation of Prxs by Trx is slower than the peroxide reducing rate 
of Prx: direct measurement of Prx activity reveals a 100 fold greater peroxidatic 
activity than indirect measurement of activity by TrxR NADPH consumption (Peskin 
et al., 2007).  Prx-SO2H is reactivated in an ATP dependent manner by the enzyme 
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sulfiredoxin (Chang et al., 2004), which catalyses the formation of a sulfinic acid 
phosphoric ester on Prx, which can be subsequently reduced by Trx (Rhee et al., 
2007).  Prx-SO3H does seem to cause an irreversible inhibition of Prx activity (Lim 
et al., 2008); however reversible cysteine hyperoxidation may allow burst activity of 
Prx, neutralising sudden increases in H2O2 without being limited by Trx or TrxR 
activity.  
 
Whilst both pathways share a diversity in substrate specificity and sub-cellular 
localisation, the causes underlying the overlapping role of peroxide neutralisation by 
GPXs and Prxs is likely to extend further than a convergent evolution of both 
systems (Flohe et al., 2011), or the restricted bioavailability of selenium for GPX 
expression (Lu and Holmgren, 2009).  Inactivation of GPXs in oxidising conditions 
appear slower than that observed of Prxs; whilst Prxs have a greater ability in 
neutralising RNS (Flohe et al., 2011).  Furthermore, genetic regulation in response to 
external stimuli could be different.  We recently observed upregulation of 
sulfiredoxin mRNA in response to synaptic activity; this was coordinated with 
downregulation of Txnip, a FOXO regulated protein that binds Trx and inhibits Trx 
activity (Papadia et al., 2008).  Sulfiredoxin is also upregulated by the ROS-
responsive transcription factor Nrf2 in response to oxidative stress or activators of 
Nrf2 (Soriano et al., 2009).  Research presented in this thesis demonstrates that genes 
encoding enzymes of the GSH pathway are similarly upregulated by synaptic activity 
and by activation of the Nrf2 transcription factor; however these increases are by 
independent mechanisms. 
 
4.3 Transcriptional control of antioxidant pathways 
 
Whilst the production of ROS occurs as a by-product of aerobic respiration, their 
production may be increased by a number of factors, including increased cellular 
metabolism, xenobiotic compounds and ultra-violet radiation (Cohen and d'Arcy 
Doherty, 1987; Devary et al., 1992; Dugan et al., 1995; Savolainen et al., 1998; 
Garcia et al., 2005).  Thus antioxidant responses must be inherently dynamic.  Whilst 
antioxidant pathway activity can be regulated by post-transcriptional changes 
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(Franklin et al., 2009), changes in gene transcription also play a vital role in 
regulating the cellular response to oxidative stress.  A key transcription factor in 




Nrf2 is a redox sensitive transcription factor belonging to the cap ‘n’ collar subfamily 
of basic region leucine zipper transcription factors (Zhang, 2006) that binds to the 
antioxidant responsive element (ARE) (Nguyen et al., 2000), leading to the 
transcription of phase II detoxifying and antioxidant enzymes (Vargas and Johnson, 
2009).  Its redox sensitivity is believed to be mediated by its interaction with its 
negative regulator Keap1, a cytoplasmic actin-bound cysteine-rich protein, which in 
non-stressed conditions tightly binds Nrf2 to its C-terminal Kelch domain.  This 
sequesters Nrf2 in the cytoplasm, and actively promotes its ubiquitination by E3 
ubiquitin ligase and subsequent degradation in the proteasome (Zhang et al., 2004).  
Under oxidative conditions Nrf2 is released from Keap1, a process that seems 
dependent on redox-sensitive cysteine residues in the linker region of the Keap1 
protein (Zhang, 2006).  In addition, phosphorylation of Nrf2 by protein kinase C 
(PKC) and PI3K enhance Nrf2-mediated transcription from the ARE by disruption of 
the interaction between Keap1 (Huang et al., 2002; Nakaso et al., 2003). 
 
The phase II detoxifying genes promoted by Nrf2 activation of the ARE consist of a 
battery of genes that prevent or reduce cellular damage in a number of tissues, 
including the CNS.  Examples include the peroxiredoxin reducing enzyme 
sulfiredoxin (Soriano et al., 2009), and haemoxygenase 1 (Vargas et al., 2005) which 
breaks down pro-oxidant haem group to radical scavenging bile pigments biliverdin 
and bilirubin.  ARE dependent transcription also upregulates a cascade of enzymes 
intrinsically involved with the GSH pathway.  GCLC, GCLM, GSS, GR, GPX2 and 
several GSTs all contain an ARE within their promoters and are upregulated by Nrf2 
activation (Vargas and Johnson, 2009).  Another Nrf2-mediated gene is the GSH 
exporter MRP1 (Hayashi et al., 2003) which mediates the supply of neurons with 
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GSH precursors.  Thus Nrf2 activation in astrocytes, leads to a positive antioxidant 
protection in neurons (Shih et al., 2003; Vargas et al., 2008; Calkins et al., 2010). 
Recently naturally occurring compounds have been shown to disrupt the Nrf2-Keap1 
interaction; isothiocyanates such as sulforaphane (McMahon et al., 2001) isolated 
from broccoli, and triterpenoids such as oleanolic acid (Dinkova-Kostova et al., 
2005) isolated from garlic, potently increase phase II antioxidant gene expression.  
Synthetic triterpenoids have been produced that exhibit greater potency as protective 
compounds (Dinkova-Kostova et al., 2005).  These compounds cause disinhibition of 
Nrf2 which confers their powerful anti-carcinogenic and cytoprotective effect.  One 
synthetic triterpenoid in particular, 2-cyano-3,12-dioxooleana-1,9-dien28-oic acid-
trifluoroethylamide (CDDO-F3), has been shown to strongly upregulate 
haemoxygenase 1 expression and confer neuroprotection in mouse models of ALS 
and Huntington’s disease (Pitha-Rowe et al., 2009; Stack et al., 2010; Neymotin et 
al., 2011).  In data presented in this thesis, we utilised this drug to investigate the 
effects of stimulating the Nrf2 pathway in neurons and astrocytes. 
 
The Nrf2 transcriptional pathway seems stronger in astrocytes than neurons (Kraft et 
al., 2004; Vargas et al., 2008; Chen et al., 2009; Vargas and Johnson, 2009), however 
there are reports of Nrf2 mediated transcription in neurons (Escartin et al., 2011; 
Hota et al., 2011).  Whilst we have observed the neuroprotective effects of neuron 
specific overexpression of Nrf2 (Soriano et al., 2008b), data presented in this thesis 
raises doubt over the activity of Nrf2 specifically in neurons, with the canonical Nrf2 
genes GCLC and GCLM unaffected by pharmacological or genetic manipulation in 
neurons.  This apparent contradiction with previously published results, which 
include our own, may be due to the highly potent antioxidant and neuroprotective 
effect of stimulating the Nrf2 pathway in astrocytes.  Genetic regulation of 







4.3b NMDAR regulated transcription: AP-1 and FOXO 
 
As mentioned previously, we recently observed the downregulation of the Trx 
inhibitor Txnip by synaptic NMDAR activity, through nuclear exclusion of FOXO 
(Papadia et al., 2008).  We also observed the upregulation by synaptic NMDAR 
activation of the neuroprotective pro-antioxidant gene sulfiredoxin by the pleiotropic 
transcription factor AP-1.  AP-1 is formed from a noncovalent dimerisation by 
members of the Fos and Jun family of proteins in response to a variety of external 
stimuli (Angel and Karin, 1991).  Expression of Fos and Jun family member mRNAs 
are quickly elevated by NMDA receptor activation (Morgan and Curran, 1988; 
Condorelli et al., 1994).  NMDAR activation also mediates phosphorylation 
dependent stabilisation of dimerised AP-1, facilitating its transcriptional activity 
(Schwarzschild et al., 1997).  Whilst it is unclear if there is a synaptic/extrasynaptic 
bias in the NMDAR dependent activation of AP-1 mediated transcription; bath 
applied glutamate is sufficient to drive AP-1 activation (Condorelli et al., 1994; 
Schwarzschild et al., 1997).  However cFos is a CREB regulated gene (Sheng et al., 
1990), and we observed no induction of sulfiredoxin mRNA by extrasynaptic 
NMDAR stimulation (Papadia et al., 2008).  We have recently identified AP-1 sites 
in the promoters of a number of pro-antioxidant genes (Soriano et al., 2009), which 
suggests that synaptic activity could mediate neuroprotection against oxidative insult 
through the increased expression of AP-1 regulated genes, alongside concurrent 
suppression of FOXO regulated genes. 
 
5 Neuronal activity dependent protection against apoptotic/oxidative insults 
 
Understanding of pathways activated by neuroprotective NMDAR signalling is of 
great importance, with huge potential for developing therapeutic strategies to combat 
CNS injury or degeneration.  Whilst the research presented in this thesis does not at 
every stage involve the increase of NMDAR activation, consideration of this 
signalling pathway is intrinsic to each chapter, which in turn describe: 
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• the requirement of synaptic activity in the neuroprotection conferred by 
PACAP treatment 
• the hitherto uncharacterised activation of the antioxidant GSH pathway by 
NMDAR signalling 
• the augmentation of the GSH antioxidant pathway through stimulation of 
astrocytes with CDDO-F3 
As will be discussed in the epilogue of this thesis, each shed new light on the 
neuroprotective pathways of the CNS, which ultimately may provide new therapeutic 









































Cortical neurons from E21 Sprague Dawley rats were cultured using the method 
described (Bading and Greenberg, 1991; McKenzie et al., 2005a).  Tissue culture 
grade plastic was incubated for at least two hours at 37 °C in poly-D-lysine 
(molecular weight 30,000 – 70,000) and Laminin (Sigma).  Embryos were 
anaesthetised with an intraperitoneal injection of sodium pentobarbital (Merial 
Animal Health) and decapitated.  Brains were removed, corticies dissected and 
placed in dissociation medium (81.8 mM Na2SO4, 30 mM K2SO4, 5.84 mM MgCl2, 
252 µM CaCl2, 1 mM HEPES, 0. 1% Phenol Red, 20 mM Glucose, and including 1 
mM Kyurenic acid to prevent excitotoxic death via NMDARs during dissection and 
enzymatic digestion).  Once the required amount of tissue had been isolated, the 
corticical hemispheres were placed in a tube, excess liquid removed and incubated 
for twenty minutes at 37 °C in dissociation medium containing 10 units/ml of papain 
(Worthington Biochemical Corporation).  This digestion step was repeated once 
more after removal of media.  Subsequently, corticies were washed twice in 
dissociation media, then twice in growth medium containing NeuroBasal-A Medium, 
B-27 Supplement, Anti-Anti Supplement (anti-bacterial/anti-mycotic) (Invitrogen), 
1mM glutamine and 1% Rat Serum (Harlan SeraLab).  After washing, corticies were 
triturated by rapid suction/expulsion using a 2 ml disposable plastic pipette in 10 ml 
of warm growth medium.  This cell suspension was then diluted using Opti-MEM 
(Invitrogen) supplemented with Glucose (20 mM), to obtain a concentration of one 
cortical hemisphere per 14 ml cell suspension.  This solution was then plated on the 
pre-coated tissue culture plastic, with 0.5 ml of cell suspension used per well of a 24-
well plate.  Culture plates were incubated at 37 °C in a humified 5% CO2 atmosphere 
for two and a half hours, after which the cell suspension was removed and replaced 
with 1 ml of growth medium.  At DiV 4, 1 ml of growth media supplemented with 
9.6 µM cytosine β-D-arabinofuranoside hydrochloride (AraC) (Sigma) was added to 
prevent proliferation of glial cells.  Pure neuronal rat cultures were prepared as above 
except anti mitotic AraC was added at Div 0.  Normal rat neuronal cultures treated 
with AraC at Div 4 contain ~5% GFAP positive cells (Papadia et al., 2008), whilst 
early AraC treatment leads to cultures containing <0.05% GFAP positive astrocytes 
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(Fig. M1).  Astrocytes were cultured as described (Soriano et al., 2008b) by plating 
mixed neuronal/glial cultures at half density in 10% FBS containing DMEM 
(Invitrogen) without anti-mitotic.  PKA RIIβ knockout mice (Watson et al., 2006), 
Nrf2 knockout mice (Chowdhry et al., 2010) and Keap1 knockout mice 
(Wakabayashi et al., 2003) and their respective wildtypes were cultured as above 
from E17 animals.  Experiments were performed after a culture period of 9-10 days 
during which neurons developed a rich network of processes, expressed functional 
NMDA and AMPA/kainate glutamate receptors, and formed synaptic contacts 
(Hardingham et al., 2001b). 
 
Stimulations and assessment of nuclear morphology 
 
Prior to stimulations, neurons were transferred from growth medium to a trophically 
deprived medium (TMo) containing 10% MEM (Invitrogen), 90% Salt-Glucose-
Glycine (SGG) medium (SGG (Papadia et al., 2005): 114 mM NaCl, 0.219 % 
NaHCO3, 5.292 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM HEPES, 1 mM 
glycine, 30 mM glucose, 0.5 mM sodium pyruvate, 0.1 % Phenol Red; osmolarity 
325mosm/l) and allowed to equilibrate before stimulation.  To quantify cell death, 
neurons were fixed and subjected to DAPI (Vectorlabs) staining and cell death 
quantified by counting (blind) the number of apoptotic nuclei as a percentage of the 
total. Approximately 1500 cells were counted per treatment. Morphologically, 
peroxide-treated and trophically deprived neurons show typical signs of apoptotic- 
like cell death (shrunken cell body and large round chromatin clumps).  GFAP 
immunocytochemistry was performed by incubating fixed cells in 1:1000 Rabbit anti 
GFAP (Sigma) overnight, incubating 1 h each in 1:200 biotinylated anti-rabbit IgG 
and 1:500 Cy3-conjugated streptavidin (Jackson Immuno) before subsequent DAPI  
staining.  Images were taken using a Leica AF6000 LX imaging system, with a 








































Figure M1. Early AraC treatment blocks proliferation of astrocytes in rat 
primary neuronal culture. (Right) Example pictures showing 
immunocytochemistry to GFAP (green) and NeuN (red) with nuclear DAPI stain 
(blue) of (Upper) regular Div 5 AraC treated rat cortical cultures and (Lower) 
Div 0 AraC treated cultures. (Left) Quantification of percentage of GFAP 
positive cells from either preparation (n = 6 cultures, with 8 10x magnification 
pictures taken, with approxiamtely 900 DAPI stained nuclei per picture).
Neuronal Mixed Culture





For stimulations the following reagents were used: PACAP-27 was purchased from 
NeoMPS, MK801, KN-62, forskolin, BSO and BCNU from Tocris, bicuculline, 
D3T, MK571 and hydrogen peroxide from Sigma, PD-98059 from Ascent Scientific, 
H-89 from LC Laboratories, staurosporine, TTX, GSH and 4-aminopyridine from 
Calbiochem, γglutamylcysteine and cysteinylglycine from Bachem.  CDDO-EA and 




For preconditioning experiments neurons were treated as indicated for 2 h, then 
transferred to aCSF (150 mM NaCl, 3 mM KCl, 10 mM HEPES, 2 mM CaCl2, 1mM 
MgCl2, 1mM glucose) similarly conditioned. Ca2+ imaging was performed as 
described (Soriano et al., 2008c). Briefly, cells were loaded with 11µM Fluo-3 AM 
(Invitrogen) (from a stock solution of 2.2 mM Fluo-3 dissolved in anhydrous DMSO 
containing 20% (w/v) Pluronic detergent) for 30mins at 37°C. Fluo-3 fluorescence 
images (excitation 488 nm, emission ≥ 515 nm) were taken at one frame per second. 
To calibrate images, Fluo-3 was saturated by adding 50 µM ionomycin to the 
perfusion chamber and quenched with 10mM MnCl2 + 50 µM ionomycin to levels 
corresponding to 100 nM Ca
2+
 (Minta et al., 1989). Free Ca
2+
 concentrations were 
calculated according to the equation [Ca
2+
] = Kd(F – Fmin)/(Fmax – F), where F is 





After stimulation cells were lysed in 45 µl of sample buffer (1.5 mM Tris, 15% 
glycerol, 3% SDS, 7.5% β-Mercaptoethanol, 0.0375% bromophenol blue, pH 6.8), 
and boiled at 100 °C for 4 minutes.  Gel electrophoresis and Western Blotting was 
performed using the Xcell Surelock system (Invitrogen) with 4-20% NuPage BisTris 
pre-cast gels (Invitrogen).  15 µl of sample was loaded per well and electrophoresis 
was performed in running buffer (50 mM MOPS, 50 mM Tris, 1 mM EDTA, 3.5 
mM SDS, pH 7.7) at 160 V for ~ 1.5 h.  Post migration, proteins were transferred 
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onto a PVDF membrane (Millipore) in transfer buffer (96 mM glycine, 12 mM Tris 
and 20% Methanol) at 45 V for ~ 2 h.  Once transferred, membranes were blocked in 
TBS solution (20 mM Tris, 137 mM NaCl and 0.1% Tween-20) supplemented with 5 
% dried milk.  The membrane was then incubated overnight at 4 °C with following 
primary antibody diluted in TBS + milk solution: Anti Phospho-p44/42 MAPK 
Thr202/Tyr204 (p-ERK1/2; 1:2000, Cell Signaling), p44/42 MAPK (ERK1/2; 
1:2000, Cell Signaling), phospho-CREB ser133 (1:500, Upstate) and CREB (1:500, 
Upstate).  After this incubation, membranes were washed 3 times for 5 min in TBS, 
and then placed with the appropriate horseradish peroxidase-conjugated secondary 
antibody diluted in TBS + milk solution at room temperature for 1 h.  Membranes 
were washed a further 3 times in TBS, then incubated for 1 min in LumiGlo reagent 
and peroxide (Cell Signaling Technology).  Chemiluminescence was then detected 
by exposing Kodak X-Omat film to the membrane; then quantified using band 
densitometry using ImageJ software.  Band density was normalised each time to an 
appropriate loading control, obtained by stripping the membrane of antibodies by 
incubating in ReBlot Plus Strong Stripping Solution (Millipore) for 15 min, followed 
by 3x 5 min TBS washes, and recapitulating the protocol from initial primary 
antibody incubation. 
 
Transfection and luciferase assays 
 
Neurons were transfected at DIV8 using Lipofectamine 2000 as described (Mckenzie 
et al., 2005b) using a total of 0.6 µg cDNA/well and 2.33 µl/well of Lipofectamine 
2000 (1 µg/ml, from Invitrogen). Under these conditions transfection efficiency is 
approximately 2-5 %, with >99% of eGFP-expressing transfected cells NeuN-
positive, and <1% GFAP positive (Papadia et al., 2008; Soriano et al., 2008b, a) 
confirming their neuronal identity. 
 
For CRE-reporter assays, neurons were transfected with 0.5 µg of CRE-Firefly 
Luciferase + 0.1 µg of pTK-Renilla (Promega); or 0.2 µg CRE-Luc, 0.1 µg Renilla 
and 0.4 µg of: β-globin control vector, pICER1 (a gift from Dr. Paulo Sassone-Corsi, 
Centre National de la Recherche Scientifique-Institut National de la Santé et de la 
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Recherche Médicale, Strasbourg, France (Stehle et al., 1993)), CRTC1 and Dominant 
negative CRTC1 (TORC1 and TORC1-N44 were a gift from Dr Yang Zhou Institute 
of Neuroscience, Chinese Academy of Sciences, Shanghai, China (Zhou et al., 2006) 
(Zhou et al., 2006)).  For CBP-reporter assays, neurons were transfected with 0.4 µg 
of GAL4-CBP (Chawla et al., 1998), 0.2 µg of a Firefly Luciferase reporter 
containing four GAL4 DNA binding sites (GAL4-Luc, Promega), and 0.1 µg pTK-
Renilla; or 0.2 µg GAL4-CBP, 0.2 µg GBD-Luc, 0.1 µg pTK-Renilla and 0.2 µg of 
vectors expressing either β-globin control or E1A (described (Bannister and 
Kouzarides, 1995)).  For GSR-promoter reporter assays, the following constructs 
were used: GSR Full-promoter (a 2kb sequence upstream of the mouse GSR gene) 
and ARE2 (a 132 bp ARE containing sequence located within the larger sequence), 
both constructs cloned into pGL3 Basic luciferase vector (Harvey et al., 2009).  
Neurons were transfected with 0.5 µg of GSR Full-promoter and 0.1 µg pTK-Renilla; 
alternatively o.2 µg of GSR Full-promoter or ARE2 reporter, 0.1 µg pTK Renilla and 
0.3 µg of β-globin control or TAM67 (described (Brown et al., 1993)). 
 
Stimulations were performed 24 h post transfection. For CRE-luciferase assays 
neurons were treated with 10 nM PACAP or 5 µM Forskolin for 4 h, or with 50 µM 
bicuculline and 250 µM 4-aminopyridine for 8 h, with inhibitors added 1 h before. 
For CBP activity assays neurons were treated with 10 nM PACAP for 8 h. For GSR-
promoter assays neurons were treated with 50 µM bicuculline, 250 µM 4-
aminopyridine and 50 µM MK801 for 4 h and 8 h.  All assays were performed using 
the Dual Glo assay kit (Promega) and were performed on a FLUOstar OPTIMA 
(BMG Labtech, Aylesbury, UK). Firefly luciferase activity was normalized to the 
Renilla control in all cases and each experiment was performed at least 4 times. 
 
Following the fate of transfected cells 
 
The overall method to do this is as described (Soriano et al., 2008a; Soriano et al., 
2010) with some modifications to the timing. Neurons were transfected with 0.5 µg 
of vectors expressing β-globin or ICER1 plus 0.1 µg of peGFP (Invitrogen). Neurons 
were placed in trophically-deprived medium and treated with 10 nM PACAP after 24 
 42 
h where indicated. After a further 24 h images were taken of GFP expressing neurons 
using a Leica AF6000 LX imaging system, with a DFC350 FX digital camera, prior 
to treatment of neurons with TTX to block AP firing. Using mark-and-find software, 
the fate of the photographed neurons was followed at 24 h and 48 h after TTX 





For CRTC1-localisation neurons were transfected with 0.6 µg GFP tagged CRTC1 
(peGFP-C2/TORC1 a gift from Dr Dong-Yan Jin, Department of Biochemistry, 
University of Hong Kong, Hong Kong China (Siu et al., 2006)). 24 h post 
transfection neurons were treated with 20 ng/ml Leptomycin B (LC Laboratories) for 
30 min in order to visualise CRTC1 import more clearly (Kovacs et al., 2007) and 
then 10 nM PACAP for a further 30 min in the presence of 1 µM TTX, 10 µM H-89 
or 10 µM FK-506 (added 1 h before). Neurons were then fixed and stained for anti-
GFP (1:750, Invitrogen) and visualised using biotinylated secondary antibody/cy3-
conjugated streptavidin. Nuclei were counter-stained with DAPI. Subcellular 
distribution of CRTC1 was scored as being nuclear if levels were higher in the 
nucleus than in the surrounding perinuclear cytoplasm. 400-800 cells were analysed 
per treatment across 4-8 independent experiments. 
 
Electrophysiological recording and analysis 
 
All electrophysiological recordings were kindly performed by Dr Marc-Andre 
Martel. Coverslips containing cortical neurons were transferred to a recording 
chamber perfused (at a flow rate of approximately 5 ml/min) with an external 
recording solution composed of (in mM): 150 NaCl, 2.8 KCl, 10 HEPES, 2 CaCl2, 1 
MgCl2 and 10 glucose, pH 7.3 (320-330 mOsm). Patch-pipettes were made from 
thick-walled borosilicate glass (Harvard Apparatus, Kent, UK) and filled with a K-
gluconate-based internal solution containing (in mM): 155 K-gluconate, 2 MgCl2, 10 
Na-HEPES, 10 Na-PiCreatine, 2 Mg2-ATP and 0.3 Na3-GTP, pH 7.3 (300 mOsm). 
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Electrode tips were fire-polished for a final resistance ranging between 5-10 MΩ . 
Currents were recorded at room temperature (21 ± 2°C) using an Axopatch-1C 
amplifier (Molecular Device, Union City, CA) and stored on digital audio tape. Data 
was subsequently digitized and analyzed using WinEDR v6.1 software (John 
Dempster, University of Strathclyde, UK). Neurons were voltage-clamped at –70 
mV, and recordings were rejected if the holding current was greater than –100 pA or 
if the series resistance drifted by more than 20% of its initial value (<35 MΩ). 
Neurons were treated ± PACAP (10 nM) for 1-2 h prior to spontaneous EPSCs being 
recorded in voltage-clamp for 5 min. Recordings were studied to determine whether 
they showed evidence of burst-like activity, defined as long periods of activity (>1 s), 
peaking at >50 pA. 
 
Glutathione content assays 
 
Total glutathione was recorded using two methods.  For basal level recordings 
neurons were treated as indicated for 24 h; for glutathione depletion assays 24 h 
stimulation was then preceded by addition of 100 µM H2O2 (50 nmoles in 500 µl) 
and incubated 24 h, with subsequent peroxide stimulations 8, 6, 4 and 2 h prior to 
cell lysis.  30 min before cessation of stimulations 50 µM Monochlorobimane (MCB) 
(Sigma) was added to cultures.  MCB forms a fluorescent product with GSH after 
conjugation by glutathione S-transferase (Shrieve et al., 1988).  After MCB 
incubation neurons were washed once in warm TMo, example pictures were taken, 
then cells were lysed in 100 µl lysis buffer (50 mM K2PO4, Triton 0.5%, pH 7) then 
centrifuged at 15,700 g (13,000 rpm) at 4 °C for 10 min.  80 µl of supernatant was 
then transferred to a black 96-well plate and fluorescence intensity was measured 
(excitation 485 nm, emission 520 nm) with a FLUOstar OPTIMA (BMG Labtech, 
Aylesbury, UK).  Fluorescence was normalised to protein levels, determined using a 
bicinchonic acid (BCA) protein assay (Pierce, Thermo Scientific). 
 
Alternatively a colorimetric method was followed using a kit (Calbiochem).  After 
stimulation cells were lysed 50 µl lysis buffer (50 mM K2PO4, Triton 0.5%, pH 7) 
then centrifuged at 15,700 g (13,000 rpm) at 4 °C for 10 min.  35 µl of supernatant 
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was then transferred to a centrifuge tube, and mixed with 35 µl of 50 mg/ml 
Metaphosphoric Acid, incubated on ice for 5 min then centrifuged at 580 g (2,500 
rpm) at 4 °C for 5 min; which precipitates protein from the lysate (Perlmann and 
Herrmann, 1938).  60 µl of deproteinated supernatant was then mixed with 120 µl 
assay buffer (K2PO4, diethylenetriamine penta-acetic (DTPA) and lubrol).  20 µl of 
reagent 1 (4-chloro-1-methyl-7-trifluoromethyl-quinolinium methylsulphate) was 
added and the mixture thoroughly vortexed, then 20 µl of reagent 2 (30% NaOH) 
was add and vortexed again.  Samples were incubated at room temperature for 10 
min, then transferred to a clear 96-well plate and absorbance was measured at 405 
nm with a FLUOstar OPTIMA (BMG Labtech, Aylesbury, UK).  A standard curve 
of GSH (five serial dilutions rangingfrom 16 µM to 1 µM and a lysis buffer blank) 
was run in parallel to calibrate GSH concentration; whilst protein concentration was 
determined from remaining lysate using a BCA assay, to allow quantification of mg 
GSH per g of protein. 
 
Glutamyl-cysteine ligase assay 
 
To determine GCL activity neurons were treated as indicated for 24 h, and enzyme 
activity was recorded as described (White et al., 2003). Briefly, post-stimulation 
samples were lysed over ice in 650 µl lysis buffer (20 mM Tris, 1 mM EDTA, 250 
mM sucrose, 20 mM sodium borate , 2 mM L-serine (borate and serine added to 
inhibit γ-glutamyl transpeptidase activity (Tate and Meister, 1978) that may 
otherwise degrade reaction products), pH 7.4), then centrifuged at 15,700 g (13,000 
rpm) at 4 °C for 10 min.  Supernatants were then redistributed to 50 µl aliquots, one 
for each time point, and placed at 37 °C in a heat block.  For buthionine sulfoximine 
samples, 15 µl of 100 mM BSO was added to 285 µl of control supernatant and 
thoroughly mixed by vortex before redistribution.  50 µl of GCL reaction buffer (400 
mM Tris, 40 mM L-glutamic acid, 2 mM EDTA, 20 mM sodium borate, 2 mM L-
serine, 40 mM MgCl2, 40 mM ATP (added fresh to buffer during sample 
centrifugation), pH 7.4) was pipetted to each sample and allowed to incubate for 5 
min.  Reaction was started by adding 50 µl of 20 mM cysteine (dissolved in ATP-
free reaction buffer) to samples and incubated for 20, 15, 10 and 5 minutes.  The 
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GCL reaction was stopped by adding 50 µl of Metaphosphoric acid (2.5 g per 100 
ml) to precipitate protein; subsequently, cysteine was added to zero time-points, 
samples were vortexed and placed on ice for 20 min.  After incubation, samples were 
centrifuged at 580 g (2,500 rpm) at 4 °C for 5 min.  Following centrifugation, 20 µl 
of reaction mixture (with at least 2 technical repeats per sample) was transferred to a 
black 96-well plate, and 180 µl of detection buffer (50 mM Tris (pH 10), 0.5 N 
NaOH and 10 mM 2,3-Napthalenedicarboxyaldehdye (NDA) (Sigma) (v/v/v – 
1.4/0.2/0.2)) was added to each well.  The NDA in this mixture rapidly forms a 
fluorescent cyclic reaction product with the cysteine thiol and glutamyl amino groups 
of GSH and GCγ (λexcitation max = 472 nm, λemission max = 528 nm) (Orwar et al., 1995).   
The plate was left to incubate in the dark at room temperature for 30 min, and 
fluorescence intensity was measured (excitation 485 nm, emission 520 nm) with a 
FLUOstar OPTIMA (BMG Labtech, Aylesbury, UK).  GCL activity was determined 
by calculating rate of fluorescence increase over time, normalised to protein content. 
 
Glutathione Reductase Assay 
 
To determine glutathione reductase activity NADPH oxidation was recorded as a loss 
of absorbance at 340 nm as described (Carlberg et al., 1985).  Post stimulation cells 
were lysed in 50 µl of lysis buffer (20 mM HEPES pH 7.9, 100 mM KCl, 300 mM 
NaCl, 10 mM EDTA, 0.1% Nonidet P-40) and centrifuged at 15,700 g (16,400 rpm) 
at 4 °C for 10 min.  Subsequently 20 µl of sample was distributed to a well of a clear 
96-well plate, with 20 µl of 1 mM GSSG and 110 µl of assay buffer (100 mM 
Potassium Phosphate, pH 7.0), with a 0.1 units/ml solution of yeast glutathione 
reductase (Sigma) as a positive control and lysis buffer as a negative control.  Using 
a multichannel pipette 50 µl of 1 mM NADPH was added to each well starting the 
reaction.  NADPH absorbance was then read every 30 s for 15 min using FLUOstar 
OPTIMA (BMG Labtech, Aylesbury, UK).  GR activity was determined by 





Glutathione Peroxidase Assay 
 
To determine glutathione peroxidise activity a kit was used (Calbiochem) following 
the method described (Flohe and Gunzler, 1984).  Post stimulation cells were lysed 
in 50 µl of lysis buffer (20 mM HEPES pH 7.9, 100 mM KCl, 300 mM NaCl, 10 
mM EDTA, 0.1% Nonidet P-40) and centrifuged at 15,700 g (16,400 rpm) at 4 °C 
for 10 min.  Subsequently 20 µl of sample was distributed to a well of a clear 96-well 
plate, with 70 µl of assay buffer (50 mM Tris-HCl, pH 7.6, 5mM EDTA), 50 µl of 
co-substrate mixture (NADPH, glutathione and glutathione reductase), with 
glutathione peroxidase as a positive control and lysis buffer as a negative control.  
Using a multichannel pipette 20 µl of cumene hydroperoxide was added to each well 
starting the reaction.  NADPH absorbance was then read every 30 s for 15 min using 
FLUOstar OPTIMA (BMG Labtech, Aylesbury, UK).  GPX activity was determined 
by calculating rate of NADPH loss over time, normalised to protein content. 
 
RNA isolation, RT-PCR and Quantitative PCR 
 
RNA was isolated using the Roche isolation reagents including a 15 min DNase I 
treatment to avoid genomic DNA contamination of samples, and eluted using 50 µl 
of RNase-free water.  For qPCR cDNA was synthesised from 1-5 µg of RNA with 
the Tanscriptor One-Step RT-PCR Kit (Roche).  Briefly, 7 µl of RNA was mixed on 
ice with 10 µl 2x cDNA Synthesis master mix, random primers: oligo primers 2:1 
(total 3 µl), 2 µl deoxynucleotide mix (1 mM each: dATP, dTTP, dCTP and dGTP), 
0.5 µl RNase Inhibitor (40 U/µl), 0.5 µl Reverse Transcriptase (20 U/µl) and 3 µl 
nuclease free water.  Reaction mixtures were vortexed and spun down and run in 
parallel with at least one NoRT control.  Samples were placed in a thermal cycler and 
incubated for 10 min at 25 °C, 30 min at 55 °C, 5 min at 85 °C, and were then cooled 
down to 4 °C. 
 
This cDNA was then diluted to 6 ng per µl for use in real-time quantitative PCR.  
qPCR was performed in an Mx3000P qPCR System (Stratagene) using 2x FastStart 
Universal SYBR Green Master Mix (Roche) according to the manufacturer’s 
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instructions.  Briefly a total volume of 15 µl qPCR reaction mix was added per well, 
containing 1 µl template DNA, 7.5 µl SYBR Green master mix (containing ROX), 
0.6 µl of forward and reverse primers at 200 nM final concentration and 5.3 µl 
nuclease free water.  Technical replicates, NoRT controls and template-free controls 
were included in each case.  The cycling program was 10 min at 95 °C; 40 cycles of 
30 s at 95 °C, 40 s at 60 °C with detection of fluorescence and 30 s at 72 °C; 
followed by one cycle of 1 min at 95 °C, 30 s at 55 °C ramping up to 95 °C over 30 s 
with continuous fluorescence detection (for dissociation curve).  Expression of the 
gene interest was calculated using the efficiency corrected ∆∆Ct method (Livak and 
Schmittgen, 2001), normalising to either GAPDH or 18s as a housekeeping gene.  
The sequence and efficiencies of primers used are shown below, with primers 






Cysteine Uptake assays 
 
Cysteine uptake assays were kindly performed by Dr Kunal Gupta.  Cortical cultures 
stimulated for 24 h in TMo with 50 µM bicuculline and 250 µM 4-aminopyridine, 50 
µM MK801 or 250 nM CDDO-F3.  Samples were washed with PBS, and incubated 
with 10 µM 
35
S-cysteine (containing 2 µM dithiothreitol) at for 10 min at 37 °C.  
Uptake was stopped by placing samples on ice.  Cells were then washed twice in ice-





All results are presented as mean ± standard error of the mean.  Statistical testing 
involved a 2-tailed paired student T-test. For studies employing multiple testing, we 

































PACAP induces long lasting 
neuroprotection through the induction of 






















Due to its neuroprotective properties both in vitro and in vivo and its ability to cross 
the blood brain barrier, the neurotrophic peptide PACAP has received considerable 
attention as a potential therapeutic agent (Somogyvari-Vigh and Reglodi, 2004; 
Shioda et al., 2006; Brenneman, 2007; Ohtaki et al., 2008; Vaudry et al., 2009).  It is 
generally assumed that PACAP-mediated PKA signalling in neurons triggers 
neuroprotective gene expression and signal pathways by direct modulation of 
upstream effectors of these processes.  However, there is an alternative explanation: 
that PACAP-induced PKA signalling exerts at least some of its neuroprotective 
effects indirectly though the enhancement of electrical activity.  G-protein coupled 
receptors that activate cAMP/PKA signals in neurons, such as type I mGluRs and 
D1-type dopamine receptors, can potentiate synaptic strength, neuronal excitability 
and ion channel properties (Nguyen and Woo, 2003).  PACAP administration has 
been recently reported to enhance AMPAR currents as well as synaptic NMDAR 
currents (MacDonald et al., 2007; Costa et al., 2009) and to suppress the apamin-
insensitive slow after-hyperpolarization (IsAHP) current (Hu et al., 2010), which can 
control neuronal excitability. 
 
Physiological patterns of synaptic activity are known to be strongly neuroprotective 
(Bell and Hardingham, 2011b), activating multiple pathways including CREB-
mediated gene expression, antioxidant gene expression and the suppression of 
apoptotic genes (Hetman and Kharebava, 2006; Al-Mubarak et al., 2009; 
Hardingham and Bading, 2010; Soriano and Hardingham, 2011; Zhang et al., 
2011b).  An episode of activity can confer neuroprotection long after that episode has 
ceased, via a mechanism involving the activation of nuclear Ca
2+
- and CREB-
dependent gene expression (Papadia et al., 2005; Zhang et al., 2009).  Microarray 
analysis of genes influenced by synaptic activity revealed an NMDAR dependent 
upregulation of PACAP, which was confirmed by qPCR (Papadia et al., 2008; Martel 
et al., 2009b), consistent with its transcriptional regulation by CREB (Fukuchi et al., 
2004; Miyashita et al., 2005).  Thus, we wished to study the effect of PACAP on 
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levels of electrical activity in cortical neurons, and the role this plays in 
neuroprotection. 
 
We found that PACAP-induced PKA signalling in cortical neurons is by itself 
insufficient to activate neuroprotective pathways; instead the anti-apoptotic effect of 
PACAP stimulation is mediated indirectly, through the induction of synchronised 
action potential (AP) firing.  Treatment of rat cortical neurons with PACAP induced 
a rapid and sustained PKA-dependent increase in AP firing and associated Ca2+ 
transients.  Exposure to PACAP protected neurons from apoptosis inducing 
staurosporine treatment, and activated protective ERK1/2 signalling; however these 
effects were both blocked in the presence of tetrodotoxin (TTX).  Transient exposure 
to PACAP induced a long-lasting neuroprotection which was reliant on AP firing and 
efficient CREB mediated gene expression, a phenomenon we have previously 
observed in neurons that have undergone a period of increased synaptic activity 
(Papadia et al., 2005).  Whilst activity independent PKA signalling was sufficient to 
phosphorylate CREB on its activating serine-133 site, further secondary-activating 
steps by activity dependent CaM kinase and calcineurin are required for full CRE-
dependent gene transcription.  PACAP induced transactivation of CREB binding 
partner CBP was demonstrated to be dependent on AP firing and subsequent 
activation of CaM kinase.  PACAP also induced nuclear import (and thus activation) 
of a further CREB coactivator CRTC1, through firing activity dependent stimulation 
of calcineurin signalling.  Overexpression of CRTC1 was sufficient to rescue 
PACAP induced CRE-dependent gene expression in the presence of TTX.  Thus the 
enhancement of AP firing may play a significant role in the neuroprotective actions 
of PACAP and other adenylate cyclase coupled signalling molecules.  These results 










PACAP triggers sustained increases in AP firing in cortical neurons. 
 
PACAP is known to promote PKA-dependent neuroprotection in a variety of systems 
in vitro and in vivo.  However, PKA activation is also capable of altering neuronal 
network activity through the control of intrinsic excitability and synaptic strength 
(Nguyen and Woo, 2003).  To investigate the effect of PACAP on levels of electrical 
activity we performed Ca
2+
 imaging experiments on cortical neurons pre-treated with 
PACAP.  This pre-treatment resulted in enhanced AP firing as evidenced by strong 
oscillatory intracellular Ca
2+
 transients that were blocked by the Na
+
 channel 
antagonist TTX (Fig. 1.1A).  In contrast, control neurons exhibited far smaller TTX-
sensitive Ca
2+
 transients (Fig. 1.1B).  Pre-treatment of neurons with the PKA 
inhibitor H-89 prevented any PACAP-induced changes in Ca
2+
 oscillations (Fig. 
1.1C).  We also performed whole-cell voltage-clamp recordings of neurons pre-
treated with PACAP which corroborated the Ca
2+
 imaging data: nine out of nine 
PACAP-treated neurons exhibited incoming excitatory post-synaptic currents 
consistent with burst-like activity (>1 s in duration, > 50 pA at peak), compared to 0 
out of 5 control neurons (Fig. 1.1E).  Further Ca
2+
 imaging experiments revealed that 
acute administration of PACAP also had a similar effect, indicating that the 
potentiating effect of PACAP on AP firing is fast-acting as well as long-lasting (Fig. 
1.1F).  Thus, PACAP-induced PKA signalling in cortical neurons induces long-
















Figure 1.1. PACAP enhances AP firing in cortical neurons. (A - D) Pre-treatment with 
PACAP (10 nM here and throughout the study) causes an increase in AP firing-dependent 
Ca2+ transients. Neurons were treated where indicated with 10 nM PACAP ± H-89 (10 µ M). 
After 2 h the neurons were subjected to Fluo-3 Ca2+ imaging studies (see methods for 
details) to monitor the size of Ca2+ transients in the different stimulation conditions. TTX (1 
µ M) was added where indicated to determine the extent to which the observed Ca2+ 
transients were due to action potential firing. Example traces are shown: black line indicates 
the mean Ca2+ concentration within a field of cells, and the grey shaded region indicates ±
s.e.m. of the Ca2+ concentration within that field. Free Ca2+ concentrations were calculated 
from fluorescence signal (F) according to the equation [Ca2+] = Kd(F – Fmin)/(Fmax – F), 
and expressed as a multiple of the Kd of Fluo-3 (which is approximately 315 nM). (D) shows 
quantification of data shown in 1a-c, i.e. quantification of the difference in mean amplitude 
of [Ca2+] before and after 1 µM TTX treatment. In order to quantitate the effect of PACAP 
on firing activity-induced Ca2+ influx, the mean [Ca2+] 30 seconds before and 30 seconds 
after TTX treatment was calculated in either control neurons or neurons treated with PACAP 
± H-89. For each cell, the degree of TTX-sensitive Ca2+ changes was calculated as the 
difference between mean [Ca2+] before and after TTX treatment. For each condition, 60 cells 
were analysed within 6 independent experiments (*P<0.05). (E) Example trace of a whole-
cell voltage-clamp recording of a control and PACAP-treated cortical neurons. PACAP 
causes an increase in burst-like activity, consistent with the Ca2+ imaging data. (F) Ca2+ 






Enhanced AP firing is essential for PACAP-induced neuroprotection. 
 
It is known that elevated electrical activity can promote neuroprotection in cortical 
neurons (Al-Mubarak et al., 2009; Bell and Hardingham, 2011b), raising the 
possibility that PACAP-induced AP firing might contribute to its neuroprotective 
effect.  We studied the capacity of PACAP to protect neurons against two different 
apoptotic insults, and studied the effect of blocking AP firing by TTX treatment.  We 
first used staurosporine which induces caspase-dependent apoptosis of cortical 
neurons (Papadia et al., 2005).  Pre-treatment of cortical neurons with PACAP before 
exposure to staurosporine for 24 h reduced levels of apoptosis (Fig. 1.2A-B).  TTX 
treatment alone enhanced basal levels of neuronal apoptosis, however staurosporine 
treatment caused additional neuronal loss.  Significantly, PACAP treatment failed to 
protect neurons against apoptosis in the presence of TTX.  
 
We next employed a model of prolonged trophic deprivation (72 h) that also induces 
progressive caspase-dependent apoptosis (Papadia et al., 2005).  Once again, PACAP 
treatment protected neurons against apoptosis in control, although overall levels of 
apoptosis were not high (Fig. 1.2C, treatment (1)).  An episode of AP firing can 
promote neuroprotection that lasts well beyond the point at which that activity ends 
(Papadia et al., 2005).  We hypothesised that PACAP-induced AP firing would 
similarly be able to exert long-lasting neuroprotection.  Neurons subjected to trophic 
deprivation were treated with or without PACAP for 24 h, after which all neurons 
were placed in PACAP-free, TTX-containing medium.  Levels of apoptosis were 
then assessed after a further 48 h.  PACAP treatment was found to confer significant 
neuroprotection (Fig. 1.2C, treatment (3)) and this was dependent on PACAP-
induced AP firing, since no protection was observed if PACAP was administered in 
the presence of TTX (Fig. 1.2C, treatment (2)). Thus, PACAP-induced AP firing 
confers long-lasting neuroprotection.  We conclude from these experiments that 
PACAP-induced enhancement of AP firing is important for its neuroprotective 
effects in these models of cortical neuronal apoptosis.  This suggests that activation 
of PKA signalling is insufficient to directly activate certain neuroprotective 
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pathways: it activates them indirectly by inducing AP firing which in turn triggers 
Ca
2+
-dependent signalling pathways that induce pro-survival events. 
 
AP firing is required for PACAP-induced ERK activation 
 
To study the molecular events required for PACAP-mediated neuroprotection we 
investigated activation of the ERK1/2 pathway, which is known to mediate some of 
the acute neuroprotective effects of PACAP (Falluel-Morel et al., 2004; Li et al., 
2005; Stumm et al., 2007).  Consistent with previous studies, PACAP treatment 
results in strong activation of ERK1/2 which is blocked by PKA inhibition with H-89 
treatment (Fig. 1.2D).  Moreover, inhibition of ERK1/2 activity by treatment with the 
MEK1 inhibitor PD98059 exacerbated apoptosis induced by trophic deprivation, and 
rendered PACAP unable to offer any protection, even when trophic deprivation was 
limited to 48 h (Fig. 1.2E).  We then looked at whether activation of ERK1/2 by 
PACAP required AP firing and found that it did: TTX prevented PACAP-induced 
activation of ERK1/2 (Fig. 1.2F), indicating that PACAP-induced PKA signalling 




















Figure 1.2. PACAP promotes resistance to apoptotic stimuli which is dependent on AP 
firing. (A,B) PACAP protects against staurosporine-induced cell death, but not in the 
presence of TTX. Neurons were treated with PACAP in the presence or absence of TTX 24 h 
and 1 h before treatment with 100 nM staurosporine (STS). After a further 24 h, the cells 
were then fixed and DAPI stained and death was measured by counting pyknotic and non-
pyknotic nuclei (*P<0.05. n = 4 (here and throughout, n indicates data from separate cultures, 
with cell death measured from 4 pictures taken from each of 2 replicate wells; with 
approximately 1500 cells counted per treatment each time)); (B) shows example pictures. (C)
PACAP-induced AP firing protects against trophic deprivation and promotes long lasting 
neuroprotection. At t=0, the neurons were placed in trophically-deprived medium and given 
one of the three treatment regimes outlined in the upper schematic (1-3). At t=72 h, cells 
were fixed, DAPI stained and levels of neuronal death analysed (*P<0.05, n=3). D) PACAP 
induced ERK 1/2 activation is blocked by PKA inhibition. Neurons were treated with 
PACAP ± 10 µM H-89. Cell lysates were obtained and analysed for phospho-ERK1/2, 
normalised to CREB protein expression (n = 4, example blot shown). E) ERK1/2 pathway 
inhibition blocks PACAP neuroprotection. Neurons were treated with PACAP for 15 min in 
the presence or absence of 50 µM PD98059 (added 1 h prior to PACAP), with cell death 
analysed 48 h later (n = 4). F) PACAP-induced ERK 1/2 activation is  blocked by TTX. 




Induction of CREB-mediated gene expression contributes to PACAP-mediated 
neuroprotection. 
 
We next investigated the mechanism by which PACAP-induced AP firing leads to 
long-lasting neuroprotection.  The CREB family controls the expression of a number 
of pro-survival genes containing CRE promoter elements and is a target for 
activation by both cAMP/PKA signals as well as activity-dependent Ca
2+
 signalling 
(Lonze and Ginty, 2002).  CREB itself is the predominant member in forebrain 
neurons (Papadia et al., 2005) and so is likely to be responsible for the majority of 
CRE-mediated gene expression.  PACAP treatment resulted in the strong activation 
of a CRE-reporter raising the possibility that CREB activation contributes to 
PACAP-mediated neuroprotection (Fig. 1.3A).  We studied the effect of blocking 
CRE-dependent gene expression by transfecting neurons with a vector encoding 
ICER1, which is an inhibitory isoform of the CREB family (De Cesare and Sassone-
Corsi, 2000).  We confirmed the efficacy of ICER1: expression of ICER1 blocked 
PACAP-induction of a CRE-reporter gene (Fig. 1.3A). 
 
To assess the importance of CREB in PACAP-induced long-lasting protection, 
neurons were transfected with vectors expressing either β-globin (control) or ICER1 
plus a peGFP transfection marker.  At 24 h post-transfection, neurons were placed in 
trophically-deprived medium and treated ± 10 nM PACAP.  After a further 24 h 
images were taken of GFP-expressing neurons, prior to the transfer of the neurons to 
PACAP-free, TTX-containing medium to block AP firing. The fate of the transfected 
neurons was followed at 24 h and 48 h after TTX treatment (see Fig. 1.3B 
schematic).  We found that the transfection procedure caused slightly higher rates of 
neuronal death than in untransfected cells.  However, in control-transfected neurons, 
PACAP treatment promoted significant protection both 24 h and 48 h after the 
removal of PACAP (Fig. 1.3B). Importantly, PACAP treatment was not significantly 
neuroprotective in ICER1-expressing neurons (Fig. 1.3B), indicating a role for 




AP firing underlies PACAP-induced CREB activation 
 
The fact that PACAP-induced neuroprotection is not observed when neurons are co-
treated with TTX suggested that activation of CRE-dependent gene expression could 
be dependent on AP firing.  Indeed, we found this to be the case: TTX treatment 
alone had little effect on basal activity of a CRE- reporter, but inhibited PACAP-
mediated activation by around 80% (Fig. 1.3C). PKA inhibition by H-89 treatment 
completely blocked the induction of the CRE reporter by PACAP, including the 
small TTX-insensitive component.  Taken together, these data show that direct 
signalling by PKA is able to support weak activation of CRE-dependent gene 
expression, but that AP firing is needed for strong CRE-induction and resultant 
neuroprotection. 
 
To further confirm the role of PKA in both activity-dependent and -independent 
activation of CREB by PACAP, we studied activation of a CRE reporter in neurons 
cultured from a mouse deficient in the RIIß subunit of PKA.  In the RIIß
-/- 
mouse, 
levels of cAMP-inducible PKA activity within the cortex are lower than wild-type, 
while basal PKA activity is similar (Brandon et al., 1998).  We found that both TTX-
sensitive and -insensitive components of PACAP-induced CRE-mediated gene 
expression were lower in RIIß-null neurons (Fig. 1.3D).  The level of reduction in 
PACAP-induced CRE-activation in the RIIß-null neurons was comparable to that 
seen in the context of the adenylate cyclase activator forskolin (Fig. 1.3D), 
confirming that PKA is central to both AP-dependent and -independent components 
of CREB activation by PACAP. 
 
Given that activity-dependent Ca
2+
 influx can activate Ca
2+
-dependent adenylate 
cyclases, it was theoretically possible that PKA could play a role in CREB activation 
downstream of AP firing.  However, we have previously shown that strong firing 
activity does not cause global levels of cAMP to rise sufficiently high to support 
PKA signalling to CREB in the nucleus (Pokorska et al., 2003).  Nevertheless, to 
investigate this directly we studied the activation of CRE-mediated gene expression 
by AP firing induced via a PKA-independent mechanism: network disinhibition by 
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the GABAA receptor blocker bicuculline plus the K
+
 channel blocker 4-
aminopyridine (to enhance burst frequency (Hardingham et al., 2001a)). Induction of 
CRE-mediated gene expression by B/4AP-induced AP firing was not lower in RIIß-
null neurons (Fig. 1.3D).  This indicates that cAMP/PKA signalling is not a major 
mediator of CRE-dependent gene expression downstream of AP firing, in agreement 
with previous studies (Pokorska et al., 2003).  Collectively these observations 
support a model whereby PACAP-induced PKA signalling weakly activates CREB 
directly, but triggers strong CREB activation by promoting AP firing which in turn 





























Figure 1.3. PACAP induces CRE-dependent gene expression, which is neuroprotective, 
and relies on AP firing. (A) PACAP induces CRE-mediated gene expression. Neurons were 
transfected with a CRE-Firefly luciferase vector, pTK renilla transfection control and vectors 
encoding either ICER1 or control (β-globin). At 24 h post transfection, neurons were treated 
with PACAP and luciferase expression was measured after a further 4 h CRE-Firefly 
luciferase activity was normalised to Renilla control (*P<0.05, n = 3) Right Effect of the 
PACAP antagonist (Antag. PACAP6-38, 1 µM) on PACAP induction of CRE-luciferase
(*P<0.05, n = 3). (B) PACAP mediated long-lasting neuroprotection depends on activation of 
CRE-mediated gene expression. Left panel illustrates the experimental protocol. Briefly, 
neurons expressing GFP plus either ICER1 or β-globin control were treated ± PACAP 24 h 
post-transfection and then all cells were placed in TTX-containing medium after a further 24 
h, at which point images of GFP-expressing neurons were taken (t=0 in the upper schematic). 
The fate of these cells was then monitored at 24 and 48 h after this medium change. 250-400 
cells were analysed per treatment across 6 cultures within 3 independent experiments. 
(*P<0.05). (C) PACAP induced CRE-dependent gene expression is dependent on AP firing. 
Neurons were treated with PACAP where indicated for 4 h; all other drugs were added 1 h 
beforehand (*P<0.05, n=7). (D) PACAP and forskolin-induced activation of CRE-mediated 
gene expression is disrupted in RIIβ-deficient neurons: both AP firing-dependent and 
independent components. Forskolin was used at 5 µ M. For comparison is an illustration of 
the RIIβ-independence of CRE activation triggered by promoting AP firing by network 
disinhibition through treatment with the GABAA receptor blocker bicuculline (50 µ M) plus 





PACAP-induced CBP, but not CREB phosphorylation, requires AP firing. 
 
We next investigated which CRE-activating molecular events triggered by PACAP 
treatment are reliant on activity-dependent Ca
2+
 signals, and whether any can be 
triggered in an activity-independent manner by direct PKA signalling.  CREB 
phosphorylation on serine-133 is essential for CREB activation since it triggers the 
recruitment of the coactivator CREB binding protein (CBP (Chrivia et al., 1993)).  
CREB phosphorylation was induced by PACAP treatment (Fig. 1.4A).  Interestingly, 
TTX treatment did not interfere with PACAP-induced CREB phosphorylation (Fig. 
1.4B), whilst the PKA inhibitor H-89 blocked CREB phosphorylation (Fig. 1.4A).  
Serine-133 of CREB is a good substrate for PKA (Gonzalez and Montminy, 1989), 
and these data indicate that PACAP-induced PKA activity is sufficient to result in the 
direct phosphorylation of CREB, and that AP firing is not needed for this particular 
activation step. 
 
However, CREB serine-133 phosphorylation is necessary but not sufficient for full 
activation of CREB.  Key secondary activation steps centre around CREB 
coactivators CBP and CRTC. CBP is recruited to serine 133 phospho-CREB and is 
itself activated by nuclear CaM kinase activity (Chawla et al., 1998; Hardingham et 
al., 1999; Impey et al., 2002).  To study activation of CBP in isolation we tested the 
ability of CBP, tethered to the promoter by means of fusion to the GAL4 DNA-
binding domain (DBD), to confer inducibility upon PACAP stimulation to a 
luciferase reporter containing four GAL4 sites.  GAL4-CBP mediates strong 
activation of the reporter gene, compared to the GAL4 DBD alone (Fig. 1.4C).  
Furthermore, PACAP strongly activated CBP-mediated gene expression (Fig. 1.4C).  
To confirm the importance of CBP in activation of CREB by PACAP, we studied the 
effect of expressing the viral oncoprotein E1A, which inhibits CBP-mediated gene 
expression by directly interacting with it (Bannister and Kouzarides, 1995).  E1A 
expression strongly inhibited GAL4-CBP-mediated gene expression (Fig. 1.4D) and 
also inhibited the activation of CRE-mediated gene expression (Fig. 1.4E).  Thus, 
PACAP activates CBP, an important coactivator of CREB-dependent gene 
expression.  Since CBP is subject to activity-dependent transactivation via CaM 
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kinase activity, which contributes to Ca
2+
-activation of CRE-mediated gene 
expression (Hardingham et al., 1999; Impey et al., 2002), we wanted to know 
whether PACAP also triggered CBP and CRE activation by this route.  Indeed, 
PACAP activation of CBP was TTX-sensitive, and was also inhibited by treatment 
with the CaM kinase inhibitor KN-62 (Fig. 1.4F).  Moreover, KN-62 inhibited 
PACAP-induced activation of the CRE-reporter, an effect that was occluded by 
blockade of AP firing with TTX (Fig. 1.4G).  This is consistent with the activity-
dependent, but not independent, components of CRE-induction being mediated partly 
by CaM kinase activity, potentially via the established route of CBP activation.  
However, the inhibitory effect of KN-62 on PACAP-induced CRE activation was not 
as strong as that of TTX (Fig. 1.4G), indicating that other activity-dependent 

























Figure 1.4. CBP activation, but not CREB phosphorylation, require PACAP-induced AP 
firing. A, B) PACAP induces phosphorylation of CREB at serine-133 in a TTX-insensitive, PKA-
dependent manner. Neurons were pre-treated with TTX or H-89 and then treated for 15 min with 
PACAP (example blots are shown) Right Quantitation of phospho-CREB levels normalised to total 
CREB (*P<0.05, n = 4). C) PACAP stimulation induces CBP-mediated gene expression. Neurons 
were transfected with GAL4-luciferase reporter, pTK Renilla and either expression vector encoding 
a GAL4-CBP fusion protein, or just the GAL4 DNA binding domain (GAL4 DBD). At 24 h post 
transfection, neurons were stimulated with  PACAP for 4 h, and luciferase expression was measured 
and normalised to Renilla control, *P<0.05 (n = 4). D) The viral oncoprotein E1A inhibits PACAP 
mediated CBP activation. Neurons were transfected with GAL4-Luciferase, pGAL4-CBP, pTK-
Renilla and vectors encoding either E1A or β-globin control. Neurons were stimulated with PACAP 
for 4 h; P<0.05* (n = 4). E) E1A inhibits PACAP mediated increase in CRE-dependent gene 
expression. The effect of E1A expression on the PACAP-induced activation of CRE-luciferase was 
measured. *P<0.05 (n=4). F) PACAP-induced activation of GAL4-CBP-mediated gene expression 
measured in the presence of the indicated inhibitors, added 1 h prior to PACAP. *P<0.05 (n=5). KN-
62 was used at 10 µM. G) CaM kinase activity contributes specifically to the AP firing-dependent 
component of PACAP-mediated CRE induction. Neurons were treated as indicated and PACAP-




PACAP-induced AP firing mediates calcineurin-dependent CRTC1 nuclear 
import 
 
Whilst CREB serine-133 phosphorylation is necessary for full activation of CREB, it 
is not sufficient.  A key secondary activation step involves the coactivator CRTC 
(CREB-regulated transcription coactivator), which is subject to Ca
2+
-dependent 
nuclear import, where it binds to CREB and enhances its affinity for both CBP and 
the basal transcriptional machinery (Conkright et al., 2003; Screaton et al., 2004; 
Zhou et al., 2006; Kovacs et al., 2007; Li et al., 2009). 
 
We confirmed the importance of CRTC for CRE activation: expression of a 
dominant negative mutant of CRTC1 (CRTC1-DN, (Zhou et al., 2006)) strongly 
inhibited PACAP-induction of the CRE-mediated gene expression, as well as that 
induced by B/4AP treatment (Fig. 1.5A).  We also investigated the importance of 
CRTC signalling in PACAP-mediated long-lasting neuroprotection, using an 
identical protocol to that used in Fig. 1.3B, except that the ICER-encoding vector 
was replaced with that of CRTC1-DN.  At the 48 h timepoint (after removal of 
PACAP from the medium) a very small, but statistically significant, amount of 
PACAP-dependent neuroprotection was still observed at 48 h in CRTC1-DN-
expressing neurons. However, levels of neuronal death in CRTC1-DN-expressing 
neurons previously exposed to PACAP were significantly higher than control-
transfected cells previously exposed to PACAP (Fig. 1.5B,C). Thus, CRTC1-DN 
interferes with neuroprotection evoked by transient exposure to PACAP, consistent 
with the role of CREB in this process, and the importance of CRTCs in CREB-
mediated gene expression. 
 
Nuclear translocation of CRTC is an important step in the full activation of CREB-
dependent gene expression (Screaton et al., 2004).  We found that PACAP treatment 
caused the nuclear translocation of CRTC that was inhibited by TTX (Fig. 1.5D,E).  
Activity-dependent Ca
2+
 influx is known to induce CRTC translocation through 
activation of the Ca
2+
-dependent phosphatase calcineurin.  Calcineurin subsequently 
dephosphorylates CRTC, triggering its nuclear import and coactivation of CREB (Li 
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et al., 2009).  This mechanism is employed in the case of PACAP signalling: 
inhibition of calcineurin activity by treatment with the inhibitor FK-506 inhibited 
PACAP-mediated CRTC translocation (Fig. 1.5D) and PACAP-mediated induction 
of CRE-mediated gene expression (Fig. 1.5F). 
  
Taken together, these observations suggest that a key reason why TTX inhibits 
PACAP-activation of CRE-mediated gene expression is that blockade of CRTC 
nuclear import renders nuclear levels of CRTC too low to efficiently coactivate 
CREB.  We postulated that if CRTC was indeed limiting, then if we overexpressed 
CRTC, then this might rescue the inhibitory effect of TTX on PACAP activation of 
the CRE reporter.  Although overexpressed CRTC would be mainly cytoplasmic, we 
reasoned that since a proportion of it is nuclear then this could rescue the deficiency 
in nuclear levels.  We found this to be the case: overexpression of CRTC reversed 
the inhibitory effect of TTX on PACAP-induction of CREB-dependent gene 
expression (Fig. 1.5G). CRTC overexpression, however, did not further enhance 
PACAP activation of CREB-mediated gene expression in the absence of TTX (Fig. 
1.5G), indicating that PACAP-induced firing causes sufficient CRTC nuclear import 
such that levels of nuclear CRTC are not limiting for efficient coactivation of CREB.  
Thus, while PACAP activation of direct PKA signalling is sufficient to induce CREB 
phosphorylation, this is insufficient to activate CREB on its own.  Enhancement of 
AP firing is critical in order to induce calcineurin-dependent CRTC nuclear 






















Figure 1.5 PACAP induces nuclear translocation of CRTC1, necessary for the AP 
firing-dependent component of CREB activation. (A) CRTC1 dominant negative inhibits 
PACAP mediated activation of CREB. Neurons were transfected with CRE-luciferase, pTK-
Renilla and vectors encoding either a CRTC1 dominant negative mutant or control (b-
globin). Neurons were stimulated PACAP or bicuculline plus 4-AP (BiC) (*p < 0.05, n = 4). 
B, C) PACAP mediated long-lasting neuro-protection depends on CRTC1. The experimental 
protocol is the same as that illustrated schematically in Fig. 3(b). Briefly, neurons expressing 
GFP plus either CRTC1-DN (dominant negative) or b-globin control were treated ± PACAP 
24 h post-transfection and then all cells were placed in TTX-containing medium after a 
further 24 h, at which point images of GFP-expressing neurons were taken. The fate of these 
cells was then monitored at 24 and 48 h after this medium change (*p < 0.05, paired T-test, n 
=3; #p < 0.05, paired T-test comparing control to PACAP within each condition/timepoint). 
(C) shows example pictures. Scale bar = 20 µm. (D ,E) PACAP induces CRTC1 nuclear 
translocation via activity-dependent calcineurin signalling. Neurons were transfected with a 
vector encoding GFP-tagged CRTC1. At 24 h post-transfection, neurons were treated with 20 
ng/mL leptomycin B for 30 min to block nuclear export [to enable import to be observed 
more clearly (Kovacs et al. 2007)], plus the indicated inhibitors (1 lM TTX, 10 lM H-89 or 
10 lM FK-506) and then PACAP added for 30 min prior to fixing of the cells and analysing
localisation of GFP-CRTC1 in 400–800 cells per treatment (*p < 0.05, n = 4–8). (E) shows 
example pictures. (F) PACAP-induced activation of CRE-mediated gene expression requires 
the Ca2+ -dependent phosphatase calcineurin. Where used, FK-506 was added 1 h prior to 
PACAP stimulation (*p < 0.05, n = 4). (G) CRTC1 over-expression rescues the inhibition of 
PACAP-mediated CRE activation by TTX. Neurons were transfected with CRE-luciferase, 
pTK-Renilla and either vectors encoding CRTC1 or b-globin control. 24 h post-transfection
the neurons were stimulated with PACAP ± TTX or bicuculline + 4-AP (BiC) as indicated. 
Over-expression of CRTC1 does not further enhance CRE activation by BiC or PACAP, 
suggesting that levels are not limiting, however, it strongly enhances levels induced by 








Figure 1.6. Schematic illustration of the role of activity-dependent Ca2+ signalling in 
PACAP-mediated neuroprotection. Activation of PACAP receptors leads to activation of 
PKA via the classical G-protein-adenylate cyclase (AC)-cAMP (pathway 1). PKA activation 
causes an increase in synaptic strength and/or neuronal excitability leading to a strong 
increase in levels of action potential firing which in turn triggers intracellular Ca2+ influx, 
likely through synaptic receptors (e.g. NMDA receptors) or voltage-gated Ca2+ channels 
(VGCCs) (pathway 2). Activation of long-lasting neuroprotection by PACAP requires 
induction of gene expression mediated by the transcription factor CREB. CREB 
phosphorylation on serine-133 can be triggered directly by PKA in an AP firing-independent 
manner (pathway 3). However, this is insufficient to fully activate CREB-mediated gene 
expression. Ca2+/activity-dependent pathway activates neuroprotective ERK1/2 kinases
(pathway 4); and  CamKIV which phosphorylates both CREB and CBP (pathway 5).  A key 
synaptic activity dependent component of PACAP stimulated gene expression involves 
CRTC1 nuclear translocation through activation of the Ca2+-dependent phosphatase
calcineurin: pathway (6). Blue arrows and molecules indicate AP firing activity-independent 
events, while red arrows and molecules highlight the events dependent on AP firing. The 















































This study shows that certain PACAP-mediated anti-apoptotic signals in cortical 
neurons are not mediated by direct cAMP/PKA-dependent activation.  Instead, the 
primary role of cAMP/PKA signalling is to enhance neuronal network activity.  The 
resulting AP-dependent Ca
2+
 transients are the direct activators of neuroprotection, 
and induce a long-lasting phase of protection dependent on activation of CREB-
mediated gene expression.  These events are illustrated schematically in Fig. 1.6. 
 
Modulation of neuronal electrical activity by PACAP and other AC-coupled 
ligands. 
 
The ability of PACAP to induce AP firing in networks of cortical neurons is 
consistent with the known influence of intracellular cAMP on neuronal excitability.  
Neurotransmitters, neuropeptides and pharmacological compounds that activate AC 
are well-known to modulate neuronal excitability, ion channel conductance, and 
synaptic transmission and plasticity, predominantly through PKA activation (Nguyen 
and Woo, 2003).  At the synapse, pharmacological activators of AC, and agonists of 
AC-coupled receptors such as the D1/D5 dopamine receptor, or the ß-adrenergic 
receptor all mimic LTP and/or enhance EPSPs (Nguyen and Woo, 2003).  Mice 
deficient in AC1 and AC8 show deficits in LTP and spatial memory (Nguyen and 
Woo, 2003; Ferguson and Storm, 2004).  At the molecular level, PKA-mediated 
GluR1 phosphorylation at serine-845 increases AMPA receptor open probability and 
stabilizes synaptic location of AMPA receptors trafficked to the synapse during LTP 
(Banke et al., 2000; Esteban et al., 2003; Lee et al., 2003).  PACAP at low doses is 
known to enhance AMPAR currents via PKA activation (Costa et al., 2009) as well 
as synaptic NMDAR currents (MacDonald et al., 2007).  Moreover, mice deficient in 
PACAP have defective LTP at the mossy fibre synapse, implicating endogenous 
PACAP signalling in synaptic potentiation (Otto et al., 2001).  In addition to 
modifying the properties of synaptic glutamate receptors, AC-coupled PKA 
signalling also can modulate neuronal excitability by controlling the IsAHP.  IsAHP 
is mediated by a Ca
2+
 activated potassium current which is activated in response to 
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bursts of AP firing. This is a key negative regulator of neuronal excitability, inducing 
a prolonged state of hyperpolarization, and this is in turn negatively regulated by 
AC-coupled PKA activity induced either pharmacologically (e.g. forskolin) or by 
treatment with AC-coupled ligands (e.g. dopamine) (Pedarzani and Storm, 1995; 
Lancaster et al., 2006; Hu et al., 2010).  PACAP treatment itself leads to inhibition of 
IsAHP in cortical pyramidal neurons (Hu et al., 2010), which could contribute to the 
enhanced AP firing that we observe (Fig. 1.1). 
 
PACAP-induced AP firing promotes CREB-dependent neuroprotection 
 
The CREB family of transcription factors is known to be an important mediator of 
activity-dependent gene expression (Lonze and Ginty, 2002).  Activation of CREB-
mediated gene expression requires serine-133 phosphorylation which is necessary to 
recruit CBP to CREB (Chrivia et al., 1993).  Several Ca
2+
-activated kinase cascades 
can mediate this event, including the Ras-ERK1/2 pathway and also nuclear CaM 
kinases (Soriano and Hardingham, 2007).  However, PACAP induced CREB 
phosphorylation does not require these activity-dependent pathways, since even 
when AP firing is blocked CREB phosphorylation is still observed (Fig. 1.4).  This is 
consistent with the fact that PKA is also a CREB kinase and indicates that PACAP-
induced PKA activity is strong enough to mediate this event directly. 
 
However, direct PKA activity induced by PACAP is not sufficient to induce 
subsequent activation steps, including nuclear translocation of CRTCs.  CRTCs 
enhance the interaction of CREB with the TAF(II)130 component of TFIID 
following its recruitment to the promoter (Conkright et al., 2003).  CRTC also plays 
an important role in assisting the recruitment of CREB's coactivator CBP to 
phosphorylated serine-133 CREB (Ravnskjaer et al., 2007).  Calcineurin promotes 
nuclear translocation of CRTC2 through calcineurin-mediated dephosphorylation of 
serine-171 (Screaton et al., 2004).  Translocation can be enhanced/synergized by 
PKA signalling with causes the inhibition of the serine 171 -kinase– salt-inducible
 
kinase-2 SIK2 (Screaton et al., 2004).  CRTC1 is the major isoform in the brain and 




 signals promote the nuclear translocation of CRTC1, dependent on 
calcineurin signalling which directly dephosphorylates CRTC1 (Bittinger et al., 
2004).  Analogously with CRTC2, cAMP signals can also trigger the translocation of 
CRTC1 (Bittinger et al., 2004), most likely through the inhibition of SIK-mediated 
phosphorylation.  In neurons, calcineurin activation is sufficient to trigger CRTC1 
translocation (Li et al., 2009).  The requirement for AP firing and calcineurin 
signalling for PACAP treatment to induce CRTC1 translocation strongly indicates 
that PACAP-induced PKA activity is not strong enough on its own to promote 
sufficient CRTC1 translocation directly, although may be playing a supporting role. 
 
A caveat of some the data presented here is the reliance of a single drug to suggest 
the involvement of a particular enzyme, which runs the risk of reporting false 
positives due to non-specific actions of the drug.  The PKA inhibitor H-89 for 
instance exhibits a moderately inhibitory effect on protein kinase G with an IC50 
concentration 10-fold higher than that required for PKA (Chijiwa et al., 1990), with 
lesser effects on other kinases; thus cannot be referred to as a specific inhibitor of 
PKA activity.  Whilst we are confident that the results are due to the loss of PKA 
activity, especially given in context of the entire body of work, use of a single drug 
can limit our conclusions.  An example of such is our extrapolation of the inhibition 
of PACAP induced CRE-mediated gene expression by the CaM kinase inhibitor KN-
62 (Fig. 1.4G).  Whilst this likely due to the inhibitory effect of KN-62 on CaMKIV, 
as constitutively active CaMKIV but not CaMKII has been shown to increase CRE-
mediated gene expression (Chawla et al., 1998); we cannot be certain of the identity 
of the specific CaM kinase blocked, since both are inhibited by the drug with very 
similar efficiencies (Enslen et al., 1994).  This highlights the benefits of using 
multiple drugs, or multiple strategies such as siRNA knockdown or dominant-






PACAP prevents neuronal loss and dysfunction in vivo: potential role of 
enhanced AP firing. 
 
PACAP has been reported to protect neurons against a variety of insults including 
ceramide, glutamate and hydrogen peroxide-induced death (Vaudry et al., 2009), 
insults that synaptic activity also protects against (Lee et al., 2005; Papadia et al., 
2005; Papadia et al., 2008).  Importantly, activation of CREB-mediated gene 
expression is implicated in activity-dependent protection against both apoptotic and 
excitotoxic insults (Lee et al., 2005; Papadia et al., 2005).  Based on this study, it 
may be that indirect activity-dependent signalling to CREB contributes to the 
neuroprotective effects of PACAP in vitro and also begs the question as to whether 
any of its in vivo effects are similarly due to enhancing neuronal activity. 
 
In vivo administration of PACAP reduces neuronal loss in the substantia nigra in 
acute models of Parkinson's disease: 6-OHDA and MPTP treatment (Reglodi et al., 
2004; Reglodi et al., 2006).  However, most neuroprotective studies on PACAP have 
centred on excitotoxic trauma: principally stroke and traumatic brain injury (TBI).  
PACAP crosses the blood brain barrier and can be administered intravenously to 
decrease damage in several models of ischemia and is effective even when 
administered several hours after the ischemic episode (Uchida et al., 1996; Reglodi et 
al., 2000; Chen et al., 2006; Ohtaki et al., 2008).  Enhanced neuronal AP firing is 
known to protect neurons against excitotoxic cell death including ischemic 
conditions (Lee et al., 2005; Tauskela et al., 2008) and so the notion that PACAP can 
reduce neuronal damage in part by promoting AP firing is plausible.  In addition to 
reducing stroke-induced damage, post-insult PACAP treatment also reduces the 
extent of axonal damage following TBI (Farkas et al., 2004; Tamas et al., 2006b).  
TBI is characterised by brief acute hyperactivity of ionotropic glutamate receptors, 
including NMDA receptors, which mediate acute excitotoxic damage, followed by 
sustained loss of function (Biegon et al., 2004; Yaka et al., 2007).  As such the 
NMDA receptor has been proposed to rapidly switch between ‘destructive’ and 
‘recovery’ roles (Biegon et al., 2004; Yaka et al., 2007).  In the immature brain, 
treatment with NMDAR antagonists reduces primary excitotoxic death but 
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exacerbates secondary apoptosis, resulting in increased overall death (Pohl et al., 
1999).  By promoting AP firing, PACAP may boost the recovery phase post-injury 
by mechanisms related to those described in this study, as well as others more 
specific to the activity-dependent protection of axons. 
 
Of course, enhanced neuronal activity is unlikely to mediate all the effects of 
PACAP in the CNS: direct activity-independent effects are likely to be exerted in 
neurons as well.  Moreover, there are well-documented neuroprotective effects of 
PACAP acting indirectly via non-neuronal cells. For example, PACAP stimulates the 
astrocytic release of neuroprotective IL-6 (Ohtaki et al., 2008) and may also suppress 
microglial activation, thus reducing the release of potentially harmful cytokines that 
can form part of the post-ischemic response (Vaudry et al., 2009). Nevertheless, the 
impact of PACAP on neuronal activity should be taken into account when assessing 
















Influence of synaptic activity on the 
























Due to the longevity of neurons, their constitutive and inducible production of ROS, 
and their low expression of antioxidant enzymes (Mavelli et al., 1982; Halliwell, 
1992; Yermolaieva et al., 2000); the dynamic regulation of antioxidant defences in 
neurons is vital.  Increased synaptic activity may raise the demands for antioxidants, 
as this increases metabolic requirements and can induce enzymatic production of 
H2O2 (Boveris and Chance, 1973; Diaz-Hernandez et al., 2005; Brennan et al., 2009).  
The GSH antioxidant pathway displays greater expression in neurons than alternative 
H2O2 detoxifying systems (Mavelli et al., 1982), and both pharmaceutical or genetic 
blockade of GSH synthesis causes oxidative stress and neuronal death (Jain et al., 
1991; Mizui et al., 1992; Diaz-Hernandez et al., 2005).  GSH synthesis can be 
regulated post-transcriptionally by its feedback inhibition (Richman and Meister, 
1975), and can be increased by supply of precursors from astrocytes (Dringen et al., 
1999; Diaz-Hernandez et al., 2005; Vargas and Johnson, 2009).  However GSH 
synthesis may also be controlled by its subunit mRNA expression, with upregulation 
of its catalytic subunit inducing increased GSH levels (Dickinson and Forman, 2002; 
Franklin et al., 2009).  We considered the possibility that synaptic activity, 
particularly through stimulation of NMDARs, could drive changes in the GSH 
pathway through changes in gene expression. 
 
We have recently observed that synaptic NMDAR activation promoted a 
neuroprotective response against oxidative insult, decreasing consequent intracellular 
ROS formation.  This protection was partly mediated by coordinated changes in gene 
expression that enhanced the action of antioxidant enzymes Trx and Prx (Papadia et 
al., 2008).  Due to the prevalence of the GSH pathway and its obvious importance in 
neurons, we wished to investigate if increased synaptic activity could cause similar 
enhancement of this antioxidant pathway. 
 
We found that the protection conferred by increased synaptic activity against 
oxidative insult was lost in the presence of a GCL inhibitor; indeed GCL inhibition 
sensitised synaptically active neurons to sub-toxic H2O2 treatment compared to 
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controls.  Whilst not increasing GSH levels in unstressed neurons, enhancement of 
synaptic activity led to a maintenance of GSH levels after oxidative insult, an effect 
dependent on GCL activity and NMDAR stimulation.  In the presence of GCL and 
GR inhibitors, electrically active neurons displayed an increased metabolism of 
GSH, suggesting an increased GPX activity.  Increases in GCL, GR and GPX 
enzymatic activity were observed in electrically active neurons; these were matched 
by changes in the mRNA expression of GCLC, GSR, GPX2 and GPX4.  NMDAR 
blockade in vivo caused a decrease in GSH pathway enzyme mRNA expression and 
GCL activity after 12 h, with a subsequent loss of GSH after 24 h.  These data 
suggest that NMDAR activation regulates the mRNA expression and thus the activity 
of the GSH antioxidant pathway, which may be intrinsic to the neuroprotective effect 
























Synaptic activity does not increase neuronal GSH levels, but requires its 
synthesis to mediate neuroprotection against oxidative insult 
 
Having previously observed an induction of antioxidant defences in electrically 
active neurons, conferring a strong resistance against oxidative insult (Papadia et al., 
2008), we wished to investigate the possible role of the GSH antioxidant pathway in 
this resistance.  To do this, neurons were treated for 24 h in trophically deprived 
media with GABAA receptor antagonist bicuculline and K
+
 channel blocker 4-
aminopyridine (B/4AP), a treatment that in turn disinhibits the network by releasing 
excitatory neurons from tonic inhibition by GABAergic interneurons and inhibits 
neuronal hyperpolarisation after action potentials, leading to an increase in action 
potential firing and synaptic NMDAR Ca
2+
 currents (Hardingham et al., 2001b).  
B/4AP treatment caused a resistance against H2O2 treatment (Fig 2.1A), in 
accordance with previously observed results (Papadia et al., 2008).  To investigate 
the role of the GSH pathway in this protection we blocked GSH synthesis with the 
potent GCL inhibitor buthionine sulfoximine (BSO), which binds to the cysteine 
accepting area of the GCL active site (Griffith and Meister, 1979).  BSO treatment 
sensitised neurons to oxidative insult, causing pronounced neuronal death in response 
to the otherwise sub-toxic 50 µM dose of H2O2, and abolished the neuroprotective 
effect of B/4AP treatment (Fig 2.1A).  Furthermore B/4AP treatment in the presence 
of BSO sensitised neurons to the lower dose of 25 µM H2O2 compared to similarly 
treated control neurons (Fig 2.1A), surprising given the observed resistance of 
synaptically active neurons to oxidative insult.  We hypothesised that these 
contrasting results could be caused by an influence of synaptic activity on the GSH 
pathway.  The GCL dependent protection by B/4AP treatment could be caused by a 
synaptic activity dependent increase in GSH synthesis or recycling.  On the other 
hand, the sensitisation of electrically active neurons to sub-toxic oxidative insult in 
the presence of BSO could be explained by an increased GSH metabolism; in the 
absence of de novo GSH synthesis this would deplete GSH levels, which could in 
turn cause a sensitisation to oxidative insult. 
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To investigate GSH levels in electrically active neurons we employed a fluorescent 
probe MCB, which passes into cells and is conjugated to GSH in a reaction catalysed 
by glutathione S-transferase (Shrieve et al., 1988).  No change in GSH levels was 
observed after 24 h treatment with B/4AP, nor after NMDAR blockade with MK801; 
however 24 h BSO treatment significantly decreased GSH levels (Fig 2.1B).  This 
was recapitulated using an alternative colorimetric assay of GSH showing 
concordant results (Fig 2.1C).  The reduction of neuronal GSH levels by GCL 
inhibition agreed with previous results (Ratan et al., 1994; Andersen et al., 1996; 
Bolanos et al., 1996; Diaz-Hernandez et al., 2005) that highlight the requirement of 
de novo synthesis for maintenance of GSH levels; furthermore this reduction in GSH 
explained the hypersensitivity of BSO treated neurons to oxidative insult.  Whilst 
B/4AP treatment did not change GSH levels, we hypothesised that this did not rule 
out an influence of synaptic activity on GSH synthesis.  GCL activity is inhibited in a 
non-allosteric fashion by GSH (Richman and Meister, 1975), which could obscure 
any increase in GSH synthesis capability in unstressed neurons.  Accordingly, we 
















































































Figure 2.1.  Inhibition of Glutathione synthesis blocks synaptic activity 
mediated neuroprotection.  A) Analysis of rat cortical neuronal death.  
Neurons were placed in trophically deprived media and treated with 50 µM
bicuculline and 250 µM 4-aminopyridine (B/4AP here and throughout) for 24 h 
in the presence with or without BSO (100 µM throughout), followed by overnight 
stimulation with concentration of H2O2 indicated, after which cells were fixed 
and DAPI stained. *p<0.05 compared to B/4AP + 25 µM H2O2, n=3. B) GSH 
levels measured using MCB fluorescent dye. Neurons were treated as indicated 
for 24 h, with 50 µM MCB, added 30 min before stimulation termination (in all 
MCB figures). Cells were then lysed, fluorescence recorded and normalised to 
protein content. Levels normalised to respective control, *p<0.05, n=4.  C) GSH 
levels measured using colorimetric assay. Neurons were treated as indicated for 







































Synaptic activity maintains GSH levels and inhibits its depletion in response to 
oxidative insult 
 
Since the concentration of GSH in neurons is influenced by feedback inhibition, we 
investigated the effect of synaptic activity on GSH depletion.  To do this, neurons 
were treated for varying lengths of time with H2O2 over at 24 h period, and their 
GSH levels were subsequently recorded using MCB (Fig 2.2A).  Under these 





)is increased by the rate of GSH 
metabolism (m), and decreased by the rate of GSH recycling (r) and the rate of GSH 






= m – (r + s) 
 
Through selective inhibition of GSH pathway enzymes, we could then determine the 













BSO + BCNU = m 
 












BSO = s 
 
Whilst B/4AP treatment of neurons had no effect on GSH levels in unstressed 
conditions, the resistance of electrically active neurons to oxidative insult made us 
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hypothesise that these neurons might maintain higher GSH levels in stressed 





 was reduced in B/4AP 
treated neurons: whilst control neurons displayed GSH depletion over time in 
response to H2O2 stimulation, electrically active neurons maintained their GSH levels 






 increased in both control and B/4AP treated neurons.  The difference 




































suggesting that increased synaptic activity causes an increased GSH synthesis in 





BSO was still 
significantly larger in controls than in B/4AP treated neurons (Fig 2.2C).  Thus, these 
data suggested that the resistance to oxidative stress in electrically active neurons is 










































































































Figure 2.2.  Synaptic activity inhibits GSH depletion.  A) Schematic of 
experiment. After 24h in trophically deprived media, control and B/4AP treated 
neurons were stimulated with 100 µM H2O2 ± 100 µM BSO between 24 and 0 h, 
followed by MCB treatment and subsequent recording of fluorescence from cell 
lysates, which was normalised to protein content and respective control. B) 
Graph showing average GSH levels at each time point and derived slope 
indicating rate of GSH depletion.  C)  Analysis of GSH depletion gradient of 
neurons in the presence of H2O2.  Each experiment is normalised to their 
respective control.  D) Difference in GSH depletion of neurons between control 





























































Synaptic activity increases GSH metabolism 
 
Taking into account the neuroprotective effect of B/4AP treatment, the increased cell 
death caused by low dose H2O2 treatment observed in neurons treated concurrently 
with B/4AP and BSO was intriguing.  We considered that this apparent contradiction 
could be explained by an increased metabolism of GSH, which would reduce GSH 
levels in the absence of de novo synthesis, thus sensitising neurons to sub-toxic 
oxidative insult.  To test this we measured GSH depletion in the presence of BSO 
and GR inhibitor carmustine (bis-chloroethylnitrosourea (BCNU)) (Fig 2.3A).  The 
presence of these two inhibitors was sufficient to deplete neuronal GSH over an 8 h 
period, the rate of which was increased by concurrent stimulation with H2O2 (Fig 































BSO + BCNU in both H2O2 
stressed and unstressed neurons (Fig 2.3C).  This data confirms an increased GSH 
metabolism in electrically active neurons, which may mediate the sensitisation 








despite the higher rate of (m) in B/4AP treated neurons, we can extrapolate that GSH 
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Figure 2.3.  Synaptic activity increases metabolism of GSH. A)  Schematic of 
experiment.  After 24h in trophically deprived media, control and B/4AP treated 
neurons were stimulated with 100 µM BSO and 20 µM BCNU ± 100 µM H2O2
between 8 and 0 h, followed by MCB treatment and subsequent recording of 
fluorescence from cell lysates, normalised to protein content and respective 
control  B) Graph showing average GSH levels at each time point and derived 
slope indicating rate of GSH depletion (n=7).  C)  Analysis of GSH depletion 
gradient of neurons treated with BSO and BCNU.  Each experiment is 


























































GSH depletion block is dependent on NMDAR but not on the presence of 
astrocytes 
 
That synaptic activity would have an effect on GSH pathway enzymes was of great 
interest.  We had previously shown that increased electrical activity upregulated 
genes regulating the antioxidant thioredoxin and peroxiredoxin pathways (Papadia et 
al., 2008), a process mediated by NMDAR signalling.  Thus we investigated whether 
the maintenance of GSH levels observed in Fig 2.2 was dependent on the activation 
of NMDARs.  Blocking NMDAR activation with MK801 abolished B/4AP mediated 





 to that of control treated neurons 





 compared to both control neurons and neurons treated with concurrently 
with B/4AP and MK801.  The difference to controls is perhaps indicative of the 
increased vulnerability of neurons after NMDAR blockade (Ikonomidou et al., 1999; 
Ikonomidou et al., 2000); whilst the difference between MK801 treated neurons and 
B/4AP and MK801 treated neurons may be mediated by Ca
2+
 entry through voltage 
gated L-type Ca
2+
 channels, which may be opened in the presence of the neuron 
depolarising 4AP. 
 
Astrocytes protect neurons from oxidative stress (Desagher et al., 1996) and 
astrocytic GSH synthesis has been shown to protect neurons from oxidative stress 
(Shih et al., 2003);  GSH synthesis in known to be greater in astrocytes than neurons 
(Raps et al., 1989), and astrocytes are thought to supply neurons with GSH 
precursors (Dringen et al., 1999), indeed neurons co-cultured with astrocytes display 
greater GSH concentrations (Bolanos et al., 1996).  Accordingly we tested whether 
the maintenance of GSH in B/4AP treated neurons was dependent on the presence of 
astrocytes by performing the experiment described in figure 2.2A on cultures treated 
with mitosis inhibitor AraC on Div 0, which reduces number of astrocytes in culture 
to below 0.1% (see methods).  Maintenance of GSH levels of neurons in astrocytes 
free cultures treated with B/4AP was observed, matching the effect demonstrated in 



























































































































































































































Figure 2.4.  Block of GSH depletion is NMDAR dependent and Astrocyte
independent. A,B) MK801 blocks B/4AP protection of GSH levels, neurons 
were treated as described by Fig 2.2A, except 50 µM MK801 was added 30 min 
before B/4AP to conditions indicated. A) Graph showing average GSH at each 
time point and derived slope indicating GSH depletion rate, and B) rate of GSH 
depletion normalised to control (n = 7, *p <0.05). C,D) B/4AP treatment protects 
GSH levels in the absence of astrocytes, neurons treated at Div 0 with AraC (A-
F: Astrocyte Free) and neurons prepared normally (Mix – AraC treated at Div 5) 
were treated in parallel as described in Fig 2.2A. C) Graph showing average GSH 
content at each timepoint and slope indicating GSH depletion rate, and D) rate of 
GSH depletion normalised to Early AraC treated control (n =  4, *p < 0.05). E) 
Difference in GSH depletion of neurons from Astrocyte Free cultures between 























BSO)) was greater in B/4AP treated astrocytes-free neuronal 
cultures (Fig 2.4E), again matching observations demonstrated in astrocytes 
containing cultures.  This indicates that the upregulation of GSH synthesis observed 
was intrinsic to neurons and independent of the presence of astrocytes in our 
cultures. 
 
Synaptic activity upregulates GSH pathway enzyme activity 
 
Whilst the previous experiments provide a novel cellular method of investigating 
GSH production, metabolism and recycling, we wished to confirm the proposed 
increase in GSH pathway enzyme activity through established enzymatic assays.  
Analysis of lysates of neurons would moreover be instructive as to the capacity of 
enzymatic activity; which in the case of GCL, though modulated by post-
translational changes, is predominantly determined by the expression of its subunits 
(Dickinson and Forman, 2002; Franklin et al., 2009).  Thus to confirm the activity of 
GSH pathway specific enzymes we performed canonical enzyme assays for each 
using cell lysates obtained from cortical cultures treated for 24 h with B/4AP and/or 
MK801.  GCL activity was recorded using a fluorescent probe NDA, which forms 
covalent bonds to the GSH precursor glutamyl-cysteine (White et al., 2003).  B/4AP 
treatment significantly upregulated GCL activity in an NMDAR dependent manner, 
evidenced by MK801 block (Fig 2.5A).  GR activity was determined by recording 
NADPH loss over time in the presence of excess GSSG (Carlberg and Mannervik, 
1985); we observed an increase after B/4AP treatment that was not blocked by 
MK801 (Fig 2.5B).  GPX activity was determined by recording NADPH loss in the 
presence of excess GSH and GR (Flohe and Gunzler, 1984); again activity of this 
enzyme was upregulated by B/4AP in an NMDAR independent manner.  Crucially 
these data confirm the increased GSH pathway enzyme activity in synaptically active 







Figure 2.5. Synaptic activity increases GSH pathway enzyme activity.         
A) Glutmaylcysteine Ligase activity; neurons were treated for 24 h as indicated, 
with 50 µM MK801 added 30 min before, then lysates were analysed for GCL 
activity, normalised to protein levels, then to control activity (n = 6, *p <0.05). 
B) Glutathione Reductase activity; neurons were treated for 24 h as indicated, 
then lysates were analysed for GR activity, normalised to protein levels, then to 
control activity (n = 9 con and B/4AP, n = 6 MK801 and B/4AP + MK801, *p 
<0.05). C) Glutathione Peroxidase activity; neurons were treated for 24 h as 
indicated, then lysates were analysed for GPX activity, normalised to protein 


















































































































































Synaptic activity upregulates GSH pathway enzyme mRNA expression 
 
It has been established that synaptic activity can mediate neuroprotection through the 
regulation of particular gene expression (Zafra et al., 1992; Papadia et al., 2008; 
Zhang et al., 2009), moreover changes in GCL enzyme activity are predominantly 
influenced by changes in its subunit mRNA expression (Dickinson and Forman, 
2002; Franklin et al., 2009).  Accordingly we investigated whether the upregulation 
of GSH pathway enzyme activity was concurrent with an increase in their mRNA 
expression.  Real-time qPCR was performed using cDNA produced from RNA 
isolated from neurons simulated with B/4AP and/or MK801 for 24 h.  Of the 
subunits involved in GSH synthesis GCLC, encoding the catalytic subunit of GCL, 
was upregulated by synaptic activity in a NMDAR dependent manner (Fig 2.6A).  
GCLM, the modifying subunit of GCL, and GSS, encoding GSH synthetase the final 
but not rate-limiting step of GSH synthesis, were not upregulated by B/4AP 
treatment (Fig 2.6B).  GSR, encoding the recycling enzyme GR, was upregulated by 
synaptic activity in an NMDAR independent manner (Fig 2.6C), mirroring the result 
of the enzymatic assay.  As mentioned before, the GPX family consists of at present 
8 known members; we investigated the expression of the selenocysteine containing 
GPXs 1-4, as GPX6 is known to be solely expressed in olfactory bulb.  Of the genes 
investigated, GPX4 and GPX2 were both upregulated by B/4AP treatment, with 
regulated GPX4 in an NMDAR dependent manner (Fig 2.6D, E). 
 
To establish a causal link between the upregulation of mRNA to the increased GSH 
pathway enzyme activity, we the GCL assay on lysates obtained from neurons 
treated with the transcription inhibitor actinomycin D.  GCL activity was inhibited by 
actinomycin, blocking any increase conferred by B/4AP stimulation (Fig 2.7).  Taken 
together we can conclude that synaptic activity increases GSH synthesis through the 





































































































































Figure 2.6. Synaptic activity upregulates GSH pathway enzyme mRNA 
expression. Neurons were treated as indicated for 24 h, mRNA was then isolated, 
converted to cDNA, and analysed using qPCR, expression normalised to 
respective control. A) γGC ligase catalytic subunit (GCLC) mRNA expression (n 
= 3, *p <0.05). B) γGC ligase modifier subunit (GCLM) and GSH synthetase
(GSS) mRNA expression (n = 3). C) GSH Reductase (GSR) mRNA expression 
(n = 4, *p <0.05). D) GSH Peroxidase 4 (GPX4) mRNA expression (n = 4, *p 








































































Figure 2.7. Inhibition of transcription blocks increase in GSH pathway 
enzyme activity. Neurons were treated for 24 h as indicated with 10 µM
Actinomycin D added 30 min before B/4AP.  Cells were then lysed and lysates
were assayed for GCL activity, normalised to protein levels, then to control 







Upregulation of GR promoter activation by NMDAR signalling 
 
To investigate the mechanism through which synaptic activity upregulates GSH 
pathway enzyme mRNA we employed the use of promoter-reporter plasmids.  
Negligible reporter activity and/or induction by B/4AP treatment was found from 
previously published GCLC (Yang et al., 2005) or GPX4 (Maiorino et al., 2003) 
constructs, suggesting that transcriptional regulation of these promoters occurs 
outwith these sites.  Significant signal was observed however using mouse GSR 
promoters: a ‘full promoter’ (- 1253 to + 624) and a previously identified ARE site (- 
857 to – 725) (Harvey et al., 2009).  B/4AP treatment significantly increased full 
promoter activity, in an NMDAR dependent manner (Fig 2.8A) in contrast to the 
enzymatic and qPCR data.  It has been shown that the ARE transcription site 
sequences may contain an AP-1 site (Nguyen et al., 2003), and synaptic activity may 
stimulate transcription of some ARE regulated genes through AP-1 signalling 
(Papadia et al., 2008; Soriano et al., 2009).  To explore the possible role of AP-1 
signalling in GSR upregulation we co-transfected neurons with either reporter 
constructs and TAM-67 (a dominant-negative form of c-Jun (Brown et al., 1993)) to 
disrupt AP-1 signalling.  Compared to globin controls, TAM-67 inhibited B/4AP 
mediated induction of GSR-ARE reporter activity (Fig2.8B).  However, TAM-67 
was unable to block induction of the full promoter by synaptic activity (Fig 2.8C), 
indicating that inhibition of AP-1 signalling is not sufficient to disrupt GSR 
induction by B/4AP treatment.  Thus the increase in GSR mRNA by synaptic activity 

















































































Figure 2.8. Glutathione Reductase promoter activity is increased by synaptic 
activity. A) GSR full promoter is activated by synaptic activity in an NMDAR
dependent manner. Neurons were transfected with GSR full promoter and pTK
Renilla. 24 h post transfection neurons were stimulated as indicated, with 50 µM
MK801 added 30 min before, then Luciferase expression was measured and 
normalised to Renilla control (n = 4, *p < 0.05). B) AP-1 inhibition impairs 
B/4AP treatment activation of GSR-ARE(2). Neurons were transfected with 
GSR-ARE(2) reporter, pTK renilla, and either β-Globin or TAM67.  Neurons 
were treated as indicated 24 h post-transfection, and Luciferase expression was 
recorded and normalised to Renilla control (n = 4, *p <0.05 to β-Globin B/4AP 8 
h). C) AP-1 inhibition does not impair B/4AP treatment activation of GSR full 
promoter. Neurons were transfected with GSR full promoter, pTK Renilla and 











Blockade of NMDARs decreases GCL activity and expression in vivo 
 
We wished to determine whether the effects of increasing synaptic activity on the 
GSH pathway were recapitulated in vivo.  Although NMDAR blockade had little 
effect on enzyme expression or activity compared to controls in vitro, this may be 
explained by the minimal activation of these receptors in untreated conditions 
(Hardingham et al., 2001b), thus we hypothesised that MK801 treatment in juvenile 
rats would have a more pronounced effect, due to an increased NMDAR activation in 
vivo.   
 
P7 rats were subjected to two consecutive intraperitoneal injections of either vehicle 
or MK801, at 0 and 8 h, and sacrificed 12 h after the initial treatment.  MK801 
treatment had no effect on total GSH levels (Fig 2.9A), GR activity (Fig 2.9B) or 
GPX activity (Fig 2.9C).  However, GCL activity was strongly inhibited by NMDAR 
blockade (Fig 2.9D).  Real-time qPCR analysis showed significant inhibition of 
GCLC, GSR and GPX4 mRNA expression in samples obtained from MK801 treated 
rats (Fig 2.9E).  We decided to check if the loss of GCL activity would impact on 
GSH levels after a longer period of NMDAR blockade, and whether changes in GSR 
and GPX4 mRNA expression might manifest changes in enzyme activity.  
Accordingly we analysed rats similarly treated but sacrificed 24 h after first MK801 
treatment.  Whilst this had no significant effect on GR or GPX activity (data not 
shown), a reduction in GSH levels was observed (Fig 2.9F).  These data suggest that 
similar to observations made in vitro, NMDAR activation is required for GSH 
pathway enzyme regulation in vivo, through control of their mRNA expression, 

































































































Figure 2.9. Blockade of NMDAR decreases GCL enzyme activity and GSH 
pathway enzyme mRNA in vivo. P7 rats received two consecutive 
intraperitoneal injections of saline vehicle (Control) or 0.5 mg/kg MK801 at 0 
and 8 h. 12 h after first injection rats were sacrificed and frontal corticies were 
collected and snap-frozen in liquid nitrogen. A,B,C and D) GSH levels, GSH 
reductase and GSH peroxidase activities were unaffected by MK801 treatment, 
whereas γGC ligase activity was significantly reduced. Frontal corticies were 
lysed on ice and lysates assayed and normalised to protein levels. A) GSH 
colorimetric assay (n = 6 animals per condition). B) GSH Reductase activity 
assay (n = 6 animals per condition). C) GSH Peroxidase activity assay (n = 6 
animals per condition). D) γGC ligase activity assay (n = 4 animals per condition, 
*p <0.01). E) GSH pathway enzyme mRNA expression was reduced by MK801 
treatment. Corticies were lysed, mRNA isolated, converted to cDNA and 
expression of GCLC, GSR and GPX4 analysed by qPCR (n = 4 animals per 
condition, *p <0.01 to respective control). F) GSH levels detected from P7 rats 
treated as above, but sacrificed 24 h after first injection (n = 4 animals per 





















































































This study demonstrates that synaptic activity, through enhanced NMDAR 
signalling, coordinates changes in gene expression of enzymes of the GSH pathway, 
hitherto uncharacterised as activity-regulated genes.  These changes in mRNA 
expression lead to increased enzymatic activity which mediates in part the 
neuroprotection conferred by synaptic activity against oxidative insult. 
 
Synaptic activity promotes GPX activity 
 
We have previously demonstrated that NMDAR stimulation strongly protects 
neurons against oxidative insult through upregulation of the peroxide neutralising 
thioredoxin-peroxiredoxin pathway (Papadia et al., 2008), thus the observation that 
synaptic activity enhanced cell death to sub-toxic doses of hydrogen peroxide in 
GSH depleted neurons was indeed surprising.  This suggests that active neurons have 
an enhanced metabolic rate and production of ROS that requires neutralisation by the 
GSH pathway.  Inhibition of de novo GSH synthesis and recycling demonstrated 
further that synaptic activity increased the rate of GSH loss which, whilst the 
increased activity of other GSH utilising enzymes such as GST cannot be excluded, 
is coordinated with an increased GPX activity and the upregulation of GPX2 and 
GPX4 mRNA. 
 
The GPX family consists of 8 currently known isozymes, each considered to fulfil 
certain distinct tissue and cellular specific roles (Brigelius-Flohe, 1999).  Whilst no 
change was observed in the expression of the ubiquitous cytosolic GPX1, the 
predominant GPX in all cells, gastrointestinal GPX2, its most similar isozyme in 
terms of substrate specificity (Chu et al., 1993), was upregulated at an mRNA level.  
Upregulation of GPX2 is intriguing; it is known to be dynamically regulated by 
oxidative stress through activation the antioxidant response element (ARE) (Singh et 
al., 2006); furthermore, studies evaluating GPX mRNA levels in cell lines treated 
with selenium (required for the selenocysteine active site) deficient media show a 
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preferential stability, and increased resynthesis after selenium repletion, of GPX2 
over GPX1 (Brigelius-Flohe, 1999). 
 
Phospholipid GPX4 is distinct from other peroxide neutralising enzymes in its broad 
substrate specificity, which crucially allows it to reduce lipid hydroperoxides (Ursini 
et al., 1982; Maiorino et al., 1990).  Lipids, in particular polyunsaturated fatty acids, 
are particularly sensitive to oxidative stress.  Abstraction of a single hydrogen atom 
from a lipid side chain by ROS produces a carbon-centred lipid radical, which 
through reaction with oxygen and neighbouring lipids sets off a free radical chain 
reaction, self propagating whilst producing lipid hydroperoxides (Halliwell, 1992).  
This severely disrupts membrane integrity, which is of course essential for cellular 
function.  The importance of GPX4 is highlighted by the embryonic lethality of 
GPX4 knockout, as compared to the oxidative stress sensitising effects of GPX1 or 
GPX2 knockout (Brigelius-Flohe, 2006).  Neurons, due to their high content of 
polyunsaturated fatty acids, are particularly vulnerable to lipid peroxidation (Coyle 
and Puttfarcken, 1993), thus GPX4 activity is essential.  Within the CNS GPX4 is 
preferentially expressed in neurons (Savaskan et al., 2007), and its overexpression 
protects neurons from oxidative insult (Ran et al., 2006).  Thus GPX4 upregulation 
presents an intriguing mechanism by which neurons protect themselves from the 
increased ROS production that is associated with increased synaptic activity, either 
through increased metabolic demand or activation of ROS producing secondary 
messenger systems (Brennan et al., 2009). 
 
NMDAR activation promotes GCL activity in an astrocyte independent manner 
 
Given the importance of de novo synthesis of GSH to neuronal function and 
viability; the regulation of GCLC by synaptic activity is an exciting prospect.  Whilst 
the observed protection against GSH depletion after hydrogen peroxide insult could 
be mediated by the known increased activity of the thioredoxin-peroxiredoxin 
detoxifying pathway, this effect is concurrent with increased GCL activity and 
GCLC mRNA expression.  Although B/4AP stimulation did not increase neuronal 
GSH content per se, this is in accordance with the feedback inhibition of GCL 
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activity by GSH (Richman and Meister, 1975); which is notably absent in the in vitro 
GCL enzyme activity assay used.  This increased GCL activity could be due to post-
translational modification of the enzyme.  GCL activity can be decreased by 
phosphorylation of its catalytic subunit by Ca
2+
/Calmodulin-dependent kinase II, 
protein kinase C and PKA (Sun et al., 1996) which are all present in neurons; thus 
theoretically synaptic activity regulated phosphatases, such as calcineurin, could 
increase GCL activity.  However, the increased GCL activity was blocked by 
transcription inhibitor actinomycin, demonstrating the importance of de novo mRNA 
expression.  Factors increasing GCLC mRNA expression have been shown to 
invariably lead to increased protein expression (Franklin et al., 2009), and this 
mechanism is considered to be the predominant method of increasing GSH synthesis 
(Dickinson and Forman, 2002). 
 
The dependence of GCLC mRNA upregulation on NMDAR signalling is instructive, 
especially when taken in context with the loss of GSH level maintenance after 
NMDAR blockade.  This suggests that the reduction of GSH depletion is NMDAR 
dependent, and due to an increased GSH biosynthesis.  GR and GPX activity and 
mRNA upregulation were not abolished by NMDAR blockade in vitro, which could 
suggest that increased activity of these enzymes, GR in particular, is not sufficient to 
protect neuronal GSH levels.  However in vivo, NMDAR blockade reduced mRNA 
expression of both of these enzymes, and study of the GR promoter showed an 
NMDAR dependent activation by synaptic activity.  Depolarisation by 4AP allows 
the activation of postsynaptic L-type calcium channels, which can activate similar 
downstream pathways as those recruited by NMDAR dependent Ca
2+
 influx 
(Hardingham et al., 1999), this could potentially be sufficient to drive GR and GPX 
gene transcription despite NMDAR blockade.  This suggests a possible difference in 
Ca
2+
 threshold required for GR/GPX transcriptional regulation that may be lower 
than that required for regulation of GCLC. 
 
Astrocytes are known to have greater GSH content than neurons (Raps et al., 1989), 
and many studies investigating GSH bioavailability within the CNS have focused on 
the ability of astrocytes to provide GSH precursors to neurons (Dringen et al., 1999; 
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Shih et al., 2003).  Whilst this is without doubt a crucial method of protecting 
neurons from oxidative stress, the data presented here demonstrates a way neurons 
can protect themselves independently of astrocytes, through NMDAR signalling.  
Importantly, this does not preclude the role astrocytes in influencing neuronal GSH 
levels.  Selective neuronal knockdown of either GCL subunit by shRNA causes 
sensitisation to oxidative and nitrosative insult and neuronal death, which is not 
rescued by coculturing with astrocytes (Diaz-Hernandez et al., 2005).  Thus neurons 
require GCL enzyme activity to facilitate astrocyte mediated protection against 
oxidative insult, to synthesise GSH from astrocytes supplied GSH; the synergistic 
effect of stimulating GSH synthesis in both neurons and astrocytes is explored in 
greater detail in chapter 5. 
 
The NMDAR dependent increase in GCL activity is especially important given the 
vulnerability of neurons undergoing NMDAR blockade (Ikonomidou et al., 1999; 
Papadia et al., 2008).  The data observed in juvenile rats injected with MK801 
showed a decrease in overall GSH levels after 24 h; however mRNA of GSH 
pathway enzymes and GCL activity were already decreased at 12 h.  This highlights 
the ability of GCL to maintain GSH levels for a limited time despite a reduced 
capacity, and moreover suggests that maintenance of the GSH pathway by NMDAR 
activity could be vital for neuronal viability and may contribute to the toxic effect of 
NMDAR blockade (Ikonomidou et al., 1999).  Intriguingly, in adult mice MK801 
treatment does not cause widespread apoptosis, but sensitises neurons to subsequent 
insult (Ikonomidou et al., 2000); analogously, whilst incomplete inhibition of GCL 
might not deplete GSH levels of otherwise unstressed neurons, GSH levels would 
likely be decreased by subsequent oxidative insult. 
 
Regulation of GSH pathway by synaptic activity 
 
Our previous study established a causal link between NMDAR activation and the 
downregulation of the thioredoxin inhibitor Txnip; the expression of which is 
elevated in ageing human brain and could influence vulnerability to oxidative stress 
(Papadia et al., 2008), potentially due to reduced synaptic activity.  Intrinsic to the 
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oxidative stress theory of ageing (Harman, 1956) is the depletion of GSH in various 
organs of the body (Hazelton and Lang, 1980; Maher, 2005), which parallels a 
reduced dynamic regulation of GCL activity (Suh et al., 2004; Morrison et al., 2005); 
furthermore GSH depletion is observed in neurodegenerative disease, such as 
Parkinson’s disease (Perry et al., 1982).  An intriguing possibility is that NMDAR 
signalling, that is protective in mature CNS (Ikonomidou et al., 2000), and its 
regulation of the GSH pathway is perturbed in age-related diseases. 
 
Exercise and environmental enrichment are both implicated with increased 
glutamatergic signalling (Molteni et al., 2002; Nichols et al., 2007) and reduction of 
cerebral oxidative stress (Herring et al., 2010); and are both implicated in 
neuroprotection (Young et al., 1999; Liebelt et al., 2010).  Whether these are 
epiphenomena, or due to NMDAR regulation of GSH pathway enzymes is of great 
interest; study of this pathway could lead to therapeutic strategies to slow 
neurodegeneration in the variety of disorders associated with oxidative damage.  Of 
particular importance, identification of the pathway that links NMDAR signalling to 
GSH pathway enzyme mRNA upregulation would be of great benefit to those 





























Neuroprotection by Nrf2 mediated 























GSH is selectively lost from neurons in a number of neurodegenerative diseases 
(Perry et al., 1982; Liu et al., 2004; Chi et al., 2007; Babu et al., 2008); strategies that 
increase GSH synthesis have shown some success in inhibiting ROS mediated 
damage and neuronal death in models of these disorders (Boyd-Kimball et al., 2005; 
Vargas et al., 2008; Chen et al., 2009).  Having demonstrated an increase in GSH 
synthesis capacity regulated by NMDAR signalling we wished to investigate 
alternative methods of maintaining GSH levels in neurons.  It is possible that 
NMDAR dependent signalling regulation of GSH is compromised by ageing or 
disease, as reports have independently observed perturbations of GSH levels and of 
NMDAR signalling (Greenamyre et al., 1987; Ulas et al., 1992; Liu et al., 2004).  
Thus alternative methods of increasing the expression of the GSH pathway may be 
able to rescue the activity of this antioxidant pathway in neurons. 
 
Activation of the Nrf2 transcription factor, through inhibition of binding to its 
negative regulator Keap1, causes an upregulation of a battery of genes involved in 
the regulation of the GSH pathway (Vargas and Johnson, 2009).  We resolved to 
investigate if Nrf2 activation could similarly maintain GSH levels in neurons, thus 
mimicking this aspect of NMDAR signalling protection.  To stimulate Nrf2 
dependent gene transcription we utilised the triterpenoid CDDO-F3, a potent 
activator of Nrf2 that has been shown to strongly promote transcription of Nrf2 
regulated genes and confer neuroprotection (Pitha-Rowe et al., 2009; Stack et al., 
2010; Neymotin et al., 2011).  Whilst the Nrf2 pathway is known to be more active 
in astrocytes than neurons (Kraft et al., 2004; Chen et al., 2009), its activation in 
astrocytes is still sufficient to protect neurons (Vargas et al., 2008; Calkins et al., 
2010).  This protection is in part mediated by the release of GSH precursors from 
astrocytes (Shih et al., 2003; Diaz-Hernandez et al., 2005).  We have previously 
demonstrated the neuroprotective effect of Nrf2 overexpression in neurons (Soriano 
et al., 2008b), and hypothesised that CDDO treatment might lead to GSH pathway 
enzyme upregulation in neurons.  Moreover, since neuroprotection against oxidative 
insult by astrocytes is dependent on neuronal GCL activity (Diaz-Hernandez et al., 
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2005), we postulated that CDDO treatment might stimulate GSH synthesis in both 
cell types in an additive manner. 
 
We observed that CDDO-F3 treatment of cortical cultures promoted an Nrf2 
dependent increase in astrocytic but not neuronal GSH levels.  This increase was 
sufficient to protect neurons and maintain their GSH levels in response to oxidative 
insult in an astrocyte dependent manner; removal of astrocytes from our culture 
preparations abolished both the neuroprotection and GSH level maintenance of 
neurons treated with CDDO-F3.  We established that CDDO-F3 treatment increased 
GCL activity in astrocytes, coinciding with an increased expression of both GCL 
subunit mRNA expression; however similar treatment of pure neuronal cultures bore 
no effect on GCL.  To characterise this further we investigated the effect of CDDO-
F3 treatment on cultures obtained from both Nrf2 knockout and Keap1 knockout 
mice.  Genetic ablation of Nrf2 in astrocytes caused a large reduction in GCL subunit 
expression, whilst Keap1 knockout astrocytes displayed an increased constitutive 
expression of these subunits, consistent with the known regulation of GCLC and 
GCLM by Nrf2.  However, knockout of either Nrf2 or Keap1 had no effect on GCL 
subunit expression of neurons, indicating its independence of Nrf2 mediated 
transcription.  We demonstrated the requirement of GSH export from astrocytes by 
the transporter MRP1 for neuroprotection by CDDO-F3 treatment, and that the GSH 
precursor γGC was sufficient to protect neurons and rescue GSH depletion in the 
presence of GCL inhibitor BSO.  Finally, we observed an additive protection of 
neurons and maintenance of GSH levels in electrically active neurons co-treated with 
CDDO-F3, demonstrating that increased GSH synthesis in both cell types is able to 















CDDO-F3 upregulates GSH levels of astrocytes but not neurons in an Nrf2 
dependent manner 
 
We previously showed that activation of the Nrf2 pathway with the small molecule 
chemopreventative agent D3T prevented neuronal apoptosis and induced expression 
of sulfiredoxin (Soriano et al., 2008b).  Since GCLC is a known Nrf2 target gene 
(Sekhar et al., 2002) we wished to see if activation of the Nrf2 pathway would lead 
to an increase in GSH content.  Analysis of GSH levels of lysates harvested from rat 
cortical neuronal cultures after 24 h treatment with Nrf2 inducers D3T, CDDO-EA 
and CDDO-F3 showed no increase in GSH, whilst treatment with BSO or H2O2 
significantly reduced GSH levels (Fig 3.1A).  Pure astrocytic cultures treated with 
Nrf2 inducing drugs showed significant increases in GSH levels, including in 
response to H2O2 treatment, with the greatest increase caused by CDDO-F3 (Fig 
3.1A).  Nrf2 wildtype mice astrocyte cultures showed a smaller but significant 
increase in GSH content, which was not present in Nrf2 knockout astrocytes cultured 
and treated in parallel (Fig 3.1B), indicating the dependence of Nrf2 activation in the 
increase in GSH content.  ImageJ analysis of MCB fluorescence intensity of rat 
neuronal cultures allowed separate determination of GSH levels in neurons and 
astrocytes of these ‘mixed’ cultures; whilst this revealed no increase of GSH content 
in neurons, a significant increase in astrocyte specific GSH after 24 h CDDO-F3 
treatment was observed (Fig 3.1C), confirmed by post-hoc GFAP 
immunocytochemistry (Fig 3.1D).  H2O2 treatment also caused an increase in 
astrocytic GSH content.  The increase of GSH in astrocytes by CDDO-F3 seemed 
substantially less in mixed cultures compared to pure astrocytic cultures, but was 
nonetheless significant; however since astrocytes make up around 5% of our rat 
cortical neuronal cultures (see methods, and (Soriano et al., 2008b)), this increase is 
insufficient to be recorded in examination of lysates harvested from mixed neuronal 
cultures.  Thus these data suggest that Nrf2 activation by CDDO treatment promotes 











































































Figure 3.1.  Synthetic triterpenoid CDDO-F3 increases astrocytic but not neuronal GSH 
levels.  A) Neuronal and pure astrocytic rat cultures were treated for 24 h in trophically
deprived medium with 100 µM BSO, 25 µM D3T, 250 nM CDDO-EA and 250 nM CDDO-
F3 (throughout unless otherwise indicated).  30 min prior to termination of stimulation cells 
were treated with 50 µM MCB. Cells were then lysed and analysed for MCB fluorescence, 
and normalised to protein content and respective control (n = 7, *p <0.05 to neuron control, 
#p <0.05 to astrocyte control). B) Pure astrocytic cultures were prepared from Nrf2 -/- mice 
and treated for 24 h as indicated. MCB fluorescence was recorded from lysates and 
normalised to protein content and respective control (n = 6, *p <0.05 to control, #p <0.05 to 
wildtype). C,D) Neuronal rat cultures were treated as indicated for 24 h. After 30 min MCB 
treatment cells were washed with warm fresh TMo and pictures of MCB fluorescence were 
taken. Nuclear fluorescence intensity was recorded using ImageJ, and normalised to 
respective control. To confirm astrocytic identity post-hoc GFAP immunocytochemistry was 

















































CDDO-F3 protects neurons from oxidative damage in an astrocyte and Nrf2 
dependent manner 
 
We have previously observed that small molecule inducers of Nrf2, and neuronal 
Nrf2 overexpression could confer potent neuroprotection against oxidative stress 
(Soriano et al., 2008b); whilst astrocytic overexpression of Nrf2 has also been 
demonstrated to protect neurons through an increased synthesis of GSH (Shih et al., 
2003).  Whilst changes in GSH levels by CDDO treatment were segregated to the 
astrocytes in unstressed cultures, we wished to determine the relevance of this to 
neuroprotection.  Rat cortical mixed neuronal cultures treated with a single dose of 
CDDO-F3 250 nM 24 h before insult were protected against H2O2 stimulation (Fig 
3.2A).  However in astrocytes free neuronal cultures, this protection was abolished 
(Fig 3.2A).  To determine the Nrf2 dependence of this protection we repeated these 
experiments in Nrf2 wildtype and knockout mice.  CDDO-F3 protection against 
oxidative insult by treatment with two doses of 100 nM CDDO-F3 was lost in 
cortical mixed neuronal cultures prepared from Nrf2 knockout mice (Fig 3.2B).  
Thus neuroprotection by CDDO treatment is both Nrf2 and astrocyte dependent. 
 
CDDO-F3 inhibits GSH depletion dependant on the presence of astrocytes 
 
Whilst CDDO stimulation did not raise GSH levels in unstressed neurons, we had 
previously observed an increase in GSH synthesis capacity of electrically active 
neurons that did not result in increased GSH levels in unstressed conditions.  This 
lack of increase was presumably due to feedback inhibition of GCL by GSH.  Whilst 
CDDO treatment required the presence of astrocytes to protect neurons, it is known 
that the Nrf2 transcriptional pathway is stronger in astrocytes than neurons (Kraft et 
al., 2004).  Nrf2 mediated transcription from the ARE upregulates a battery of genes 
related to the GSH pathway including both GCL subunits (Vargas and Johnson, 
2009).  We hypothesised that upregulation of enzymes of the GSH pathway induced 
by CDDO treatment might still occur in neurons, but that this effect was masked by 







 in response to H2O2 stimulation (as described in Fig 2.2).  24 h 






 compared to controls (Fig 3.3A-B).  This maintenance of GSH levels was 
abolished when H2O2 stimulation was concurrent with GCL inhibitor BSO, 
indicating an increased GSH synthesis in cells.  In contrast to observations made 





+ BSO between 
control and CDDO-F3 treated cells, suggesting no increase in GR activity by CDDO 






, these experiments were performed in parallel with regular neuronal 
cultures (with astrocytes making ~ 5% of total cell number) and astrocyte free 
neuronal cultures.  The maintenance of GSH levels in neurons treated with CDDO-
F3 was not observed in astrocytes free cultures (Fig 3.3C-D).  These data suggest 
that the effects of CDDO treatment on the GSH antioxidant pathway are restricted to 
astrocytes, though this is sufficient to both maintain neuronal GSH levels and protect 











































Con CDDO-F3 250 µM




























Figure 3.2. CDDO-F3 protects neurons from oxidative damage in an 
astrocyte and NRF2 dependent manner. A) Rat cortical neuronal cultures (Mix 
Neurons, AraC Div 5) and pure neuronal cultures (A-F Neurons, Astrocyte Free -
AraC Div 0) were treated with CDDO-F3 for 24 h in TMo, then with 200 µM
H2O2 overnight. Cells were then fixed, nuclei stained with DAPI, and cell death 
was measured by counting pyknotic and non-pyknotic nuclei (n = 4, *p <0.05 to 
H2O2). B) Neuronal cultures were prepared from Nrf2 
-/- mice and treated with 
two consecutive doses of 100 nM CDDO at 0 and 23 h. At 24 h cells were treated 
with 100 µM H2O2 and left overnight. Cells were then fixed and DAPI stained 

























































































































Figure 3.3.  CDDO-F3 inhibits GSH depletion in an astrocyte dependent 
manner.  A,B) CDDO-F3 treatment protects GSH levels. Rat neuronal cultures 
were treated as described in Fig 2.3A, with CDDO-F3 for 24 h and 100 µM BSO 
added 30 min before H2O2 treatment where indicated. A) shows average GSH 
levels at each timepoint and curve indicating GSH depletion rate. B) GSH 
depletion rates, normalised to control (n = 6, *p <0.05). C,D) CDDO-F3 
treatment does promote the maintenance of GSH levels in the absence of 
astrocytes. Neuronal cultures (M - Mix Neurons, AraC Div 5) and pure neuronal 
cultures (A-F – Astrocyte Free, AraC Div 0) were treated as above. C) shows 
average GSH levels at each timepoint and curve indicating GSH depletion rate. 





















































CDDO-F3 upregulates GCL enzyme activity and GCLC expression in 
astrocytes 
 
To confirm the effect of Nrf2 activation by CDDO-F3 on GSH synthesis we 
performed a cell-free GCL enzymatic assay on lysates obtained from mixed neuronal 
cultures treated with CDDO-F3 for 24 h.  A two-fold increase of GCL activity was 
observed (Fig 3.4).  Running these samples in parallel with those obtained from 
similarly treated astrocytes free cultures and pure astrocytic cultures revealed striking 
differences in GCL activity between these preparations; when normalised to protein 
content, astrocytes displayed a greater basal GCL activity, in accordance with the 
known increased presence of the enzyme in astrocytes (Raps et al., 1989).  
Furthermore, the induction of enzyme activity was greater in astrocytic cultures, 
whilst CDDO-F3 treatment of astrocytes free neuronal cultures failed to increase 
GCL activity (Fig 3.4). 
 
Since changes in GCL enzymatic activity are largely governed by the expression of 
its two subunits (Franklin et al., 2009), we investigated mRNA expression of GCLC 
and GCLM using qPCR.  The results observed closely agreed with those made in the 
GCL enzymatic assay; basal mRNA expression in astrocytes was increased 
compared to mixed neuronal cultures and astrocyte free cultures, whilst CDDO-F3 
treatment caused an upregulation of both GCLC (Fig 3.5A) and GCLM mRNA 



































Figure 3.4. CDDO-F3 increases GCL activity in astrocytes not neurons. 
Neuronal (Mixed Neurons, AraC Div 5), pure neuronal (Astrocyte Free, AraC
Div 0) and pure astrocytic cultures were treated in parallel with CDDO-F3 for 
24h.  Cells were then lysed and assayed for GCL activity; activity normalised to 






























































Figure 3.5. CDDO-F3 increases GCLC and GCLM mRNA expression 
in astrocytes not neurons. Neuronal (Mixed Neurons, AraC Div 5), pure 
neuronal (Astrocyte Free, AraC Div 0) and pure astrocytic cultures were 
treated in parallel with CDDO-F3 for 24h.  Cells were then lysed, mRNA 
was isolated, converted to cDNA and assayed for gene expression using 
qPCR. A) GCLC mRNA expression (n = 4, *p <0.05). B) GCLC mRNA 












Nrf2 and Keap1 regulate GCLC and GCLM in astrocytes but not neurons 
 
The lack of induction of GCL enzymatic activity or subunit mRNA expression by 
CDDO-F3 treatment in neurons led us to hypothesise that this was due to a 
diminished role of Nrf2 signalling in these cells.  To investigate this we analysed 
GCL subunit expression of cultures prepared from Nrf2 null mice.  In pure astrocytic 
cultures, basal GCLC mRNA expression was significantly reduced in Nrf2 knockout 
cultures compared to wildtypes, with a complete loss of induction by CDDO-F3 (Fig 
3.6A).  In contrast, pure neuronal samples displayed no induction in GCLC or 
GCLM mRNA expression by CDDO-F3 treatment; and intriguingly, no difference in 
basal mRNA levels between Nrf2 wildtypes and knockouts (Fig 3.7A).   
 
To examine this apparent Nrf2 independence further we analysed GCL subunit 
expression of cultures prepared from Keap1 knockout mice.  These mice show 
constitutive induction of Nrf2 target genes (Wakabayashi et al., 2003), and in retinal 
pigment epithelial cells have increased levels of GSH (Gao and Talalay, 2004).  
Keap1 knockout astrocytes showed increased basal expression of GCLC, which 
occluded further upregulation by CDDO-F3 (Fig 3.7A).  Basal GCLM expression 
was also elevated; though additional induction by CDDO-F3 treatment was observed 
(Fig 3.7B) indicating some Keap1 independence of either treatment or gene 
regulation.  However, in pure neuronal cultures neither CDDO-F3 treatment nor 
Keap1 knockout had any effect on GCLC (Fig 3.7C) or GCLM mRNA expression 
(Fig 3.7D).  Thus Nrf2 signalling, upon which basal GCLC mRNA expression and 
inducible increases in astrocytes are dependent, does not regulate GCL subunit 
































































Figure 3.6. GCL subunit expression is regulated by Nrf2 in astrocytes but 
not neurons. A) Pure astrocytic cultures were prepared from Nrf2 -/- mice and 
treated with CDDO-F3 for 24 h, after which cells were lysed, mRNA isolated and 
GCLC mRNA analysed by qPCR (n = 8, *p <0.05 to control). B) Astrocyte free 
neuronal cultures (A-F Neurons, AraC Div 0) from Nrf2 -/- mice were stimulated 


















































































































Figure 3.7. Keap1 regulates astrocytic GCL subunit mRNA expression but 
not neuronal levels. Cultures were prepared from Keap1 -/- mice and treated 
with CDDO-F3 for 24 h, after which cells were lysed, mRNA isolated and 
mRNA analysed by qPCR. A) GCLC mRNA expression from pure astrocyte
cultures (n = 5). B) GCLM mRNA expression from pure astrocyte cultures (n = 
4, *p <0.05 to wildtype control, #p <0.05 to Keap1KO control). C) GCLC 
mRNA expression from pure neuronal (A-F Astrocyte Free, AraC Div 0) cultures 













GSH precursor γGluCys protects neurons from oxidative insult 
 
Despite acting independently of neurons, Nrf2-mediated increase in GCL activity 
restricted to astrocytes was sufficient to protect neurons from oxidative insult and 
maintain GSH levels.  Nrf2-overexpressing astrocytes have been shown to be 
neuroprotective (Shih et al., 2003), through the release of GSH.  Release of GSH 
from astrocytes is known to be mediated in part by the transporter MRP1 (Cole and 
Deeley, 2006; Minich et al., 2006).  To investigate the role of GSH release in 
mediating CDDO-F3 neuroprotection we used the potent MRP1 blocker MK571 
(Leier et al., 1996), which inhibits the release of GSH from astrocytes (Minich et al., 
2006).  MK571 inhibited CDDO-F3 mediated protection against H2O2 (Fig 3.8A).  
Since neurons cannot import GSH (Vargas and Johnson, 2009) it is postulated that 
the positive effect on neuronal GSH levels by its astrocytic release are through two 
mechanisms: through non-enzymatic extracellular detoxification of ROS (Drukarch 
et al., 1998); or through breakdown by astrocytic extracellular membrane bound 
γglutamyltranspeptidase to CysGly (Dringen et al., 1999) and subsequent hydrolysis 
by aminopeptidase N to readily imported cysteine and glycine (Dringen et al., 2001).  
To explore this we examined the effect of GSH and its precursors CysGly and 
γGluCys on neuronal survival against oxidative insult (the effect of cysteine 
supplementation was not investigated due to its highly excitotoxic effect at high 
doses (Olney et al., 1990)).  500 µM γGluCys, but neither GSH nor CysGly, 
protected neurons against H2O2 administration (Fig 3.8B).  Detection of GSH content 
using MCB showed that γGluCys, but not GSH or CysGly, protected neuronal GSH 
levels in the presence of GCL inhibitor BSO (Fig 3.8C), suggesting its whole 
incorporation into cells could allow neurons to bypass this step of GSH synthesis.  
To investigate if GSH synthesis in astrocytes or neurons led to an increased cysteine 
uptake, radioactive 
35
S cysteine uptake assays were performed.  Neither CDDO-F3 
nor B/4AP treatment changed cysteine uptake (Fig 3.8D); indicating that increased 


























































Con GluCys CysGly GSH
Figure 3.8. GSH precursor γGluCys protects neurons from oxidative insult. A) MRP1 
inhibition blocks CDDO-F3 neuroprotection. Rat cortical cultures were treated with CDDO-




overnight.  Cells were then fixed, DAPI stained and cell death assesed by counting pyknotic
and non-pyknotic nuclei (n = 4, *p <0.05). B) γGlutamylcysteine protects neurons against 
oxidative insult. Rat cortical cultures were treated with 500 µM of γglutamylcysteine, 




was added and cells were left overnight; 
then fixed, DAPI stained and assessed for cell death (n = 4, *p <0.05). C) γGlutamylcysteine
sustains GSH levels in the presence of GCL inhibitor. Neurons were treated with 500 µM
GluCys, CysGly and GSH; after 1 h cells were treated with 100 µM BSO for 24 h.  After 24 
h cells were treated with 50 µM MCB for 30 min, and lysates were analysed for fluorescence, 
with levels normalised to protein and controls (n = 4, *p <0.05 to BSO control). D) Cysteine 
uptake is not affected by modulation of synaptic activity or CDDO-F3 treatment. Neurons 
were treated for 24 h as indicated and 35S cysteine uptake was analysed.  Cysteine uptake was 
normalised to control rates (n = 4); cell numbers and death of neurons cultured and treated in 









































































CDDO-F3 and B/4AP treatment protect neurons in an additive manner 
 
Having previously demonstrated an astrocyte independent upregulation of GSH 
synthesis by increased synaptic activity, and determined that the increase in GSH 
synthesis by Nrf2 induction is restricted to astrocytes, we wished to see if these two 
protective treatments would have synergistic effects.  Stimulation with both CDDO-
F3 and B/4AP protected neurons against H2O2 insult significantly more than either 
treatment alone (Fig 3.9A).  We next investigated the effect of dual stimulation on 
GSH depletion.  Since both B/4AP and CDDO-F3 treatment alone were sufficient to 
largely prevent the depletion of GSH by 100 µM H2O2, higher doses of H2O2 were 
used.  Even after 24 h exposure to 250 µM H2O2, GSH levels in neurons treated with 
both CDDO-F3 and B/4AP were largely unaffected, whilst the ∆[GSH] of either 
treatment alone were significantly larger (Fig 3.9B).  Thus upregulation of GSH 
synthesis in these two distinct cellular types, through two distinct molecular 
pathways, can be stimulated to have an additive effect on GSH levels, potently 



































































































Figure 3.9. CDDO-F3 and B/4AP treatment protect neurons in an additive 
manner. A) Synaptic activity and Nrf2 activation potently protect against
oxidative insult. Rat cortical cultures were treated with 50 µM bicuculline and 
250 µM 4-aminopyridine (B/4AP) and CDDO-F3 either separately or 
simultaneously for 24 h.  200 µM H2O2 was then added overnight, cells were 
then fixed, DAPI stained and cell death calculated by counting number of 
pyknotic and non-pyknotic nuclei (n = 8, *p <0.05 to H2O2 treated B/4AP + F3, 
#p <0.05 to H2O2 control). B) Synaptic activity act synergistically to protect GSH 
levels. Neurons were treated as described in Fig 2.3A except H2O2 dose was 
increased to 250 µM; after 24 h simultaneous or separate treatment with B/4AP 
and CDDO-F3. MCB fluorescence was recorded from lysates, and normalised to 
protein content.  GSH depletion over time was then calculated and rates 














This study demonstrates the neuroprotective potential of the synthetic triterpenoid 
CDDO-F3, through Nrf2-dependent upregulation of GSH synthesis.  Whilst Nrf2-
dependent GSH regulation is restricted to astrocytes, the resultant upregulation is 
however sufficient to confer neuroprotection, dependent on the release of GSH.  
Separate upregulation of GSH synthesis in neurons and astrocytes by synaptic 
activity and Nrf2 signalling do not occlude each other, and can act additively to 
promote powerful neuroprotection. 
 
GCL subunit mRNA expression is not regulated by Nrf2 in neurons 
 
Both GCLC and GCLM are canonical Nrf2 regulated genes (Mulcahy et al., 1997; 
Solis et al., 2002), their basal expression is controlled by Nrf2 (Wild et al., 1999) and 
the attenuation of Nrf2 signalling causes a reduction in GSH synthesis in liver (Suh 
et al., 2004).  Thus the finding that neuronal GCL subunit mRNA expression is 
unchanged between wildtype and Nrf2 knockouts is surprising.  Whilst it is possible 
that compensatory genetic mechanisms, for instance possible regulation by Nrf1, 
could account for this lack of change; the results found in neurons are in stark 
contrast with those in astrocytes, which display reduced subunit expression in Nrf2 
knockouts, and constitutive upregulation in Keap1 knockouts.  The upregulation of 
Nrf2 target genes, particularly those involved in oxidant detoxification, by Keap1 
knockout has been shown to be more extensive than that by CDDO (Yates et al., 
2009). Thus the observation that neither genetic nor pharmacological activation of 
Nrf2 increased GCL subunit mRNA expression suggests firmly that Nrf2 dependent 
transcription does not regulate GSH synthesis in cortical neurons.   
 
It has been demonstrated that the Nrf2 signalling pathway is diminished in neurons in 
comparison to astrocytes (Kraft et al., 2004; Chen et al., 2009), and that GSH 
synthesis in response to oxidative/nitrosative stress and Nrf2 inducers is restricted to 
astrocytes (Eftekharpour et al., 2000; Gegg et al., 2003).  We have considered the 
further possibility that the Nrf2 transcriptional pathway is not at all active in neurons, 
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with current investigations in our lab indicating to that effect.  H2O2 or Nrf2 
activating compounds do not increase the expression of other Nrf2 target genes in 
neurons; neither does genetic ablation of Keap1.  This is likely due to decreased 
expression of Nrf2 and/or increased expression of Keap1 in neurons.  Loss of Nrf2 
dependent transcription could be due to epigenetic changes, for instance histone 
deacetylation, which might restrict access to ARE transcription sites in neurons; 
however the Nrf2 target-gene sulfiredoxin can still be upregulated by neuron-specific 
Nrf2 overexpression (Soriano et al., 2008b), suggesting that the lack of Nrf2 
dependent gene transcription may be due to diminished Nrf2 expression.  However 
epigenetic changes of Nrf2 mRNA expression may underlie the loss of its 
transcriptional pathway in neurons.  Strategies that induce an increase in Nrf2 mRNA 
expression may be able to rescue its signalling in neurons.  Cyclo(His-Pro), an 
endogenous dipeptide produced by the cleavage of hypothalamic thyrotropin 
releasing hormone, has been demonstrated to increase Nrf2 mRNA expression in 
neurons, with a resultant increase in GSH synthesis and haemoxygenase-1 expression 
(Minelli et al., 2009).  Thus it is probable that cyclo(His-Pro) may be able to rescue 
Nrf2 signalling, and concurrent treatment with CDDO-F3 could be able to potently 
increase GSH levels in neurons; this remains an intriguing future experiment. 
 
CDDO-F3 is potently neuroprotective 
 
Despite its effects on the GSH pathway being restricted to astrocytes, CDDO-F3 
treatment was sufficient to protect neurons from oxidative insult, allowing them to 
maintain their GSH levels.  This effect is remarkable considering that astrocytes 
represent only a small percentage of cells within our cultures.  Nrf2 overexpression 
in astrocytes has been shown to confer profound neuroprotection (Shih et al., 2003; 
Chen et al., 2009; Calkins et al., 2010), predominantly through increased GSH 
synthesis and export.  Our results agree, as MRP1 inhibition attenuated CDDO-F3 
mediated protection; however there is some discrepancy with previous reports of 
GSH precursors.  CysGly supplementation was ineffective at protecting neurons 
from subsequent oxidative insult, whereas γGluCys was protective. Since there is 
little evidence of a specific neuronal transporter for γGluCys, its ethyl-ester 
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conjugate which passes independently through membranes has been used to enhance 
neuronal GSH levels in models of compromised GCL activity in vivo (Drake et al., 
2002), and has promising therapeutic potential as it can cross the blood brain barrier.  
However γGluCys itself has been shown to be transported into kidney cells 
(Anderson and Meister, 1983) and elevate neuronal GSH levels in vitro (Dringen et 
al., 1997b; Diaz-Hernandez et al., 2005; Le et al., 2010).  We observed a rescue by 
γGluCys of GSH levels of neurons treated with GCL inhibitor BSO.  Since 
equimolar GSH did not rescue GSH levels or protect against oxidative insult, we 
assume that this rescue is caused by γGluCys entry into cells and subsequent 
conversion to GSH by GSS, rather than through extracellular non-enzymatic 
scavenging of ROS that might alleviate stress on the GSH pathway. 
  
Whilst we do not rule out the supply of cysteine to neurons by release and 
subsequent extracellular hydrolysis of astrocytic GSH, it is possible that CDDO-F3 
treated astrocytes could mediate neuroprotection through supply of γGluCys.  A 
potential mechanism for this, first proposed to explain the high concentration of 
γGluCys in urine of animals and humans with γglutamyl transpeptidase deficiency 
(Griffith and Meister, 1980), could be through cleavage of glycine from GSH by 
carboxypeptidase.  Carboxypeptidases are essential in the CNS for cleaving C-
terminal amino acids from neuropeptides (Fricker, 1988), and are excreted by 
astrocytes and neurons depolarised by KCl treatment (Vilijn et al., 1989).  It is 
suggestive that carboxypeptidase E (the predominant neuronal isozyme) knockout 
mice show profound neurodegeneration, whilst its overexpression protects neurons 
against oxidative insult (Woronowicz et al., 2008).  This could be an intriguing 
potential mechanism of astrocyte mediated neuroprotection that certainly requires 
further study 
 
The unexpected nature of this result, and indeed all the GSH measurements made 
using MCB presented in chapters 4 and 5, signifies the importance of repeating these 
experiments using alternative techniques.  Whilst MCB allows us to detect small 
changes in cellular GSH whilst using a minimum of material, two aspects of its 
function are a cause for concern: it may form fluorescent adducts with all thiol 
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containing compounds, albeit at a vastly reduced rate than the specific reaction to 
GSH catalysed by GST (Sun et al., 2006); there is also the potential that differences 
in GST expression in neurons could belie differences in MCB fluorescence, rather 
than actual GSH concentration.  The incubation time of 30 minutes was specifically 
chosen to circumvent these problems, allowing the GST-catalysed exponential 
reaction of GSH with MCB to reach its plateau, whilst giving insufficient time to 
allow interference by non-specific thiol reaction to the remaining probe; however, it 
is imperative that we also use alternative GSH assay to recapitulate some these data.  
Future experiments shall also include alternative methods of inhibiting GCL activity, 
since the action of the GCL inhibitor BSO is not wholly specific, causing inhibition 
of the glutamyl amino acid transporter (Griffith et al., 1979) which may perturb other 
unkown biochemical pathways.  To counter this, we shall use siRNA to knock down 
GCLC expression, and investigate the effect of this on B/4AP mediated 
neuroprotection. 
  
CDDO-F3 and B/4AP treatment have an additive neuroprotective effect 
 
Astrocytic synthesis of GSH is greater than that of neurons (Raps et al., 1989), with a 
portion of this GSH used to supply and protect neurons.  Neurons co-cultured with 
astrocytes display higher GSH levels (Bolanos et al., 1996), a trend we also observed 
(Fig 3.3D).  However, we have demonstrated that increasing synaptic activity by 
B/4AP stimulation confers a GSH synthesis dependent protection against oxidative 
insult that is independent of the presence of astrocytes (chapter 4).  Since Nrf2 
signalling to GCL subunit mRNA expression is restricted to astrocytes, we can 
conclude that the two GCL activating treatments used act through two distinct 
pathways, one Nrf2 dependent the other Nrf2 independent.  As a proof of principle: 
B/4AP treatment upregulated GCL activity through increased GCLC mRNA 
expression, without increasing GCLM mRNA expression or GSH above 
unstressed/basal levels; whereas CDDO-F3 treatment increased (astrocytic) GCLC 
and GCLM mRNA expression, GCL activity and astrocytic GSH levels.  GCLM 
alleviates the feedback inhibition of GCL by GSH (Huang et al., 1993), thereby 
facilitating extensive GSH synthesis.  Thus whilst B/4AP treated neurons increase 
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GCL activity but not overall GSH levels, Nrf2 signalling in astrocytes is able to 
overcome feedback inhibition and increase GSH even in unstressed conditions 
through the upregulation of GCLM. 
 
Whilst increasing synaptic activity alone had a profound neuroprotective effect 
against oxidative insult, concurrent activation of Nrf2 signalling in astrocytes had a 
further protective effect.  Synaptic activity increased expression and activity of GSH 
pathway enzymes; thus stimulation with both treatments causes an interesting 
dynamic, whereby neurons are primed for GSH synthesis and metabolism, with 
astrocytes acting as providers of GSH.  Circumstantial evidence for this additive 
protection is available from studies providing environmental enrichment, a 
conditioning known to increase glutamatergic signalling in animal models (Nichols 
et al., 2007), simultaneously with antioxidant-rich diet, which together strongly 
attenuate neurodegeneration in animal models (Pop et al., 2010). 
 
Whilst bolus antioxidant supplementation has had mixed results as a therapeutic 
strategy, these results demonstrated here display an attractive therapeutic potential 
for Nrf2 activating compounds, which could be used to facilitate neuronal 
antioxidant defences; in particular the GSH pathway, which has shown to be 
compromised in neurodegenerative disease.  Design and synthesis of Nrf2 activating 
compounds that can cross the blood brain barrier and target astrocytes may be a 
promising avenue of research, especially when used in concert with strategies that 











































Neuronal activity dependent protection against apoptotic and oxidative insults 
 
Whilst the pathways, and even the cell type, studied during the course of this 
research have changed; the primary focus, study of signalling pathways that promote 
the protection of neurons, has not.  I have presented here three different 
neuroprotective pathways: 
 
• CREB-activating PACAP signalling, that mediates its protection not through 
activation of PKA alone, but by increasing the action-potential firing activity 
of the neuronal network. 
• Synaptic-activity mediated neuronal increase of enzymes of the antioxidant 
GSH pathway. 
• Nrf2 dependent increase of GSH synthesis, that although completely 
segregated to astrocytes, is sufficient to protect neurons from oxidative stress. 
 
Each chapter has alluded to the protective potential of NMDAR signalling.  In the 
first we demonstrated a previously unobserved requirement for on-going synaptic 
activity to mediate protection by the neurotrophic signalling molecule PACAP.  In 
the second we revealed the influence of NMDAR signalling on the antioxidant GSH 
pathway.  This observation was investigated further in the third chapter, where we 
demonstrated the Nrf2-independence of GSH synthesis in neurons, but through its 
activation in astrocytes we could promote a neuroprotective response, increasingly 
potent when concurrent with increased synaptic NMDAR signalling. 
 
Our understanding of the protective potential of NMDAR signalling has advanced 
dramatically since the failure of antagonists as potential neuroprotective drugs for 
use in stroke and neurodegenerative disorders.  Current therapeutic strategies based 
on this knowledge focus on the selective inhibition of extrasynaptic NMDAR 
activation.  Memantine, an NMDAR antagonist that preferentially inhibits 
extrasynaptic NMDARs, has been shown to be well tolerated in clinical trials of 
cognitively impaired adults (Jones et al., 2007; Ott et al., 2007; Zhao et al., 2010), in 
stark contrast to the increased morbidity/mortality observed with classical NMDAR 
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antagonists (Ikonomidou and Turski, 2002).  Recent observations of the multi-
faceted protective potential of memantine in models of Huntington’s disease 
(Okamoto et al., 2009; Milnerwood et al., 2010), suggest that therapies based around 
this strategy may be capable of, if not arresting, attenuating ongoing 
neurodegeneration caused by diseases of the CNS. 
 
On the basis of the research presented here, a further strategy of accentuating the 
neuroprotective signalling by synaptic NMDARs, and of astrocytes, should be 
considered.  This is particularly relevant when considering that ageing, the 
predominant risk factor of all neurodegenerative disorders, is associated with a 
decline in protective signalling.  Endogenous Nrf2 pathway signalling has been 
observed to be attenuated in aged rodents (Suh et al., 2004; Duan et al., 2009); 
however this can be rescued by Nrf2 inducing agents, demonstrating their therapeutic 
potential.  The neuroprotective potential of compounds such as CDDO-F3, as 
demonstrated in Chapter 5, has led to the proposal of their use as possible therapies 
for neuronal injury and neurodegenerative disorders (Vargas et al., 2008; Siebert et 
al., 2009; Alfieri et al., 2011; Neymotin et al., 2011).  Alternatively naturally 
occurring compounds, such as polyphenols found in apple juice, have been shown to 
activate transcription of Nrf2 target genes (Soyalan et al., 2011), thus dietary 
regulation may have therapeutic potential in the treatment of neurodegenerative 
disorders (Ramesh et al., 2009; Remington et al., 2010). 
 
Evidence that synaptic NMDAR signalling might be compromised with age is more 
circumstantial, though remains an intriguing possibility.  Synaptic plasticity is 
attenuated with age in humans (Freitas et al., 2011), and decreased synaptic plasticity 
is a hallmark of many neurodegenerative diseases; in particular Alzheimer’s disease, 
where a reduction of glutamatergic signalling is observed (Greenamyre et al., 1987; 
Ulas et al., 1992; Esteban et al., 2003).  Furthermore soluble Aβ, a pathological 
hallmark of the disease, has been shown to impair neurotransmission and increase 
extrasynaptic NMDAR activation (Costa et al., 2009; Li et al., 2011).  Exercise and 
environmental enrichment, factors demonstrated to potentiate glutamatergic 
signalling and synaptic plasticity (Molteni et al., 2002; Nichols et al., 2007), have 
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been shown to attenuate age-related and Alzheimer’s disease neurodegeneration 
(Wilson et al., 2002; O'Callaghan et al., 2009; Lazarov et al., 2010).  A recent study 
investigating the therapeutic potential of glucagon like peptide in Alzheimer’s 
disease demonstrates this link between synaptic NMDAR signalling and 
neurodegenerative processes that occur in this disease: treatment reduced β amyloid 
plaques and soluble Aβ, whilst facilitating synaptic plasticity in both wildtype and 
disease model mice (McClean et al., 2011). 
 
Possible pharmacological enhancement of synaptic NMDAR signalling is fraught 
with difficulty, due to the epileptogenesis associated with disinhibition of the CNS.  
However mild disinhibition by serotonin uptake inhibitor fluoxetine has recently 
been observed to restore synaptic plasticity in adult mice (Chen et al., 2011), a 
treatment which could in turn provide neuroprotection through enhanced synaptic 
NMDAR signalling.  Another intriguing possible therapy could be the use of 
PACAP.  As a neurohormone it can cross the blood brain barrier, and as observed in 
Chapter 3, it exerts its neuroprotective effects through enhancement of synaptic 
activity.  PACAP has recently been shown to slow down Alzheimer’s disease 
progression in mouse models (Rat et al., 2011), and is known to confer protection in 
a variety of neurodegenerative models (Reglodi et al., 2002; Reglodi et al., 2006; 
Tamas et al., 2006a; Vaudry et al., 2009). 
 
Understanding of the intrinsic protective pathways of the CNS will eventually give 
rise to molecular strategies to combat the inevitable morbidity and mortality of 
neurodegenerative diseases and brain injury.  A powerful tool in understanding these 
processes has been generated in the form of induced pluripotent stem cells (iPSCs).  
The generation of these cells (Takahashi et al., 2007) and their neuralisation 
(Chambers et al., 2009) represent the greatest scientific breakthrough of this century 
so far.  Whilst cell replacement therapies, or complete substitution of rodent based 
models may be hyperbole at present, these cells do provide a valuable resource to 
augment our knowledge of neuroprotective signalling.  In particular patient specific 
iPSCs will hopefully rapidly advance our understanding of neurodegenerative 
pathological processes.  It remains an intriguing possibility that some of the findings 
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